{
  "OPTISAGE": {
    "TITLE": "phase iii study compare gvhd prophylaxis anti thymocyte globulin thymoglobulin atlggrafalon elderly patient acute myeloid leukemia myelodysplatic syndrome receive allogeneic hematopoietic stem cell transplantation 10 10 hla match unrelated donor follow reduced intensity condition regimen fludarabinetreosulfan",
    "JUSTIFICATION": "allogeneic hematopoietic stem cell transplantation allo hsct remain curative therapy acute myeloid leukemia myelodysplastic syndrome mds patient require allohsct 50 year age transplant reduced intensity condition regimen optimal reduced intensity conditioning gvhd prophylaxis regimen allow good control disease prevent gvhd remain determine elderly patient phase iii trial compare conventional reduced intensity condition fludarabinebusulfan day fludarabinetreosulfan demonstrate advantage flutreosulfan arm term event free survival therefore consider new standard reduced intensity condition regimen acute myeloid leukemia mds gvhd prevention crucial role posttransplant outcome potentially interfere graftversusleukemia effect immune reconstitution antithymocyte globulin recommend reduce risk acute chronic gvhd transplant perform match unrelated donor however optimal type anti thymocyte globulin approve brand anti thymocyte globulin thymoglobulin atlggrafalon display distinct characteristic optimal dose anti thymocyte globulin still unknown retrospective study patient transplant mainly reduced intensity conditioning match related unrelated donor haematological malignancy observe atlg associate reduction grade iiiv acute gvhd comparison anti thymocyte globulin without increase incidence relapse phase iii randomize study propose compare gvhd prevention anti thymocyte globulin versus atlg acute myeloid leukemia mds patient 50 year age transplant match unrelated donor follow fludarabinetreosulfan reduced intensity conditioning hypothesis atlg would better control gvhd population patient thus limit risk morbidity mortality procedure",
    "OBJECTIVE": "main objective compare incidence grade iiiv acute gvhd day 100 posttransplantation mds acute myeloid leukemia patient transplant 10 10 match unrelated donor follow reduced intensity conditioning fludarabinetreosulfan patient receive gvhd prophylaxis anti thymocyte globulin thymoglobulin versus atlggrafalon primary endpoint incidence grade iiiv acute gvhd accord magic classification appendix 19 section day 100 posttransplantation secondary objective evaluate effect gvhd prophylaxis engraftment graft failure evaluate effect gvhd prophylaxis incidence grade acute gvhd chronic gvhd evaluate effect gvhd prophylaxis incidence infection evaluate effect gvhd prophylaxis progression free survival evaluate effect gvhd prophylaxis relapse incidence evaluate effect gvhd prophylaxis nonrelapse mortality evaluate effect gvhd prophylaxis overall survival evaluate effect gvhd prophylaxis gvhd relapse free survival evaluate effect gvhd prophylaxis healthrelated quality life fact bmt 10 evaluate effect gvhd prophylaxis chimerism 11 evaluate effect gvhd prophylaxis immune reconstitution nk regulatory cell level peripheral blood 12 evaluate effect gvhd prophylaxis day hospitalisation first 12 month posttransplantation 13 evaluate effect gvhd prophylaxis incidence severity vod 14 identify prognostic factor associate primary endpoint prophylaxis arm search treatmentbycovariate interaction primary endpoint 15 evaluate effect gvhd prophylaxis incidence late acute gvhd day 100 overlap syndrome chronic gvhd secondary endpoint hematopoietic recovery least 7consecutive day neutrophils platelet 20 immune reconstitution analyze nk regulatory cell gammaglobulin level peripheral blood month d+100 month month 12 month 24 posttransplantation chimerism month d+100 month month 12 grade acute gvhd incidence appendix 19 section acute gvhd treatment first line treatment response steroid treatment course refractory acute gvhd chronic gvhd incidence date grading month 12 month 24 nih classification 48 appendix 19 section relapse incidence month 12 month 24 relapse define reappearance leukemic cell mds feature allohsct bonne marrow cytology cytogenetic analysis bone marrow aspiration extramedullary site prove biopsy progression free survival month 12 month 24 severe infection ctae grade 34 d+100 month 12 fully describe incidences cmv ebv reactivations d+100 month month 12 10 nonrelapse mortality month month 12 month 24 11 overall survival month 12 month 24 12 gvhd relapse free survival define alive without disease relapse without develop acute grade iiiiv severe chronic gvhd 13 healthrelated quality life assess use factbmtv4 questionnaire inclusion d+100 month month 12 posttransplantation 14 number day hospitalization transplant hospitalization transplantation relate complication month 12 15 incidence severity vod d+100 16 lymphocyte count standard blood count conditioning day 17 late acute gvhd overlap syndrome chronic gvhd d+100 d+120",
    "DESIGN": "phase iii multicenter randomize control openlabel trial compare gvdh prophylaxis anti thymocyte globulin versus atlg patient acute myeloid leukemia mds transplant match unrelated donor follow fludarabinetreosulfan reduced intensity conditioning bio collection pbmc plasma dry pellet total blood cell perform day base line day 14 21 28 56 100 month month 12 60 patient per arm future biological study would perform find complementary funding collection organize via cryostem order good understand modulation immune response two anti thymocyte globulin brand plasma collection anti thymocyte globulin pk analysis atlg arm sample collect administration atlg days3 day 14 month month d+100 frozen center data analyze accord preconditioning lymphocyte count correlate posttransplant outcome gvhd relapse nrm able determine formula optimize atlg dose lymphocyte count future study plasma collection start include patient find complementary funding",
    "INCLUSION CRITERIA": "patients 50 year age present acute myeloid leukemia mds indication allogeneic stem cell transplantation age 50 70 year patient 50 55 year unfit myeloblative conditioning acute myeloid leukemia require allogeneic stem cell transplantation intermediate highrisk acute myeloid leukemia complete cytologic response cr1 mds require allogeneic stem cell transplantation ipss ipssr ipssr 34 risk feature rapide blast increase lifethreatening neutropenia thrombopenia 30g high transfusion need month month without hla match related donor identify match hla 10 10 unrelated donor usual criterion hsct ecog performans status severe uncontrolled infection cardiac leave ventricular ejection fraction 50 lung dlco 40 adequate organ function asat alat 3n total bilirubin 2n creatinine clearance 50 ml min except abnormality link hematological disease health insurance coverage sign write informed consent contraception method must prescribe duration research nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable implantable progestogenonly hormonal contraception intrauterine device iud intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom",
    "EXCLUSION CRITERIA": "carcinomas last year except basal cell carcinoma skin situ carcinoma cervix uncontrolled infection seropositivity hiv htlv1 active hepatitis yellow fever vaccine others live virus vaccine within month transplantation heart failure accord nyha ii left ventricular ejection fraction 50 lung dlco 40 preexisting acute hemorrhagic cystitis renal failure creatinine clearance 50ml min pregnancy hcg positive breastfeeding 10 patients debilitate medical psychiatric illness would preclude realization sct understanding protocol 11 patient state medical aid 12 patient legal protection protection court curatorship guardianship 13 grafalon contraindication mention smpc grafalon 14 thymoglobulin hypersensitivity rabbit protein excipients 15 participation clinical trial medicinal product human use exclusion period end previous study 16 contraindication mention smpc auxiliary medicinal product plan use trial cyclosporine mycophenolate mofetil fludarabine treosulfan",
    "INTERVENTION": "phase iii grafalon 10 mg kg day iv consecutive day day transplantation thymoglobuline mg kg iv day transplantation conditionning regimen patient receive conditioning regimen fludarabine 30 mg month day iv day day6 day treosulfan 10 month day iv day day day donor stem cell source hla 10 10 match unrelated donor gcsfmobilized peripheral blood stem cell accept cd34 target dose 10 kg body weight gvhd prophylaxis prophylaxis gvhd depend randomization arm atlggrafalon 10 mg kg day iv consecutive day day atlggrafalon anti thymocyte globulin thymoglobuline anti thymocyte globulin thymo two schedule administration antithymocyte globulin accept mg kg day iv consecutive day day3 mg kg iv day follow mg kg iv day mg kg day addition patient receive cyclosporine csa mg kg day mycophenolate mofetil mmf 30 mg kg day follow csa day1 month progressive withdrawal start month post sct agvhd accord practice center mmf day day +45 arm",
    "STATISTICS": "hypothesis base reduction incidence day 100 posthsct grade iiiv acute gvhd 40 anti thymocyte globulin arm 23 atlg arm assume 10 risk randomised patient would reach transplant incidence compete risk death without gvhd arm account compete risk twosided logrank test overall sample size 324 subject 162 control group 162 treatment group achieve 91 power 05 significance level detect hazard ratio 50 followup time 100 day total 162+162 324 patient include interim analysis schedule perform"
  },
  "CAALLF01": {
    "TITLE": "caallf01 french protocol treatment acute lymphoblastic leukemia child adolescent",
    "JUSTIFICATION": "acute lymphoblastic leukemia curable disease 8090 child 7080 adolescent nevertheless numerous problem remain good result obtain intensive prolonged treatment include risk toxic death sequela secondary malignancy results still insufficient highrisk form particularly exhibit early resistance chemotherapy early bone marrow relapse less 30 month diagnosis still dismal prognosis render prevention mandatory acute lymphoblastic leukemia extremely heterogeneous disease term biology response treatment envisage targeted treatment future render key decipher heterogeneity two cooperative group fralle french center eortcclcg decide elaborate common protocol treatment childhood adolescent acute lymphoblastic leukemia childhood adolescent acute lymphoblastic leukemia france 01 caallf01 two previous study group comparable result eventfree survival overall survival year year year year fralle 2000 2146 pt 84 82 91 89 eortc 58951 1947pts 82 81 89 88 still major question field acute lymphoblastic leukemia optimal use lasparaginase asnase know administer asnase result depletion asparagine circulating blood starve leukemic cell result death indeed use asnase varies protocol consider different brand dose administration modality rythm route intramuscular intravenous infusion three major form asnase currently available coli asparaginase kidrolase france erwinia asparaginase erwinase patient allergy pegylated form coli asparaginase oncaspar usa europe oncasparin usa oncaspar pegylated coli asparaginase pegaspargase manufacture initially enzon shire servier develop goal reduce immunogenicity native asnase addition oncaspar prolonged serum terminal halflife t1 dose less frequently native asnase achievement similar pd usa ccg1962 pivotal clinical trial support firstline use oncaspar children standard risk acute lymphoblastic leukemia 118 randomize receive native pegylated coli asparaginase active pharmaceutical ingredient merck part induction delayed intensification di phase oncaspar administer intramuscularly dose 500 iu month 4week induction phase two 8week di phase native coli asparaginase merck elspar administer intramuscular dose 000 iu month three time weekly dos induction dos di phase children treat oncaspar rapid clearance lymphoblast day day 14 bone marrow aspirate prolonged asparaginase activity treat native form first di phase 26 native asparaginase patient hightiter antibody compare patient receive oncaspar high titer antibody associate low asparaginase activity native arm oncaspar arm rate infection hospitalization safety profile similar arm avramis et al 2002 oncaspar approve treatment acute lymphoblastic leukemia component multiagent chemotherapy usa since 1994 include firstline use since 2006 first line use transfer new oncaspar manufacture sigmatau pegaspargase asparaginase lonza 2011 shire oncasparin europe oncaspar currently available europe differ oncaspar market usa term asparaginase origin kyowahakko lonza although product pegylated sigmatau usa germany poland oncaspar kh kyowahakko register component antineoplastic combination therapy reinduction patient know hypersensitivity native lasparaginase secondline oncaspar kh use first line asparaginase preparation least three european acute lymphoblastic leukemia protocol uk mrc protocol acute lymphoblastic leukemia since 2003 uk bfmaieop protocol acute lymphoblastic leukemia since 2010 germany italy austria switzerland czech republic israel interfant protocol dedicate infant acute lymphoblastic leukemia since 2006 many country since january 2016 european commission grant marketing authorization use oncaspar combination therapy acute lymphoblastic leukaemia paediatric patient birth 18 year adult patient approval baxalta authorize market oncaspar 28 member country european union eu well iceland liechtenstein norway authorization relate onacaspar incorporate active pharmaceutical ingredient manufacture lonza current status asparaginase preparation france january 2016 kidrolase register first line use erwinase available patient allergic native pegylated asparaginase maa france 30 03 2015 oncaspar oncaspar kh available named patient program atuon 19 november 2015 oncaspar receive marketing authorization january 2016 different dose schedule use oncaspar induction therapy currently propose accord firstline acute lymphoblastic leukemia protocol 2500 iu month one infusion cog dfci protocol us use oncaspar lonza 3500 iu month one infusion st jude protocol us oncaspar lonza 2500 iu month two infusion aieopbfm protocol europe oncaspar kh 2500 iu month two infusion eortc protocol belgium oncaspar kh 2500 iu month one infusion interfant 06 protocol mainly europe oncaspar kh 1000 iu month two infusion ukall protocol uk oncaspar kh 1500 iu month two infusion dcog protocol nl oncaspar kh result 2003 protocol ukall interest eventfree survival 86 year overall survival year 92 vora et al lancet oncol 2013 2014 obtain use low dosage per infusion oncaspar kh 1000 iu month intramuscular repeat 15 day interval induction subgroup 482 patient treat ukall 2003 cyk fong et al ash 2011 show dose provide adequate asparaginase activity 100 iu 86 sample study 1st second injection",
    "OBJECTIVE": "french protocol first europe use oncaspar lonza use usa since 2012 first approval 1994 another oncaspar manufacture merck active pharmaceutical ingredient randomized question best way administer pegaspargase cohort child adolescent standard medium risk acute lymphoblastic leukemia randomize receive induction either one infusion oncaspar lonza 2500 iu month day 12 two infusion oncaspar lonza 1250 iu month day 12 day 26 patients receive 2500 iu month 1250 iu month per dose consolidation delay intensification accord initial arm randomization non randomized question high high risk group non randomized intensification scheme asparaginase administration propose induction therapy infusion 2500 iu month day day 12 day 26 administer patient receive 2500 iu month per dose consolidation delayed intensification child adolescent standard medium risk acute lymphoblastic leukemia study two primary objective assess superiority term pk day 33 fractionated scheme assess equivalence tolerance scheme day 12 induction day 49 high high risk group two primary objective define assess pk day 33 assess toxicity intensified scheme day 12 induction day 49 adequate asparaginase activity 100 iu day 33 induction toxicity incidence severe toxicity grade directly asparaginase relate central nervous system thrombosis pancreatitis anaphylaxia hyperbilirubinemia day 12 day 49 treatment anyway day consolidation linked study drug pharmacokinetics pharmacodynamics immunogenicity comparison arm make patient standardrisk mediumrisk acute lymphoblastic leukemia non comparative assessment make patient belong highrisk high riskgroups criterion include cid 16 asparaginase activity asparagine level define timepoints cid 16 incidence asparaginase antibody cid 16 incidence silent inactivation arm induction consolidation intensification phase cid 16 allergic reaction rate arm induction consolidation intensification phase cid 16 percentage patient without switch erwinia asparaginase cid 16 percentage patient receive 95 intend dose asparaginase efficacy comparison arm make patient standardrisk mediumrisk acute lymphoblastic leukemia non comparative assessment make patient belong highrisk high riskgroups criterion efficacy include cid 16 morphological complete remission rate assess whole population subgroup blineage acute lymphoblastic leukemia tcell acute lymphoblastic leukemia cid 16 minimal residual disease end induction tp1 late timepoint tp2 tp3 subgroup patient assess ig tcrbased rqpcr evaluation make whole population within subgroup cid 16 cumulative incidence relapse overall cid 16 cumulative incidence bm relapse central nervous system relapse gonadal relapse combine relapse toxicity comparison arm undertake patient standardrisk mediumrisk acute lymphoblastic leukemia non comparative assessment make patient belong highrisk high riskgroups cid 16 adverse event ae relate asparaginase occur within first week day 49 treatment anyway day consolidation hyperglycemia induce diabetes coagulopathy allergy hyperlipidemia hypertriglyceridemia hypercholesterolemia non central nervous system thrombosis grade 12 ae pancreatitis hyperbilirubinemia cid 16 adverse event relate asparaginase occur day 49 induction anyway day consolidation cid 16 incidence acute lymphoblastic leukemia grade 34 adverse event whatever imputability survival timepoints 5year eventfree survival diseasefree survival overall survival classical outcome measure evaluation survival child acute lymphoblastic leukemia eventfree survival survival time free treatment failure relapse secondary malignancy day treatment randomization randomize arm disease free survival eventfree survival responder measure time complete remission follow induction treatment failure define induction day 35day 42 least blast minimal residual disease 5x102 case available minimal residual disease blast criterion require 2other secondary objective cid 16 evaluate incidence rare subgroup acute lymphoblastic leukemia prognostic value socalled bother subgroup bcrabl like include ebf1pdgfrb mef2dx znf384x tcf3hlf cid 16 year eventfree survival diseasefree survival overall survival rare patient suboptimal reponse therapy induction failure mrdtp1 103 ablclass fusion alls treat imatinib cid 16 imatinib related adverse event immediate long term cf appendix rare patient suboptimal reponse therapy induction failure mrdtp1 103 ablclass fusion alls treat imatinib",
    "DESIGN": "french prospective multicentric cohort study child adolescent acute lymphoblastic leukemia stratify type acute lymphoblastic leukemia ii anticipate risk stratify group bcp acute lymphoblastic leukemia group tcell acute lymphoblastic leukemia randomized clinical trial perform population patient compose standard risk medium risk standard risk check eligibility criterion use two paralell arm randomization design patients allocate either receive one infusion oncaspar 2500 iu month vs infusion 1250 iu month induction therapy dose per infusion induction therapy dose per infusion attribute initial randomization randomized question ask high high risk group lineage patient receive infusion oncaspar 2500 iu month induction 2500 iu month infusion afterwards nevertheless patient submit evalauation term pk pd toxicity efficacy patient include caallf01 study day induction treatment randomization take place day day 11 14 day first infusion pegaspargase day 12 patient belong standard risk medium risk standard risk group",
    "INCLUSION CRITERIA": "cid 120 children adolescent age 12 month 18 yearsblineage lineage acute lymphoblastic leukemia cid 120 written informed consent obtain day treatment nb patient syndrome include randomize see detail protocol section 532",
    "EXCLUSION CRITERIA": "cid 120 l3 burkitt leukemia lmb type protocol cid 120 mixed phenotype acute leukemia criteria cid 120 infant acute lymphoblastic leukemia age 365 day interfant 06 protocol cid 120 secondary leukemia cid 120 patients previously treat chemotherapy steroid expose pt include stratify accord section known allergy pegylated product cid 120 pregnancy women childbearing potential define acute lymphoblastic leukemia woman physiologically capable become pregnant must negative serum pregnancy inclusion reliable contraception exceptoral contraceptive contraception maintain throughout study month treatment discontinuation cid 120 known hiv positivity cid 120 central nervous system thrombosis prophase cid 120 ph+ bcrabl acute lymphoblastic leukemia esphall protocol cid 120 central nervous system thrombosis day 12",
    "INTERVENTION": "oncaspar pegaspargase supply sterile solution beginning trial replace powder solution injection package type singleuse vial contain 750 international units native asparaginase per ml solution oncaspar store refrigeration 2c 8c product must shake frozen must protect light",
    "STATISTICS": "perform base acute lymphoblastic leukemia patient randomize january 2018 request dsmb study november 2017"
  },
  "HAPLO-EMPTY": {
    "TITLE": "haploidentical allogeneic hematopoietic stem cell transplantation posttransplant cyclophosphamide patient acquired refractory aplastic anemia nationwide phase ii study",
    "JUSTIFICATION": "outcomes patient severe aplastic anemia refractory firstline immunosuppressive therapy ist lack match unrelated donor remain poor recently use eltrombopag show blood count improvement 40 patient however refractory patient respond eltrombopag secondline treatment therefore expose lifethreatening infection bleed past decade significant decrease infection related mortality patient severe aplastic anemia unresponsive initial ist clonal evolution include paroxysmal nocturnal hemoglobinuria myelodysplastic syndrome mds acute myeloid leukemia still occur longterm grim prognosis overall overall survival patient acquired refractory severe aplastic anemia eltrombopag 6070 year hematopoietic stem cell transplantation use alternative donor source mismatch unrelated donor cord blood cbt haploidentical family donor may curative patient refractory severe aplastic anemia despite carry much high rate complication transplantation match relate unrelated donor recently group show cbt valuable curative option young adult refractory severe aplastic anemia however patient available cb cbt treatment related mortality high adult patient haploidentical haplo relate donor stem cell transplantation haplosct improve dramatically outcomes use tcell replete graft administration posttransplantation cyclophosphamide ptcy preliminary result little number patient refractory severe aplastic anemia kings college london uk john hopkins baltimore usa seem promise retrospectively analyze data 36 patient median age 42 year transplant 2010 2017 europe behalf severe aplastic anemia work party european blood marrow transplantation group 1year overall survival 80 suggest approach might valid option particular poor clinical situation",
    "OBJECTIVE": "main objective demonstrate benefit term 2year overall survival rate 60 historical rate patient acquired refractory idiopathic aplastic anemia 80 use haplosct ptcy primary endpoint 2year overall survival rate 80 secondary objective clinical biological outcome graft failure graft versus host disease progression free survival relapse nonrelapse mortality overall survival quality life chimerism immune reconstitution secondary endpoints graft failure incidence neutrophils platelet engraftment day 100 consecutive day neutrophile consecutive day platelet 20 absolute number neutrophil platelet month month month month month 12 day last platelet red blood cell transfusion incidence use growth factor poor hematopoietic reconstitution acute graft versus host disease incidence month month date maximum grading first line treatment response steroid treatment course case steroid refractory graft versus host disease chronic graft versus host disease incidence date grading month 24 relapse incidence month 12 month 24 progression free survival month 12 month 24 incidence cmv ebv infection month 12 severe infection ctae grade 34 month month month 12 month 24 nonrelapse mortality month 24 incidence cardiac toxicity month 12 overall survival month 12 quality life questionnaire inclusion post transplantation month month month 12 month 24 chimerism month month month month 12 month 24 immune reconstitution analyze nk regulatory cell level peripheral blood month month month 12 month 24 posttransplantation ferritin level month month month 12 month 24",
    "DESIGN": "phase ii multicenter national prospective cohort study",
    "INCLUSION CRITERIA": "patients age 35 year acquired refractory idiopathic aplastic anemia indication haploidentical allogeneic hematopoietic stem cell transplantation patients aged 35 year old suffering refractory acquire idiopathic aplastic anemia least one course immunosuppression antithymocyte globulin absence genoidentical donor 10 10 match donor identification haploidentical donor brother sister parent adult child cousin absence donor specific antibody detect patient mfi 1500 antibody direct towards distinct haplotype donor recipient usual criterion hematopoietic stem cell transplantation ecog severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function asat alat 5n total bilirubin 2n creatinine 150 mol health insurance coverage contraception method must prescribe duration research women men childbearing age must use contraceptive method within 12 month month last dose cyclophosphamide respectively sign write informed consent parent patient age less 18 nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable transdermal progestogenonly hormonal contraception intrauterine hormonalreleasing system ius sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom",
    "EXCLUSION CRITERIA": "patients morphologic evidence clonal evolution patient isolated bone marrow cytogenetic abnormality also eligible uncontrolled infection seropositivity hiv htlv1 active hepatitis define positive pcr hbv hcv associate hepatic cytolysis cancer last year except basal cell carcinoma skin situ carcinoma cervix pregnant hcg positive breastfeeding receive attenuated vaccine within month transplantation uncontrolled coronary insufficiency recent myocardial infarction month current manifestation heart failure uncontrolled cardiac rhythm disorder ventricular ejection fraction 50 heart failure accord nyha ii preexisting acute hemorrhagic cystitis renal failure creatinine clearance 30ml min urinary tract obstruction contraindication treatment use research debilitating medical psychiatric illness preclude understand inform consent well optimal treatment followup tutorship curatorship",
    "INTERVENTION": "conditioning regimen fludarabine 30mg month day day day pretransplant cyclophosphamide 14 mg kg day day day total body irradiation gray day1 stem cell source bone marrow graft versus host disease prophylaxis rabbit atg dose mg kg day mg kg day cyclophosphamide 50 mg kg day d+3 d+4 tacrolimus residual 812 microg mycophenolate mmf d+5 absence graft versus host disease mmf stop day 35 tacrolimus day 365 prevention ebv reactivation rituximab 150mg month intravenously day+5 post hematopoietic stem cell transplantation infusion rituximab precede administration antipyretic antihistaminic paracetamol diphenhydramine",
    "STATISTICS": "justification sample size hypothesize 2year overall survival 80 versus 60 historical control twosided onesample logrank test calculate sample 31 subject achieve 80 power 050 significance level detect proportion overall survival 80 new group proportion overall survival historic control group 60 year terminal analysis realize observation required number event"
  },
  "KAPVEC": {
    "TITLE": "phase ii multicenter study talimogene laherparepvec classic endemic kaposi sarcoma",
    "JUSTIFICATION": "kaposi sarcoma lymphangioproliferation associate human herpes virus hhv8 promote immunosuppression hivrelated kaposi sarcoma iatrogenic posttransplantation kaposi sarcoma treat immune restoration association local systemic therapy chemotherapy require conversely classic endemic kaposi sarcoma underlie relative immunosuppression directly target treatment poorly codify mostly base surgery radiotherapy localized kaposi sarcoma aggressive form visceral involvement treat chemotherapy interferon give best 3060 transient response may well tolerate elderly patient talimogene laherparepvec first oncolytic immunotherapy approve fda metastatic unresectable melanoma injectable nodal cutaneous lesion design induce tumor regression injected lesion direct lytic effect uninjected lesion induction systemic antitumor immunity merkel cell carcinoma another virusinduced tumor treatment pd1 pdl1 axis inhibitor prove efficacy thus provide proof principle immunotherapy could effective virusinduced tumor two case metastatic merkel cell carcinoma succesfully treat talimogene laherparepvec recently report suggest talimogene laherparepvec may also effective therapeutic option considering high immunogenicity viral epitope kaposi sarcoma tumor role immune evasion development kaposi sarcoma cutaneous manifestation 90 patient easily inject classic endemic kaposi sarcoma good tumor model target talimogene laherparepvec",
    "OBJECTIVE": "main objective assess whether talimogene laherparepvec clinically inactive partial+complete response probability 10 truly active partial+complete response probability 40 classic endemic kaposi sarcoma primary endpoint best overall response rate define occurrence complete response partial response injected lesion follow pga criterion pga record start treatment month beginning specific therapy kaposi sarcoma occur month secondary objective safety profile talimogene laherparepvec classic endemic kaposi sarcoma parameter efficacy best response response rate duration response efficacy injected uninjected lesion quality life exploratory objectives characterize efficacy talimogene laherparepvec relate immunologic viral assessment tumor biopsy blood sample secondary endpoint adverse event follow ctcae v5 best overall response rate accord actg criterion response rate month response rate lymphedema time response duration response response injected uninjected target lesion deaths cause kaposi sarcoma adapted dlqi score exploratory endpoint characterize immune tumor infiltrate immune cell quantification viral infiltrate tumor necrosis treatment hhv8 viral load blood tumor cell hhv8 sequence",
    "DESIGN": "phase ii multicentre single arm open label trial kaposi sarcoma",
    "INCLUSION CRITERIA": "adult patient classic endemic histologically confirm kaposi sarcoma progressive require systemic therapy injectable measurable disease define least cutaneous lesion 10mm large diameter previously irradiated field least cutaneous lesion 10mm large diameter available repeat cutaneous biopsy previously irradiate field nb cutaneous lesion replace cluster small lesion edge edge distance mm big diameter cluster meet previous criterion willing provide tissue cutaneous biopsy least week washout kaposi sarcoma specific therapy include topical treatment chemotherapy radiotherapy immunotherapy include interferon provide write informed consent prior performance study specific procedure 18 year age day sign informed consent performance status ecog performance scale demonstrate adequate organ function haematological absolute neutrophil count 1500 mm3 platelets 100 000 mm3 haemoglobin dl renal serum creatinine upper limit normal calculate creatinine clearance 40ml min use mdrd formula subject creatinine level upper limit normal hepatic ast sgot alt sgpt 5xuln serum total bilirubin 5xuln direct bilirubin upper limit normal subject total bilirubin level 5xuln pt1 ptt tca female subject childbearing potential negative serum pregnancy within 72 hour prior receive first dose study medication health insurance",
    "EXCLUSION CRITERIA": "known history organ transplantation include allogeneic stemcell transplantation hiv hiv antibody detect selection symptomatic visceral involvement kaposi sarcoma include brain metastasis active autoimmune disease require systemic treatment require systemic treatment past year use disease modify agent corticosteroid immunosuppressive drug replacement therapy eg thyroxine insulin physiologic corticosteroid replacement therapy adrenal pituitary insufficiency etc consider form systemic treatment patients vitiligo type diabetes mellitus hypothyroidism psoriasis non require systemic treatment permit enrol evidence clinically significant immunosuppression following primary immunodeficiency state severe combined immunodeficiency disease concurrent opportunistic infection receiving systemic immunosuppressive therapy include oral steroid dose 10 mg day prednisone equivalent within day prior enrolment clinically significant cardiac dysfunction symptomatic heart failure clinically significant arrhythmia conduction disorder active herpetic skin lesion prior complication hsv infection eg herpetic keratitis encephalitis intermittent chronic systemic intravenous oral treatment antiherpetic drug eg acyclovir intermittent topical use previous treatment talimogene laherparepvec oncolytic virus prior radiotherapy field overlap injection sit prior immunosuppressive chemotherapy radiotherapy biological cancer therapy major surgery within 28 day prior enrollment recover ctcae grade good adverse event due kaposi sarcoma therapy administer 28 day prior enrollment prior therapy tumor vaccine received live vaccine within 28 day prior enrolment currently treatment another investigational device drug study less 28 day since end treatment another investigational device drug study acute chronic active hepatitis hbs ag detect infection hcv rna detect inclusion active tb bacillus tuberculosis known additional malignancy currently progress require active treatment within last year exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergo potentially curative therapy situ cervical cancer sensitivity product component administer psychiatric substance abuse disorder would interfere cooperation requirement trial pregnant breastfeeding expect conceive father child within projected duration trial month last dose talimogene laherparepvec subjects unwilling minimize exposure blood body fluid individual high risk hsv1 induced complication immunosuppressed individual individual know hiv infection pregnant woman infant age month talimogene laherparepvec treatment 30 day last dose talimogene laherparepvec pregnant breastfeeding expect conceive father child within projected duration trial female subject childbearing potential unwilling use acceptable method effective contraception study treatment month last dose talimogene laherparepvec sexually active subject partner unwilling use male female latex condom avoid potential viral transmission sexual contact treatment within 30 day treatment talimogene laherparepvec addition male participant donate sperm month last dose vulnerable subject prisoner incarcerate follow administrative court decision subject psychiatric disorder involuntary hospitalize subject legal protection measure subject express consent",
    "INTERVENTION": "talimogene laherparepvec dose 10 pfu ml week 10 ml week every week 4ml injection route intralesional injection duration treatment month 12 cycle",
    "STATISTICS": "simon stage optimal design interim analysis plan patient"
  },
  "FIBRAPLO": {
    "TITLE": "haploidentical transplantation patient myelofibrosis phase prospective multicentric study",
    "JUSTIFICATION": "curative treatment patient primary secondary myelofibrosis allogeneic hematopoietic stem cell hsct report intermediate high risk patient accord international prognostic score benefit hsct term survival kroger et al 2015 2013 conduct france prospective trial test use ruxolitinib transplantation jakallo study nct01795677 outcome patient well patient transplant matched sibling donor unrelated donor confirm study kroger et al 2009 rondelli et al 2014 jakallo trial acute gvhd incidence high often hyperacute severe recently ebmt group report registry study familial haploidentical transplantation haplo patient myelofibrosis raj et al 2018 posttransplant cyclophosphamide use 59 case oneyear overall survival diseasefree survival 61 58 favorably compare outcome unrelated transplantation genova team also report impressive result haploidentical transplantation center bregante et al 2015 bregante et al report outcome cohort transplant 2000 2010 2011 2014 main difference period frequent use haplo second period 54 versus outcome much well second period overall survival 70 versus 49 author suggest improvement relate best outcome among haplo transplantation improvement outcome haplo attribute good gvhd prophylaxis especially use posttransplant cyclophosphamide given poor outcome unrelated transplantation especially hla mismatch unrelated setting encouraging result family haplo identical transplantation current study proposes test haploidentical transplantation myelofibrosis patient without match related donor",
    "OBJECTIVE": "main objective diseasefree survival without rejection one year haploidentical transplantation patient primary secondary myelofibrosis main criterion judgement disease rejection free survival 12 month hsct assess incidence acute gvhd grade 100 day incidence acute gvhd grade 100 day engraftment 100 day incidence chronic gvhd 12 month nonrelapse mortality 12 month overall survival 12 month relapse progression incidence 12 month rejection incidence 12 month time neutrophil engraftment 100 day time platelet engraftment 100 day infection incidence 100 day 12 month cytokine profile transplantation day7+ day day day 7+ day impact genetic alteration overall survival 12 month nonrelapse morality 12 month",
    "DESIGN": "phase multicentric study goal show haploidentical hsct use thiotepa fludarabine combination treosulfan give acceptable result even good transplantation hla mismatch 10 donor close match unrelated donor patient myelofibrosis",
    "INCLUSION CRITERIA": "patients myelofibrosis contraindication transplant advanced disease international score could propose trial hlamatched donor patients age 18 70 year primary myelofibrosis myelofibrosis secondary essential thrombocythemia polycythemia vera proven marrow biopsy myelofibrosis combine least following criterion constitutional symptom weight loss 10 one year fever without infection recurrent muscle bone join pain extreme fatigue anemia hemoglobin 10 gr dl red blood cell transfusion requirement thrombocytopenia 100 peripheral blast count least find time white blood cell count 25 cytoreductive treatment karyotype +8 7q 17q 5q 12p inv 11q23 performance status accord ecog health insurance coverage sign write informed consent women agree take nomegestrol acetate contraception month treatment treosulfan men agree conceive child month treatment treosulfan",
    "EXCLUSION CRITERIA": "myelofibrosis transform acute leukemia poor performance status ecog cardiac failure ef 50 currently past even correct treatment renal failure creatininemia 130 mol clearance 50ml min respiratory function alter vital capacity 70 force expired volume 70 biological significant liver abnormality asat alat normal range bilirubin normal range hla match donor available tutorship curatorship unwilling unable comply protocol pregnant woman breastfeed contraindications treosulfan hypersensitivity active substance active noncontrolled infectious disease fanconi anaemia dna breakage repair disorder administration live vaccine contraindications circumstance preclude use drug involve protocol especially thiotepa fludarabine",
    "INTERVENTION": "treosulfan investigational medicinal product use condition regimen haploidentical transplantation treosulfan receive euwide approval toxicity reduce conditioning therapy prior allogeneic haematopoietic stem cell transplantation june 25 2019 provide medac treosuflan conditioning regimen administer followed 10 gr month per day iv route use combination standard association thiotepa mg kg day fludarabine 30 mg month per day day day therefore thiotepa fludarabine indissociable treosulfan also consider medicinal product na",
    "STATISTICS": "analysis base intenttotreat basis include patient whatever administer treatment study sensitivity analysis perform patient actually receive graft patient consent withdrawal positive report use data exclude baseline summary statistic namely percentages median interquartile range iqr perform right censor endpoint estimate use nonparametric method kaplan meier curve cumulative incidence curve consider case noninformative informative censoring base logrank test gray test respectively adjustment potential confounders use cox proportional hazard model model assumption check use test proportional hazard spline smoothing residual loglinearity assumption statistical analysis perform sas sas inc cary nc http www rproject org software package"
  },
  "SONIMEL": {
    "TITLE": "safety efficacy blood brain barrier open implantable device sonocloud combine nivolumab use alone association ipilimumab brain metastasis patient malignant melanoma",
    "JUSTIFICATION": "anti pd1 monoclonal antibody nivolumab pembrolizumab alone association antictla4 ipilimumab establish indisputable treatment metastatic melanoma unprecedented overall survival indicate firstline treatment include patient braf mutation given high molecular weight penetration brain sanctuary uncertain relies disruption blood brain barrier occur occasionally sonocloud implantable device deliver low intensity pulse ultrasound along systemic injection ultrasound resonator sonocloud demonstrate safe efficient repetitively open blood brain barrier anticipate blood brain barrier opening could help increase brain penetration monoclonal antibody potentially boost immunity brain could translate control brain disease magnitude extracranial disease would also open avenue optimize treatment brain metastasis combination checkpoint inhibitor many cancer",
    "OBJECTIVE": "one single objective one single endpoint main objective determination successful dose define dose high probability blood brain barrier open efficacy without toxicity directly relate ultrasound emission primary endpoint success define grade blood brain barrier opening disruption pulsed ultrasound use sonocloud system without toxicity relate device assess clinically use brain mri dlt evaluate first week treatment nivolumab alone week treatment nivolumab ipilimumab thus primary endpoint success define efficacy without toxicity first week treatment nivolumab alone week treatment nivolumab ipilimumab secondary objective clinical efficacy nivolumab ipilimumab context blood brain barrier opening study population safety nivolumab alone combine ipilimumab context blood brain barrier open secondary endpoint best overall response rate objective response rate month best intracranial overall response rate bicorr icorr month best extracranial overall response rate becorr ecorr month progression free survival month month 12 18 24 month intracranial progression free survival intracranial ipfs month month 12 18 24 month extracranial progression free survival extracranial epfs month month 12 18 24 month overall survival month month 12 18 24 month safety use ctcae version clinical activity assess use tep tdm scans extracranial lesion mri intracranial metastasis clinical objective response rate define rano immunotherapy rano recist version immunerelated response criteria progression free survival define time day immunotherapy perfusion sonication disease progression accord recist version 1and rano immune relate response criteria death whichever first",
    "DESIGN": "21 patient treat maximum considering maximum 10 would withdraw participate research budget 21+2 23 patient consider",
    "INCLUSION CRITERIA": "advanced brain metastasis melanoma patient age 18 year patients histologically confirm metastatic melanoma patients must recover side effect recent systemic local treatment metastatic melanoma grade least one measurable brain metastasis 5mm 35mm diameter previously treat surgery radiosurgery locate less cm skull patients may receive prior radiosurgery surgery brain metastasis receive prior local treatment must least 1new rano recist assessable brain metastasis braf status wild type mutate case previous treatment braf inhibitor mek inhibitor allow eastern cooperative oncology group performance status age 18 year hemoglobin 10g dl platelets 100000mm3 neutrophils 1500 mm3 creatinine clearance 50ml mn ast 3n alt 3n total bilirubin 5n alkaline phosphatase 3n inr prothrombin 70 tca hepatocellular insufficiency unhealed wound head allergy poly isoprene signed informed consent patient health insurance coverage life expectancy month",
    "EXCLUSION CRITERIA": "ocular melanoma symptomatic leptomeningeal involvement symptomatic hemorrhagic brain metastasis symptoms incoercible intracranial pressure patient receive corticosteroid patient present intermittent seizure enrol stable dose corticosteroid 30mg day corticotherapy antiepileptic treatment since least week enrolment indication urgent neurosurgery radiotherapy prior malignancy active within previous year except locally curable cancer apparently cure stage untreated chronic lymphoid leukemia known hiv infection ongoing infectious disease significant background concurrent administration anticancer therapies administer study treatment cytotoxic investigational drug antictla4 target therapy week halflives targeted therapy chemotherapy prior day study prior whole brain radiotherapy pregnant lactate woman patient auto immune disease contraindications nivolumab alone association ipilimumab define spc http www vidal fr substances 24410 nivolumab serious uncontrolled medical disorder opinion investigator may increase risk associate study participation study drug administration impair ability patient receive protocol therapy interfere interpretation study result allergy iodine gadolinium lidocaine contraindications sonovue hypersensibility sulfur hexafluoride recent acute coronary syndrome unstable ischemic heart disease congestive heart failure class iii iv define new york heart association concurrent treatment dobutamine severe pulmonary arterial hypertension uncontrolled systemic hypertension respiratory distress syndrome concurrent treatment cns benzodiazepin sedative hypnotic antihistaminic pro convulse drug butyrophenons phenothiazin conventional antipsychotic barbituric mao inhibitor anticholinergic drug accord investigator cause cerebral toxicity due blood brain barrier open concurrent anticoagulant antiplatelet therapy uncontrolled epilepsy mri contra indication claustrophobia intracorporal metallic material phlebitis active pulmonary embolism prisoners subject involuntarily incarcerate psychological familial sociological geographical condition potentially hamper compliance study protocol followup schedule condition discuss subject registration trial treatment drug authorize special condition stable dosage month prior inclusion inhibitors acetylcholine esterase donepezil aricept galantamine rivastigmine memantine atypical antipsychotic eg quetiapine antidepressants mao inhibitor anticholinergic dose 20 mg kg thyroid hormone implantation sonocloud possible accord neurosurgeon patient morphological characteristic skin characteristic bone thickness neurosurgeon opinion prevent implantation device may impair ability patient receive treatment sonocloud would exclude",
    "INTERVENTION": "",
    "STATISTICS": "adaptive bayesian doseescalation model continual reassessment method crm use selected version crm modelbased design dose dlt relationship model cumulative function correspond oneparameter power model parameter sequentially estimate data via bayesian estimation setting mtd populationparameter refers 10th percentile dosetoxicity relationship total ultrasound dose level evaluate 78 03 mpa minimum three patient include dose level october 2022 patient treat level 78mpa patient level 9mpa side effect toxicity observe good tolerance since crm design recommend new patient could treat high level 03mpa patient n5 receive 03mpa dose"
  },
  "DREPA-RIC": {
    "TITLE": "prospective multicenter trial compare allogeneic match related haematopoietic stem cell transplantation reduced intensity condition regimen standard care adolescent adult severe sickle cell disease",
    "JUSTIFICATION": "although survival child sickle cell disease dramatically improve last decade us europe mortality remain high adult moreover many child adult develop chronic debilitating condition due organ damage allogeneic hematopoietic stem cell transplantation currently unique curative approach allow cure 95 child transplant match relate donor myeloablative conditioning regimen date study address role hematopoietic stem cell transplantation sickle cell disease adult due risk graft versus host disease toxicity expect old patient high risk organ damage development safe nonmyeloablative conditioning regimen allow stable mixed chimerism avoid graft versus host disease appear attractive option hematopoietic stem cell transplantation cure adult severe sickle cell disease four group previously report encouraging result total 81 patient transplant match related mobilized peripheral blood cell non myeloablative conditioning regimen alemtuzumab low dose total body irradiation follow posttransplant sirolimus study demonstrate high sickle cell disease free survival rate death relate transplant graft failure graft versus host disease ninety two percent patient cure normalized hemoglobin level resolution hemolysis stable hemoglobin level identical proportion observe donor 36 however outcome comparison patient transplant patient transplant lack design prospective multicenter trial target patient 15 year severe sickle cell disease compare nonmyeloablative transplant match related donor identify versus hematopoietic stem cell transplantation patient lack match related donor",
    "OBJECTIVE": "main objective assess benefit hematopoietic stem cell transplantation year event free survival calculate inclusion compare standard care primary endpoint 2year event free survival event define death cause acute grade iiiv graft versus host disease accord magic consortium 2016 appendix 20 moderate severe chronic graft versus host disease accord nih classification hospitalization voc define accord usual criterion one acs define usual clinical criterion pulmonary infiltrate chest film thoracic computedtomography scan stroke define clinical event confirm mri cerebral cervical stenosis 25 new territory evaluate mri mra apparition silent infarct increase least +10 tricuspid regurgitation velocity confirm echocardiography perform delay least month compare pre inclusion value patient trv inclusion hypothesize 2year event free survival 80 hematopoietic stem cell transplantation versus 40 notransplant group secondary objective compare group year overall survival total day require hospitalization first month postinclusion acute complication sickle cell disease voc acs priapism stroke silent infarct cerebral cervical stenosis mra mri hemolytic index hematologic biochemical parameter organ function kidney eye heart lung liver bone grade iiiiv infectious complication need transfusion month postinclusion alloimmunization rate iron overload chronic use oral opioids nutritional involvement gonadic function fertility quality life anxiety depression cost evaluate transplant group chimerism engraftment graft versus host disease patient free sirolimus year posttransplant secondary end point death number day require hospitalization exclusion first month postinclusion clinical adverse event number voc acs require hospitalization number hospitalization intensive care unit number priapism number stroke changes biological parameter ldh aminotransferase gammagt alkaline phosphatase bilirubin pr aptt hemoglobin level hematocrit mean corpuscular volume percentage hemoglobin variant reticulocyte white blood cell platelet count estimate glomerular function rate microalbuminuria creatininuria ratio ferritin transferrin saturation level gonadic function spermogram men lh fsh oestrogen woman testosterone men month 24 number amenorrhea woman number parity eye function heart pulmonary hypertension auricular ventricular dilatation leave ventricular mass function transthoracic echocardiography lung function pulmonary function test min walk test bone function new episode avascular osteonecrosis fracture central nervous system function mra mri liver heart magnetic resonance imaging iron overload evaluation patient ferritin 1000 microg inclusion month 12 month 24 number red blood cell pack transfuse month postinclusion number delayed hemolytic transfusion reaction oral opioid consumption quality life questionnaire mos sf36 hospital anxiety depression scale questionnaire change weight severe infection ctae score grade 34 gvhd incidence grading hematopoietic stem cell transplantation patient chimerism hematopoietic stem cell transplantation assess total blood population lymphocyte subset cost evaluate day hospitalization inclusion",
    "DESIGN": "quasi experimental design phase prospective control multicenter cohort study group patient define genetic randomization eligibility criterion informed consent obtain hla typing perform identify potential hla match related donor define group group expose patient hla identical sibling identify patient receive hematopoietic stem cell transplantation group unexposed patient patient lack hla identical sibling receive best standard care transplant arm redcell exchange perform reduce hemoglobin level 30 less month precede transplant condition regimen consist 300cgy total body irradiation day alemtuzumab iv total dose 1mg kg day day day stem cell source gcsf mobilized peripheral blood stem cell cd34 target dose 10 106 per kg body weight graft versus host disease prophylaxis consist sirolimus year sirolimus taper stop 15 month post transplant transplant arm patient receive best standard care accord situation previous treatment initiation hydroxyurea continuation optimization dose hydroxyurea initiation continuation transfusion program initiation new drug prove improve sickle cell disease authorization use france",
    "INCLUSION CRITERIA": "adolescents young adult 1545 year sickle cell disease patient ss s0 aged 15 45 year least one non sickle cell disease sibling 16 year parental couple present least one following criterion voc require hospitalization last year least severe acs within past year define follow acs require red cell transfusion hospitalization intensive care unit acs pao2 60mmhg arterial blood ph 35 pac02 50mmhg need liter 02 mn reach sat02 98 voc require hospitalization last year history recurrent acs three history ischemic stroke cerebral cervical arterial stenosis 25 apparition silent infarct last year pulmonary hypertension define mean pulmonary artery pressure 25 mmhg rest determine right heart catherization osteonecrosis least joint include one diagnose past year sickle nephropathy estimate glomerular filtration rate ckd epi formula 100 ml min 73m2 persistant microalbuminuria microalbuminuria creatininuria ratio 10 mg mmol without cause nephropathy requiring treatment hydroxyurea chronic transfusion already treat hydroxyurea transfusion program inclusion patients already receive chronic transfusion voc acs respond hydroxyurea eligible provide beginning chronic transfusion least voc require hospitalization last year least severe acs within past year define follow acs require red cell transfusion hospitalization intensive care unit acs pac02 60mmhg arterial blood ph 35 pac02 50mmhg need liter o2 mn reach sat02 98 voc require hospitalization last year history recurrent acs three contraception study period sirolimus woman child bear potential signed informed consent amenable hla typing hematopoietic stem cell transplantation hlaidentical sibling available patients affiliate french health care insurance age 16 60 year hb electrophoresis aa ac donor usual clinical biological eligibility criterion gcsf mobilization peripheral blood stem cell bone collection include legal viral serology assessment authorize transplant hla identical patient negative covid19 test time hematopoietic stem cell transplantation mobilization patient several potential donor several match sibling donor abo match donor choose priority",
    "EXCLUSION CRITERIA": "performance status ecog scale pulmonary function fev1 et fvc 50 theorical value post capillary severe precapillary pulmonary hypertension measured mean pulmonary artery pressure rest 35 mmhg cardiac ejection fraction 45 estimated glomerular fraction rate 50ml mn 73m2 conjugate bilirubin 50 mole cirrhosis alat 4n severe uncontrolled infection known hypersensitivity alemtuzumab known hypersensitivity murin protein following excipients disodium edetate polysorbate 80 potassium chloride potassium phosphate monobasic sodium chloride dibasic sodium phosphate water injection positivity hiv pregnancy breastfeeding woman alloimmunization delayed hemolytic transfusion reaction preclude red cell transfusion previous solid organ transplant hematopoietic stem cell transplant uncontrolled hypertension history arterial dissection cervicocephalic artery history angina pectoris myocardial infarction",
    "INTERVENTION": "patients receive best standard care accord situation previous treatment initiation hydroxyurea continuation optimization dose hydroxyurea initiation continuation transfusion program initiation new drug prove improve sickle cell disease authorization use france",
    "STATISTICS": "single efficacy analysis plan efs compare two group use logrank test effect hematopoietic stem cell transplantation assess hazard ratio use cox model primary endpoint event free survival year calculate inclusion event define followed death cause acute grade iiiv graft versus host disease accord magic consortium 2016 appendix 20 moderate severe chronic graft versus host disease accord nih classification hospitalization voc define accord usual criterion one acs define usual clinical criterion pulmonary infiltrate chest film thoracic computedtomography scan stroke define clinical event confirm mri cerebral cervical stenosis 25 new territory evaluate mri mra increase least +10 tricuspid regurgitation velocity confirm echocardiography perform delay least month compare pre inclusion value patient trv inclusion apparition silent infarct cerebral cervical stenosis 25 new territory increase 25 previous stenosis evaluate mri mra event free survival year calculate inclusion also describe hematopoietic stem cell transplantation group overall survival define time date inclusion death due cause date last followup propensity score matching analysis also perform sensitivity analysis handle potential residual imbalance arm confounders sequential analysis tolerance data perform use bayesian method hypothesize 2year event free survival 80 hematopoietic stem cell transplantation versus 40 notransplant group"
  },
  "PARADISE": {
    "TITLE": "prospective randomize controlled trial crohn disease exclusion diet vs corticosteroid adult pediatric patient active crohn disease",
    "JUSTIFICATION": "",
    "OBJECTIVE": "main objective assess whether crohn disease exclusion diet superior corticosteroid term endoscopic response patient mildly moderately active luminal inflammatory crohn disease primary endpoint endoscopic response week 16 without corticosteroid far therapeutic intervention assess centralized pseudonymized blind double lecture panel panenteric pillcam crohn capsule endoscopic response define decrease least 50 lewis score patient small bowel crohn disease decrease ses crohn disease least 50 patient colonic crohn disease patient small bowel colonic crohn disease compare baseline value compare arm trial steroidfree clinical remission harveybradshaw index response decrease least point harveybradshaw index steroidfree clinical remission crohn disease activity index 150 response decrease least 70 point crohn disease activity index need therapeutic intervention steroid immunosuppressant new biologic surgery decrease fecal calprotectin least 50 steroid fecal calprotectin less 250 less 100 less 50 creactive protein serum level median harveybradshaw index crohn disease activity index calprotectin creactive protein endoscopic remission define lewis score 135 small bowel ses crohn disease 02 colon without therapeutic intervention surgery biologics dietary intervention endoscopic response remission grade eliakim score segmental endoscopic response remission gut microbiota composition pcr 16 pcr 18s fungi protist metabolomics shotgun metagenomics compliance corticosteroid treatment medication adherence report scale compliance crohn disease exclusion diet dietary habit questionnaires 72h food diary body weight arterial pressure fast serum glucose safety assess adverse event either severe suspect unexpected serious adverse reaction quality life assess short inflammatory bowel disease questionnaire work productivity activity assess work productivity index questionnaire",
    "DESIGN": "multicentre openlabel comparative randomize control single blind superiority",
    "INCLUSION CRITERIA": "patients active crohn disease patients age 16 70 year mild moderate luminal active crohn disease define harveybradshaw index 16 involve small bowel colon treat corticosteroid baseline patients either naive previously expose maximum two class biologics currently receive biologic therapy expose maximum two class biologic therapy include current one patent small bowel assess patency capsule active endoscopic lesion define lewis score 225 small bowel ses crohn disease colon eligibility patient determine least one central reader informed consent participate study patient france israel age less 18 parent informed consent participate study parent agreement require patient age 16 18 netherlands affiliation social security health insurance",
    "EXCLUSION CRITERIA": "inability follow crohn disease exclusion diet 16 week prior intolerance corticosteroid ongoing infection evolve virus disease live vaccine psychotic state control treatment arthritis uveitis main presenting symptom patients severe predominant rectal perianal disease heavy smoker 10 cigarette per day infliximab adalimumab vedolizumab ustekinumab rizankizumab upadacitinib methotrexate azathioprine initiate less month inclusion trial change methotrexate azathioprine infliximab adalimumab vedolizumab upadactinib risankizumab ustekinumab dosage less month inclusion severe pubertal delay tanner tanner height velocity zscore bone mineral density zscore hip lumbar spine know pregnant lactating woman patients already include biomedical research observational study registry cohort biobank persons deprive liberty judicial administrative decision person subject psychiatric care section 32121 32131 person admit health social institution purpose research 11216 france present past history eat disorder include anorexia nervosa",
    "INTERVENTION": "oral corticosteroid prednisolone budesonide",
    "STATISTICS": "base intenttotreat principle based available literature hypothesize 50 patient reach primary endpoint crohn disease exclusion diet arm versus 20 corticosteroid arm plan screen 140 patient include 80 patient 54 randomize crohn disease exclusion diet 26 corticosteroid"
  },
  "MARVEL": {
    "TITLE": "explore venlafaxine pharmacokinetic variability phenotyping approach",
    "JUSTIFICATION": "regarding direct cost social value depression decision antidepressant treatment prescription must optimize much possible development personalized medicine psychiatry may reduce treatment failure intolerance resistance hence burden cost affective disorder hope biomarkers find guide treatment selection might decisive interest able assess individual metabolism activity propose explore relationship activity drugmetabolizing enzyme transporters assess phenotypic approach efficacy antidepressant focus venlafaxine provide reasonable secondstep choice patient depression use extensively psychiatric practice metabolism involve several cytochrome cyp p450 enzyme transporter pgp",
    "OBJECTIVE": "study correlation concentration metabolite odesmethylv v+ odemethylv drug metabolism variability assess phenotypic approach compare responder non responder well patient without side effect cyp2c19 activity prevalence profile metabolism cyp2d6 activity prevalence profile metabolism cyp3a4 activity prevalence profile metabolism pgp activity prevalance profile transport study correlation v+ odemethylv concentration dose v+ odemethylv concentration antidepressant efficacy tolerance study correlation ratio odemethylv cyp2d6 activity study correlation concentration hour auc hour metabolic ratio hydroxyomeprazole omeprazole conduct exploratory association analysis blood biomarkers candidate mrna mirna tolerance efficacy analyse role genetic variation dna determination cyp2c19 2d6 phenotype patient pm profile v+ odemethylv concentration cyp2c19 activity 5hydroxyomeprazole omeprazole hour auc metabolic ratio hour omeprazole oral administration cyp2d6 activity dextrorphan dextromethorphan ratio two hour dextromethorphan oral administration cyp3a4 activity 1hydroxymidazolam midazolam ratio two hour midazolam oral administration pgp activity fexofenadine auc base fexofenadine concentration hour fexofenadine oral administration antidepressant efficacy madrs hamd qids antidepressant tolerance prisem fisber antidepressant observance mars circulating mrna mirna transcript allelic variation cyp2c19 cyp2d6",
    "DESIGN": "interventional study recherche biomedicale",
    "INCLUSION CRITERIA": "patient major depressive disorder madrs 20 despite week regardless dose patient hospitalized outpatient major depressive disorder madrs 20 visit selection patients non responder week regardless dose decision psychiatrist increase dose visit selection male female age 18 year understanding french language able give write inform consent informed consent sign participate study individuals cover social security regimen",
    "EXCLUSION CRITERIA": "patients treat one antidepressant mirtazapine mianserine patients currently treat one drug substrate cocktail esomeprazole sensitivity contraindication substrate drug use current pregnancy desire get pregnant breastfeed bipolar disorder schizophrenia",
    "INTERVENTION": "assessment drugmetabolizing enzyme activity patient give cocktail probe drug oral route one time study capsule omeprazole 10mg ml oral liquid formulation dextromethorphane bromhydrate tussidane 5mg ml syrup mg injectable solution midazolam oral administration midazolam 1mg ml injectable solution tablet fexofenadine 120mg",
    "STATISTICS": "statistical analysis perform sample size reach end point measure available hypothesis prevalence patient cyp2c19 um profile twice high nonresponders comparison responder cyp2c19 metabolic profile comparable caucasians 20 demonstrate prevalence two fold observe nonresponders type error 05 statistical power 80 sample size tabulate accord prevalence response thus anticipate potential large disproportion responders non responder define study inclusion decide include 205 patient allow control type type ii error rate comparison prevalence cyp2c19 um profile among group addition sample size allow study sufficient number cyp2d6 pm im um determine effect cyp2d6 variation odemethylv plasma level efficacy risk adverse event type error rate fix 05 test twosided compare thus 05 multiple imputation popular approach handle pervasive problem miss data biostatistics use usually perform miss random assumption multiple imputation chained equation knowledge flexible approach handle complex pattern miss data include categorical data quantitative data survival data primary analysis perform intenttotreat basis secondary exploratory analysis consider population compliers complete treatment accord schedule protocol"
  },
  "PIPAC": {
    "TITLE": "pressurize intraperitoneal aerosol chemotherapy pipac gastric carcinomatosis phase ii randomize study",
    "JUSTIFICATION": "peritoneal metastasis common pattern advanced gastric cancer lead terminal condition short time whatever recent progress regard systemic chemotherapy use multi drug association median survival limit month altered quality life month patient postulate new innovative health technology deliver intraperitoneal pressurize aerosol chemotherapy doxorubicin cisplatin laparoscopy transform situation offering double survival quality life preservation interestingly pipac procedure make apply repeatedly every week week therapeutic strategy allow improve ip drug impregnation maintain iv chemotherapy meanwhile pipac estok 01 project support six main carcinomatosis national center gather medical surgical team daily support peritoneal carcinomatosis demonstrate efficacy pipac procedure gastric carcinomatosis make radical shift management patient break past strategy",
    "OBJECTIVE": "main objective clinical study primary objective evaluate compare 24 month progression freesurvival patient peritoneal carcinomatosis gastric cancer treat either iv chemotherapy pressurized intraperitoneal aerosol chemotherapy pipac iv chemotherapy alone preservation quality life primary endpoint primary endpoint corresponds 24month progression freesurvival define number patient clinical morphological sign progression death 24 month treatment secondary objectives assessment criterion patients relate morbidity evaluate postoperative day 30 claviendindo classification 17 comprehensive complication index range 100 calculate website https www assessurgery com cci calculator 19 evaluation treatmentrelated toxicity base ct cae classification v5 postoperative pain measure use numeric rating scale 10 postoperative day day every hour obligatory sleep night break quality life evaluate visit patient eortc qlqsto22 questionnaire specific gastric cancer annexe 19 eortc qlqc30 questionnaire annexe 19 quality health status evaluate visit patient eq5d5l questionnaire annexe 19 treatment relate feasibility successive pipac procedure define possibility perform pipac problem access peritoneal cavity disease relate overall survival 24 month define time randomization death secondary resecability rate define ipc laparoscopy treatment",
    "DESIGN": "prospective multicenter randomize openlabel control parallelgroup phase ii clinical trial design evaluate effect pipac doxorubicin cisplatin patient gastric peritoneal metastasis pci peritoneal carcinomatosis gastric cancer",
    "INCLUSION CRITERIA": "major subject peritoneal carcinomatosis gastric cancer patients relate age 18 year performance status white blood cell 500 mm3 neutrophil 500 mm3 platelet 100 000 mm3 creatinemia mg dl creatinine clearance 60 ml min serum total bilirubin mg dl acceptable nutritional condition bmi 18 kg month albumin 30 pre albumin 110 mg effective contraception patient childbearing age written consent obtain prior act research patient social insurance disease relate patient synchronous metachronous peritoneal ovarian metastasis pathologically proven gastric siewert iii adenocarcinoma cancer include adci adenocarcinoma independent cell linitis 10 patients without primary gastric tumor include 11 pci peritoneal cancer index",
    "EXCLUSION CRITERIA": "patients relate weight loss 20 total body weight last three month presence uncontrolled comorbidities include severe chronic disease organ insufficiency contraindication drug contain chemotherapy regimen accord summary product characteristic rcp contraindication cisplatin iv doxorubicin iv accord summary product characteristics force allergy severe toxicity cisplatin renal function impairment contraindicate calculated cockcroft formula measure creatinine clearance less 60 ml min measure creatinine adequately reflect renal function cisplatin cumulative nephrological toxicity doxorubicin risk cardiotoxicity occur immediately delay sinus tachycardia electrocardiogram abnormality cf rcp following website http agence prd ansm sante fr php ecodex rcp r0289737 htm complete deficiency enzyme dihydropyrimidine dehydrogenase patient arm pipac debulking surgery ovariectomy omentectomy permit pipac surgical procedure schedule accordance protocol successive pipac debulking surgery pipac procedure authorize pregnancy breastfeed patient guardianship disease relate malignancy within last year curatively treat basal cell carcinoma skin situ carcinoma cervix systemic metastasis liver lung bone brain lomboaortic lymph node involvement 10 pleural effusion require evacuation respiratory failure 11 small bowel occlusion possible food intake 12 ascites liter 13 participation clinical trial treatment gastric peritoneal metastasis year precede inclusion",
    "INTERVENTION": "intraperitoneal pressurize aerosol chemotherapy cisplatin 10 mg month doxorubicin mg month laparoscopy give 30 min 37c 12 mmhg 6weeks week interval least successive pipac schedule protocol patient receive pipac procedure progression toxicity nonfeasibility procedure research open sponsor center already practice pipac procedure part treatment investigator declare part research undergo training use new pipac procedure patient receive standard poly chemotherapy propose oncologist eox epirubicin oxaliplatin capecitabine ecx epirubicin cisplatin capecitabine folfox folfiri ecf epirubicin cisplatin fluorouracil flot new standard validate study progression toxicity",
    "STATISTICS": "24month progression freesurvival estimate use kaplan meier estimator total sample per arm estimation 95 confidence intervals give test survival curve perform use logrank test hazard ratio estimate use cox model sensitivity analysis perform consider per protocol population"
  },
  "JAKAHDI": {
    "TITLE": "jak inhibitor acquire hemophagocytic syndrome intensive care unit",
    "JUSTIFICATION": "hemophagocytic syndrome rare condition responsible severe organ failure therapeutic guideline mainly base observational study expert opinion therapeutic advance develop year explain mortality hemophagocytic syndrome remain high icu mortality range 40 70 etoposide remain gold standard critically ill hemophagocytic syndrome patient nearly 20 patient refractory therapy treatment escalation common often require administration intensive treatment generate high toxicity ruxolitinib first approve jak inhibitor associate improvement hemophagocytic syndrome manifestation survival preclinical murine model data human scarce promising",
    "OBJECTIVE": "aim demonstrate ruxolitinib association standard care may reverse organ failure represent sofa score good standard care alone critically ill patient acquire hemophagocytic syndrome primary end point survival decrease sofa score point day demonstrate ruxolitinib may improve overall survival hemophagocytic syndrome critically ill patient demonstrate ruxolitinib may reverse clinical temperature sofa score biological ferritin level cd25 soluble receptor dosage fibrinogen level triglyceride level hemoglobin level white blood cell count platelet count manifestation relate hemophagocytic syndrome analyse impact ruxolitinib biological inflammatory marker il2 il6 il10 il12 gmcsf ifn gamma tnf alpha demonstrate safety ruxolitinib critically ill hemophagocytic syndrome patient",
    "DESIGN": "multicenter national uncontrolled phase ii trial base fleming 2stage design",
    "INCLUSION CRITERIA": "adult patient old 18 year adult patient old 18 year acquire hemophagocytic syndrome regardless etiology define presence hlh2004 criterion hscore 200 admission icu need symptomatic treatment hemophagocytic syndrome relation organ failure define sofa score informed consent sign patient inform consent sign family members trustworthy person condition allow express consent write per l11116 emergency situation absence family members trustworthy person patient enrol consent participate research request soon condition patient allow inclusion woman childbearing potential require use highly effective contraceptive measure contraception maintain treatment one day",
    "EXCLUSION CRITERIA": "moribund define life expectancy 48 hour pregnant lactating patient woman childbearing potential must negative urine blood human chorionic gonadotropin pregnancy test prior trial entry affiliation health insurance known hypersensitivity ruxolitinib lactose intolerance hypersensitivity cellulose microcrystalline magnesium stearate silica colloidal anhydrous sodium starch glycolate type povidone k30 hydroxypropylcellulose 300 600 cps preexisting decision withholding withdrawing care history progressive multifocal leukoencephalopathy uncontrolled cutaneous cancer persons psychiatric care would impede understanding informed consent optimal treatment followup adults subject legal protection measure guardianship curatorship safeguard justice patients deprive liberty judicial administrative decision participation another interventional research",
    "INTERVENTION": "patients receive oral ruxolitinib twice day 10 mg 28 day association standard care hemophagocytic syndrome none",
    "STATISTICS": "based 2stage fleming design interim analysis perform day status 21th consecutively enrolled patient observe terminal analysis base intentiontotreat population perform patient recruit unless early stopping"
  },
  "GRAALL-2014/B": {
    "TITLE": "",
    "JUSTIFICATION": "",
    "OBJECTIVE": "primary objective prospectively validate new risk model base mrd1 response level kmt2a mll ikzf1 gene status compare historical result graall 2005 graall2014 identical population patient ph lineage acute lymphoblastic leukemia age 18 59 year old evaluate efficacy blinatumomabbased consolidation maintenance therapy term disease free survival high risk patient graallquest substudy compare historical result graall2005 identical population patient high risk feature graallquest study secondary objective appreciate tolerance blinatumomabbased consolidation cycle bridge allosct within consolidation maintenance therapy evaluate mrd level monitor igtcr evaluate cumulative incidence relapse nonrelapse mortality diseasefree survival overall survival evaluate relapsefree survival cumulative incidence relapse non relapse relate mortality overall survival censor anti thrombin sct first complete remission primary evaluation criterion disease free survival anti thrombin year depend status kmt2a mll ikzf1 gene mrd1 assess induction cure day consolidation disease free survival anti thrombin year graallquest study secondary evaluation criterion cumulative incidence relapse non relapse relate mortality overall survival disease free survival cumulative incidence relapse non relapse relate mortality overall survival censor anti thrombin allosct first complete remission mrd followup anti thrombin different treatment time cf infra mrd monitoring adverse event blinatumomab graallquest",
    "DESIGN": "multicenter open control study standard risk patient phase ii multicenter open non control graallquest high risk patient",
    "INCLUSION CRITERIA": "patients age 1859 year old de novo phnegative blineage acute lymphoblastic leukemia patient whose blood bone marrow exploration complete steroid prephase aged 18 59 year old previously treat include intrathecal injection blineage acute lymphoblastic leukemia newly diagnose accord 2008 definition 20 bone marrow blast whose karyotype show 22 absence molecular biology bcrabl eastern cooperative oncology group without central nervous system testis involvement without evolve cancer except basal cell carcinoma skin situ carcinoma cervix radiotherapy chemotherapy treatment finish anti thrombin least since month sign write informed consent efficient contraception woman childbearing age exclude estrogen intrauterine device health insurance coverage 10 receive receive steroid prephase secondary acute lymphoblastic leukemia antecedent chemo radiotherapy include patient included graall2014 high risk acute lymphoblastic leukemia eastern cooperative oncology group complete remission one two induction cure receive three block consolidation n1 without allogeneic donor",
    "EXCLUSION CRITERIA": "patient lymphoblastic lymphoma bone marrow blast 20 burkitttype acute lymphoblastic leukemia antecedent chronicmyelogenous leukemia myeloproliferative neoplasm contraindication anthracyclines general visceral contraindication intensive therapy except consider relate acute lymphoblastic leukemia aspartate amino transferase alanineaminotransferase upper limit normal total bilirubin upper limit normal creatinine 5x upper limit normal creatinine clearance 50 ml mn myocardial infarction within month prior inclusion trial cardiomyopathy new york heart association grade iii intravenous lvef 50 rf 30 hiv htlvi hcv seropositivity chronic hbv hepatitis hbsagpositive pregnant hcg positive nurse woman able bear procedure frequency visit plan trial unable consent tutelage curatorship judiciary safeguard women childbearing potential willing use effective form contraception participation study anti thrombin least three month thereafter patients willing ensure beget child participation study anti thrombin least three month thereafter treated investigational agent participation another trial within 30 day prior enter study patient eastern cooperative oncology group status consolidation abnormal laboratory value define consolidation ast alt upper limit normal total bilirubin upper limit normal creatinine upper limit normal creatinine clearance 50 ml min serum amylase lipase upper limit normal active uncontrolled infection concurrent disease medical condition deem interfere conduct study judge investigator new york heart association grade 34 cardiac disease infection human immunodeficiency virus hiv chronic infection hepatitis virus hbsag positive hepatitis virus antihcv positive primary monitoring asparaginase activity ammoniemia annex 48h 3rd injection theoretically day 14 secondary monitoring 48 6th injection theoretically day 26 acute lymphoblastic leukemia patient 45 year old sample collection must perform immediately 7th injection able bear procedure frequency visit plan trial",
    "INTERVENTION": "blinatumomab blincyto high risk patient enrol graallquest study cyclophosphamide methotrexate vincristine cytarabine etoposide dexamethasone mercaptopurin daunorubicin idarubicin prednisone lasparaginase granulocyte colony stimulate factor cerebro spinal fluid induction patient receive induction course patients without hematologic complete remission anti thrombin end induction receive salvage therapy differential diagnosis ph+ blineage acute lymphoblastic leukemia prephase patient receive graaph2014 igtcr mrd1 level evaluate anti thrombin end induction cycle orat day first consolidation phase consolidation patient hematologic complete remission induction eventually follow salvage receive interim standby block first consolidation comprise block chemotherapy block s1 s2 s3 standby block allow recover potential toxicity induction notably hepatic avoid modify order following consolidation block respect dosage intensity high risk versus standard risk patients attribute risk group first consolidation accord mrd1 level need salvage obtain chr presence ikzf1 gene deletion kmt2a mll gene rearrangement high risk patient propose phase ii graallquest study 95 inclusion number reach high risk patient would eligible graall quest continue participate study followup plan graall 2014 igtcr mrd2 level evaluate anti thrombin end consolidation day one consolidation consolidation first consolidation standard risk patient continue standard protocol receive consolidation block s4 s5 s6 95 high risk patient traited phase ii graallquest study receive blinotumomab consolidation compose block b4 blina b5 high dose arac b6 high dose methotrexate high risk versus high risk mrd high risk mrd define mrd1 103 need salvage cure reach hematologic complete remission mrd2 104 patients eligible allosct suitable donor receive blinatumomab continuous infusion condition regimen igtcr mrd3 level evaluate anti thrombin day late intensification prior sct allografted patient late intensification administer acute lymphoblastic leukemia nonallografted patient whatever risk group consolidation late intensification patient standard risk receive third consolidation block s7 s8 s9 high risk patient receive second investigational blinatumomabbased consolidation compose block b7 blina b8 high dose arac b9 high dose methotrexate igtcr mrd4 level evaluate anti thrombin day maintenance therapy day 100 sct maintenance therapy whole duration two year classical maintenance therapy acute lymphoblastic leukemia patient base association mercaptopurin methotrexate monthly reinductions associate vincristine prednisone first year patients high risk patient receive blinatumomab course instead vincristine pulse anti thrombin month allogeneic stem cell transplantation sct allogeneic sct first complete remission offer acute lymphoblastic leukemia high risk mrd patient genoidentical familial unrelated donor 10 10 10 allosct early possible second consolidation phase patient 45 year old conditioning myeloablative total body irradiation 12 gy fractionate cyclophophamide 120 mg kg anti thymoglobulin mac myelo ablative conditioning case unrelated allosct patients age 45 year old comorbidity criterion benefit reduce intensity condition total body irradiation fractionate gy dose fludarabine 120 mg month anti thymoglobulin mac myelo ablative conditioning case unrelated allosct patients high risk becarfull sct earlier end first blinatumomab cycle central nervous system involvement patients central nervous system disease anti thrombin diagnosis receive intensified intrathecal therapy lumbar puncture induction central nervous system irradiation perform consolidation intrathecal central nervous system irradiation maintenance induction graall2014 prednisone 60 mg month day 114 vincristine mg ivd day day day 15 day 22 daunorubicin 50 mg month intravenous 30 min day day day 30 mg month intravenous 30 min day 15 day 16 cyclophosphamide 750mg month intravenous 3h day day 15 lasparaginase 6000 ui month slow intravenous 1h day day 10 day 12 day 20 day 22 day 24 day 26 day 28 cerebro spinal fluid kg subcutaneous intravenous day 18 neutrophil 1g intrathecal methotrexate arac depomedrol day day day day age 45y reduce 30 mg month age 45y anti thrombin day day 10 day 12 day 20 day 22 day 24 age 45y substitute erwinase immunization coli lasparaginase salvage idarubicin 12 mg month intravenous 1h day day day aracytine 2000 mg month 12h intravenous 3h day day day day cerebro spinal fluid kg subcutaneous intravenous day neutrophil 1g standard consolidation standard risk patient weekly standby block need etoposide 150 mg month intravenous 1h day aracytine 30 mg month 12h day day blocks s1 s4 s7 d1d14 aracytine 2000 mg month 12h intravenous 2h day day dexamethasone 10 mg 12h day day cerebro spinal fluid kg subcutaneous intravenous day tod12 blocks s2 s5 s8 d15d28 methotrexate 5000 mg month continuousintravenous 24h day 15 vincristine mg ivd day 15 6mercaptopurin 60 mg month day 15 21 cerebro spinal fluid kg subcutaneous intravenous day 22 26 intrathecal methotrexate arac depomedrol day 16 h24 start methotrexate 500 mg month 30 minute 23 hour 30 minute follow folinic acid rescue reduce 3000 mg month age 45y block s3 s6 s9 d29d35 cyclophosphamide 500 mg month intravenous 3h day 29 day 30 etoposide 75 mg month intravenous 1h day 29 day 30 methotrexate 25 mg month day 29 cerebro spinal fluid kg subcutaneous intravenous day 31 neutrophil 1g intrathecal methotrexate arac depomedrol day 29 late intensification patient receive salvage induction prednisone 60 mg month day 14 vincristine mg ivd day day day 15 day 22 daunorubicin 30 mg month intravenous 30 min day day day day 15 day 16 cyclophosphamide 750mg month intravenous 3h day day 15 lasparaginase 6000 ui month slow intravenous 1h day day 10 day 12 day 20 day 22 day 24 day 26 day 28 cerebro spinal fluid kg subcutaneous intravenous day 18 neutrophil 1g intrathecal methotrexate arac depomedrol day day day day age 45y day 1516 age 45y anti thrombin day day 10 day 12 day 20 day 22 day 24 age 45y substitution erwinase immunization coli lasparaginase late intensification patient receive salvage induction idarubicin mg month intravenous 1h day day day aracytine 2000 mg month 12h intravenous 3h day day day day cerebro spinal fluid kg subcutaneous intravenous day neutrophil 1g intrathecal methotrexate arac depomedrol day day 15 maintenance therapy year vincristine mg ivd day month 12 prednisone 40 mg month day day month1 12 methotrexate 25 mg month wk 24 month 6mercaptopurin 60 mg month 24 month intrathecal methotrexate arac depomedrol day month blinatumomab consolidation patient proceed asct begin block s3 blocks b4 b7 d1d34 dexamethasone 40 mg day blina blinatumomab 28 ivc day day 28 intrathecal methotrexate arac depomedrol day blocks b5 b8 d35d49 aracytine 2000 mg month 12h intravenous 2h day day dexamethasone 10 mg 12h day day cerebro spinal fluid kg subcutaneous intravenous day tod12 blocks b6 b9 d50d65 max methotrexate 5000 mg month continuousintravenous 24h day vincristine mg ivd day 15 6mercaptopurin 60 mg month day day cerebro spinal fluid kg subcutaneous intravenous day 12 intrathecal methotrexate arac depomedrol day h24 start methotrexate 500 mg month 30 minute 23 hour 30 minute follow folinic acid rescue reduce 3000 mg month age 45y late intensification patient receive salvage induction prednisone 60 mg month day 14 vincristine mg ivd day day day 15 day 22 daunorubicin 30 mg month intravenous 30 min day day day day 15 day 16 cyclophosphamide 750mg month intravenous 3h day day 15 lasparaginase 6000 ui month slow intravenous 1h day day 10 day 12 day 20 day 22 day 24 day 26 day 28 cerebro spinal fluid kg subcutaneous intravenous day 18 neutrophil 1g intrathecal methotrexate arac depomedrol day day day day age 45y day 1516 age 45y anti thrombin day day 10 day 12 day 20 day 22 day 24 age 45y substitution erwinase immunization coli lasparaginase late intensification patient receive salvage induction idarubicin mg month intravenous 1h day day day aracytine 2000 mg month 12h intravenous 3h day day day day cerebro spinal fluid kg subcutaneous intravenous day neutrophil 1g intrathecal methotrexate arac depomedrol day day 15 blinatumomabbased maintenance therapy year 24 dexamethasone 40 mg day 1h blinatumomab blinatumomab 28 ivc day day 28 month vincristine mg ivd day month 12 prednisone 40 mg month day day month 12 methotrexate 25 mg month wk 24 month 6mercaptopurin 60 mg month 24 month intrathecal methotrexate arac depomedrol day month except 4week blinatumomab month blinatumomab consolidation patient proceed asct begin block s3 dexamethasone 40 mg day blina blinatumomab 28 ivc day day 28 intrathecal methotrexate arac depomedrol day high risk patient suitable donor receive blinatumomab continuously allosct condition regimen stop day",
    "STATISTICS": "year approximately 100 patient phnegative bcell precursor acute lymphoblastic leukemia may recruit frontline graall2014 trial hematologic complete remission achievement one may anticipate approximately 40 standard risk patients year 50 high risk patients year include 3035 high risk mrd patient consolidation standard risk patient treat standard graall protocol without new agent haematopoietic stem cell transplantation first chr objective demonstrate uncontrolled study noninferiority term 4year disease free survival must anti thrombin least 60 control group historical reference margin inferiority 15 justify absence allosct first complete remission 05 unilateral alpha risk 90 power calculated sample size 110 patient 50 high risk patients year eligible graallquest study disease free survival primary endpoint disease free survival compare historical graall2005 result 50 anti thrombin year objective demonstrate 50 65 disease free survival improvement 05 alpha risk 90 power twosided setting calculated sample size 91 patient considering dropout rate 95 patient include present study ref sample size table clinical study machin campbell et al wiley 2009"
  },
  "METIMGAST": {
    "TITLE": "phase ii trial evaluate combination capmatinib spartalizumab advanced oesogastric adenocarcinoma",
    "JUSTIFICATION": "oesoastric advance adenocarcinoma poor prognosis without improvement last decade recently immunotherapy antipd1 antibody provide encouraging result subset patient capmatinib met inhibitor show imunomodulatory effect synergy spartalizumab pd1 inhibitor combination currently evaluate treatment hepatocellular carcinoma whatever met expression",
    "OBJECTIVE": "evaluate tumor response regimen month inclusion overall response rate assess image every week define proportion patient least one objective tumour response complete partial accord recist v1 criterion within month evaluate safety regimen first second cycle administration day 42 day 42 cf chap evaluate safety tolerability regimen whole course treatment kind toxicity year immunotherapyrelated toxicity cf chap 10 characterize tumor response regimen duration time response estimate progression free survival year inclusion estimate overall survival year inclusion according result interim analysis evaluate tolerance efficacy spartalizumab monotherapy patient nonamplified met tumor ancillary study evaluate pharmacokinetics capmatinib accord presence gastrectomy concurrent treatment proton pump inhibitor evaluate tumor response specific subgroup according residual level capmatinib cycle day1 c2d1 according met amplification level fish archival tumor sample according baseline c2d1 neutrophil count circulate hgf level",
    "DESIGN": "multicenter singlearm phase ii trial cohort accord met amplification level cohort tumor without met amplification copy cohort tumor met amplification copy treatment capmatinib 400 mg mgbid spartalizumab300 mg q3w maximum 12 month progression patient refusal unacceptable toxicity cohort interim analysis primary endpoint first 30 evaluable enrolled patient rule stop continue trial specify table paragraph 12",
    "INCLUSION CRITERIA": "patients advanced oesogastric adenocarcinoma receive least one previous chemotherapy line platinium salt fluoropyrimidin documented progression chemotherapy histologically cytologically document locally advanced metastatic oesogastric adenocarcinoma unresectable tumor patients must receive least one prior systemic chemotherapy base platinium salt fluoropyrimidine documented progression chemotherapy patients must receive trastuzumab case her2 positive tumor her2 +++ her2++ fish sish+ determination tumor met amplification fish available ecog performance status measurable tumoral disease accord recist criterion patients must willing able swallow retain oral medication age 18 year women childbearing potential male sexually active must agree follow instruction method contraception duration study treatment capmatinib spartalizumab day last dose capmatinib 150 day last dose spartalizumab consent participate trial information affiliated social security system",
    "EXCLUSION CRITERIA": "previous treatment immunotherapy met inhibitor impossibility take oral medication persistent toxicity relate prior treatment grade great except alopecia grade grade neuropathy relate previous treatment platinium salt presence history another malignant disease diagnose require therapy within past year exceptions exclusion include completely resect basal cell squamous cell skin cancer completely resect carcinoma situ type use live vaccine within week initiation study treatment history severe hypersensitivity reaction monoclonal antibody mabs history current interstitial lung disease non infectious pneumonitis active autoimmune disease documented history autoimmune disease patients vitiligo control type diabetes mellitus stable insulin dose residual autoimmunerelated hypothyroidism require hormone replacement psoriasis require systemic treatment permit allogenic bone marrow solid organ transplant uncontrolled active infection human immunodeficiency virus infection untreated active hepatitis infection hbsag positive patients active hepatitis hbsag positive may enrol provided viral load hbv dna screening 100 ui ml patients may receive antiviral treatment lamivudine tenofovir entecavir antiviral agent initiation study treatment suppress viral replication untreated active hepatitis hcv rna positive patient achieve sustained virological response antiviral treatment show absence detectable hcv rna month cessation antiviral treatment eligible untreated symptomatic central nervous system lesion however patient eligible know central nervous system lesion treat radiotherapy surgery patient remain without evidence central nervous system disease progression week treatment patient must corticosteroid therapy week clinically significant uncontrolled heart disease recent acute coronary syndrome unstable ischemic heart disease congestive heart failure class iii iv define new york heart association long qt syndrome 480 woman 470 men family history idiopathic sudden death congenital long qt syndrome uncontrolled hypertension define systolic blood pressure 150 mm hg diastolic blood pressure 100 mm hg without antihypertensive medication initiation adjustment antihypertensive medication allow prior screen surgery less week radiotherapy less week pregnancy breastfeeding woman childbearing potential unless use highly effective method contraception sexually active male unless use condom intercourse take capmatinib day stop treatment father child period participants receive treatment strong inducer cyp3a could discontinue week prior start treatment systemic chronic steroid therapy 10 mg day prednisone equivalent immunosuppressive therapy day prior plan date first dose study treatment patient range laboratory value define total bilirubin upper limit normal alkaline phosphatase alp upper limit normal alanine aminotransferase alt upper limit normal aspartate aminotransferase ast upper limit normal coagulation prothrombin time second upper limit normal international normalized ratio absolute neutrophil count 109 platelet count 75 109 hemoglobin dl creatinine clearance calculate use cockcroft gault formula measure 45 ml min serum lipase upper limit normal cardiac troponin ctni elevation upper limit normal potassium magnesium phosphorus total calcium correct serum albumin outside normal limit patient may enrol correct within normal limit supplement screen patients legal protection participation another interventional study whith treatment",
    "INTERVENTION": "capmatinib 400 mg bid spartalizumab 300 mg q3w maximum 12 month progression patient refusal unacceptable toxicity applicable",
    "STATISTICS": "two cohort constitute cohort enrol patient met amplification copy specifically total 81 patient ensure 90 power type error rate detect 30 response rate compare reference 15 include interim analysis 30 patient include futility stopping rule use bayesian optimal timeto event phase ii design lin et al jnci 2020 case trial terminate early futility inclusion continue spartalizumab monotherapy 51 additional patient cohort total 81 case sample 50 patient spartalizumab monotherapy allow detect 20 response rate patient monotherapy unacceptable 80 power type error rate use binomial exact comparison cohort enrol patient met amplification copie exploratory purpose enrolment cohort ongoing cohort complete maximum patient sequential continuous toxicity montoring conduct across cohort ivanova et al clin invest 2015 endpoints describe count percentage categorical endpoint toxicity aes mean median 95 confidence interval 95 credibility interval appropriate interquartile range continuous endpoint timeto event endpoint pfs os estimate use nonparametric kaplan meier estimator obtain survival estimate 24 month inclusion analyses perform use statistical platform along datamanagement analysis conduct department biostatistics medical information hopital saint louis paris pr sylvie chevret labelled centre de traitement de donnees inca"
  },
  "RUBI": {
    "TITLE": "multicenter randomize multiarm trial compare efficacy safety adalimumab anakinra tocilizumab subject noninfectious refractory uveitis",
    "JUSTIFICATION": "rubi first prospective randomize head head study compare adalimumab either anakinra tocilizumab refractory niu firm evidence randomize controlled trial directly address best biologic agent severe refractory niu niu cause devastate visual loss 20 legal blindness corticosteroids immunosuppressant fail demonstrate sustainable remission 70 refractory relapsing severe uveitis incidence blindness niu dramatically reduce recent year use biologics raise question whether compound use earlier treatment severe non infectious uveitis contrasting immunosuppressor biotherapies act rapidly highly effective steroid spar thus prevent occurrence cataract glaucoma despite strong rationale compound yet approve uveitis guarantee innovative nature study aim select drop arm evidence efficacy already exist",
    "OBJECTIVE": "primary objective evaluate efficacy adalimumab 80mg 40mg 14 day compare anakinra 100mg day tocilizumab 162mg day subject refractory noninfectious intermediate posterior pan uveitis niu prednisone dose mg kg day prednisone equivalent oral corticosteroid week 16 primary endpoint efficacy measure percentage patient least 2step reduction vitreous haze accord miami 9step scale dose mg kg day prednisone equivalent oral corticosteroid week 16 secondary objectives evaluate change best correct visual acuity evaluate safety adalimumab anakinra tocilizumab patient niu evaluate change macular edema evaluate change sign ocular inflammation evaluate effect retinal vessel leakage evaluate effect adalimumab anakinra tocilizumab steroid sparing evaluate change ocular inflammation anterior chamber evaluate effect underlie systemic disease appropriate evaluate effect ocular disease evaluate number time relapse uveitis characteristic uveitis worsen evaluate time treatment failure secondary endpoints measure 16 week best correct visual acuity change macular edema change sign ocular inflammation retinal vessel leakage steroid sparing ocular inflammation anterior chamber underlying systemic disease appropriate ocular disease number time relapse uveitis characteristic uveitis worsen adverse event time treatment failure",
    "DESIGN": "prospective phase ii clinical trial multicenter multiarm randomize clinical trial compare efficacy safety adalimumab anakinra tocilizumab subject active refractory noninfectious intermediate posterior panuveitis oral corticosteroid stable dose 30 day prior first study drug administration day systemic immunosuppressant must discontinue 30 day prior first study drug administration day patients access oral corticosteroid need day",
    "INCLUSION CRITERIA": "adult patient active refractory noninfectious uveitis niu active disease either presence vh miami 9step scale macular edema crt 300 micron sign intraocular inflammation eg perivascular sheathing retinal vessel leakage retinal vessel fa recently active disease evidence activity within month prior inclusion visit per vh miami 9step scale vh 1+ accord standardization uveitis nomenclature classification macular edema crt 300 micron sign intraocular inflammation perivascular sheathing retinal vessel leakage retinal vessel fa activity status active disease recently active disease confirm patient randomization reading center evaluation vh optical coherence tomography fa assessment refractory disease inclusion subject must receive oral corticosteroid 10 mg day prednisone equivalent 80mg day least one immunosuppressive azathioprine methotrexate mycophenolate mofetyl cyclosporine leflunomide cyclophosphamide interferon ifn intolerant immunosuppressive therapy eligibility criterion check selection visit take place four week maximum prior inclusion visit inclusion randomization visit adult patient meet following criterion may include study provide write informed consent prior performance studyspecific procedure diagnosis noninfectious intermediate posterior panuveitis least one eye fulfil international study group classification criteria standardization uveitis nomenclature standardization uveitis nomenclature criterion posterior pan uveitis confirm documented medical history currently uncontrolled uveitic disease uncontrolled uveitic disease define fulfil two follow criterion within week prior inclusion active inflammatory chorioretinal inflammatory retinal vascular lesion macular edema crt 300 micron vitreous haze grade miami 9step scale vh 1+ accord standardization uveitis nomenclature national eye institute classification patient receive prednisone 10 mg day 80mg day equivalent dose another corticosteroid stable dose 30 day prior first study drug administration day receive least systemic immunosuppressant systemic immunosuppressant must discontinue 30 day prior first study drug administration day patient receive ifn systemic immunosuppressant must discontinue 30 day prior first study drug administration day intolerant immunosuppressant best correct visual acuity early treatment diabetic retinopathy study 20 400 either eye stable dose two week prior inclusion topical corticosteroid nsaids male female age 18 year inclusion weight 40 120 kg 88 264 lb inclusion chest xray thoracic ct scan result posteroanterior lateral within 12 week prior inclusion evidence active tuberculosis active infection malignancy 10 female subject childbearing age negative serum urine pregnancy test 11 subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study month stop therapy roactemra adalimumab respectively birth control method may consider highly effective method achieve failure rate less per year use consistently correctly consider highly effective birth control method accord ctfg recommendation method include combine estrogen progestogen containing hormonal contraception associate inhibition ovulation oral intravaginal transdermal progestogenonly hormonal contraception associate inhibition ovulation oral injectable implantable intrauterine device intrauterine hormonereleasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence consider highly effective method define refrain heterosexual intercourse entire period risk associate study treatment reliability sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle subject 12 quantiferontuberculosis test within month prior screening",
    "EXCLUSION CRITERIA": "subjects include study meet following criterion infectious uveitis masquerade syndrome idiopathic uveitis permit isolated anterior uveitis presence cataract posterior capsular opacification severe assessment posterior segment either eye inadequate impossible contraindication mydriasis either eye presence posterior synechiae study eye mydriasis inadequate posterior segment examination intraocular pressure 25mmhg goldmann tonometry advanced glaucoma either eye monocular patient active tuberculosis known positive syphilis serology human immunodeficiency virus antibody hepatitis surface antigen antinucleocapsid antibody hepatitis virus hepatitis virus within month prior inclusion history malignancy within year prior inclusion carcinoma situ cervix nonmetastatic squamous basal cell carcinoma skin 10 history severe allergic anaphylactic reaction monoclonal antibody 11 infectious disease fever infection require treatment antibiotic within week prior inclusion history recurrent infection predisposition infection 12 known immunodeficiency 13 history multiple sclerosis demyelinate disorder 14 laboratory value assess inclusion hemoglobin 8g dl white blood cell count 103 mm3 platelet count 80 103 mm3 glomerular filtration rate gfr 30ml min transaminases time upper normal value 15 use following systemic treatment specify period previous systemic biologic therapy treatment systemic alkylating agent within 12 month prior inclusion inclusion day cyclophosphamide chlorambucil live attenuate vaccine within month prior inclusion 16 use following ocular treatment specify period previous antivegf intravitreal therapy applies eye within month prior inclusion anticipated use study period treatment dexamethasone intravitreal implant ozurdex within month prior inclusion intravitreal corticosteroid within month prior inclusion previous subtenon corticosteroid injection permit administer least month prior inclusion 17 stage iii intravenous new york heart association nyha cardiac insufficiency",
    "INTERVENTION": "eligible patient active refractory niu randomize ratio arm adalimumab 80mg 40mg 14 day subcutaneously 40 16 week arm anakinra 100 mg day subcutaneously 40 16 week arm tocilizumab 162 mg day subcutaneously 40 16 week three treatment group receive corticosteroid regimen patient niu receive oral prednisone mg kg day maximum 40 mg day prednisone equivalence following schedule reduction prednisone apply group long disease inactive mg kg day prednisone week mg kg day prednisone week week mg kg day prednisone week week mg kg day prednisone week week 12 mg kg day prednisone week 12 week 16 due csi recommendation 18 06 2019 inclusion anakinra arm stop investigational medicinal product anakinra discontinue patient undergo follow thus modify plan analysis randomisation accordingly inclusion randomisation 54 patient next patient randomize either remain arm arm adalimumab 80mg 40mg 14 day subcutaneously 40 16 week arm tocilizumab 162 mg day subcutaneously 40 16 week practice mean remain 66 planned patient randomize 33 arm 33 arm",
    "STATISTICS": "use bayesian multiarm multistage mams design aim compare several new treatment multiarm order select drop treatment arm move forward evidence already exist base interim analyse randomization stratify retinal vasculitis macular oedema underlying disease randomization patient treatment prednisone single therapy"
  },
  "MSC-AT-SSC": {
    "TITLE": "phase ii randomize clinical trial allogeneic adipose tissuederived mesenchymal stromal cell systemic infusion severe systemic sclerosis",
    "JUSTIFICATION": "systemic sclerosis rare severe chronic systemic autoimmune disease characterize vasculopathy immune dysregulation fibrosis lead multiorgan dysfunction primarily skin lung heart gastrointestinal tract kidney high morbidity mortality alter healthrelated quality life high cost patient society treatment mostly symptomatic autologous hematopoietic stem cell transplantation show long term improvement overall eventfree survival diseasemodifying property however autologous hematopoietic stem cell transplantation contraindicated case advanced visceral involvement eligible patient still associate risk toxicity urgent need identify safe effective treatment severe systemic sclerosis mesenchymal stromal cell multipotent cell carry immunomodulatory proangiogenic anti fibrotic property target systemic sclerosis pathogenesis clinical manifestation increase use mesenchymal stromal cell harvest bone marrow mesenchymal stromal cell adipose tissue mesenchymal stromal cell umbilical cord mesenchymal stromal cell uc variety indication provide consistent evidence support safety human efficacy mesenchymal stromal cell intravenous injection treat acute graft versus host disease lead marketing approval 2012 mesenchymal stromal cell alofisel approve severe crohn fistula 2018 mesenchymal stromal cell represent promising therapeutic approach systemic sclerosis previously show diseasespecific abnormality mesenchymal stromal cell systemic sclerosis patient provide strong rationale use allogeneic mesenchymal stromal cell treat systemic sclerosis patient publish first phase ii dose escalation trial use allogenic mesenchymal stromal cell infusion 20 severe systemic sclerosis patient clinicaltrials gov nct02213705 phrc aom 11250 safety issue significant improvement skin fibrosis month infusion appear low thereafter thereby support need repeated infusion vitro experimental clinical study suggest mesenchymal stromal cell property vary accord tissue origin source demonstrate compare mesenchymal stromal cell mesenchymal stromal cell easy harvest display high proliferative capability enter senescence high genetic stability superior immunosuppressive property considering rationale hypothesize use healthy donor allogeneic mesenchymal stromal cell produce etablissement francais du sang efs demonstrate safety issue efficacy profile increase repeated infusion allogeneic mesenchymal stromal cell treat systemic sclerosis",
    "OBJECTIVE": "main objective evaluate safety one month allogeneic 2x106 mesenchymal stromal cell kg intravenous administration twice month interval month month severe systemic sclerosis patient primary endpoint rate treatmentrelated severe adverse events define adverse events grade equal use nci common terminology criteria adverse events ctcae v5 classification one month infusion month month adverse event adjudicate data safety monitoring committee secondary objective safety infusion within first 24 hour infusion study followup efficacy signal inform future study use outcome measure skin sclerosis lung function quality life previously validate systemic sclerosis use cell therapy trial analysis response treatment progressionfree survival global rank composite score month m6and month 12 acr provisional composite response index clinical trials early diffuse cutaneous systemic sclerosis early systemic sclerosis patient month month month 12 analysis overall survival assess cause death impact allogeneic mesenchymal stromal cell intraveinous twice month interval immune response include immunophenotyping alloimmunization month start therapy cost effectiveness allogeneic mesenchymal stromal cell infusion twice versus treatment severe systemic sclerosis patient secondary endpoint rate treatmentrelated severe adverse event define adverse event grade equal ctcae v5 time within first 24 hour infusion followup month month month month month 12 main efficacy endpoint modify rodnan skin score difference month month 12 efficacy disease related endpoint modify rodnan skin score month month month performance status ps healthrelated quality life questionnaire sclerodermahealth assessment questionnaire short form 36 health survey sf36v2 euroqol 5dimension 5level month month month month 12 forced vital capacity diffusing capacity lung carbon monoxide month month month 12 response treatment define following decrease modify rodnan skin score 25 increase force vital capacity 10 increase diffuse capacity lung carbon monoxide 10 without need immunosuppression except low dose steroid 10mg daily month month month 12 progressionfree survival month 12 progression define following decrease forced vital capacity 10 diffuse capacity lung carbon monoxide 15 decrease lvef 15 decrease weight 15 decrease creatinine clearance 30 increase modify rodnan skin score 25 increase sclerodermahealth assessment questionnaire global rank composite score value month month month 12 acr provisional composite response index clinical trial early diffuse cutaneous systemic sclerosis value early systemic sclerosis patient month month month 12 overall survival month 12 myeloid lymphocyte subpopulations included patient month month month month month alloimmunization include patient detection identification donorspecific antihla antibody month month month extracost per qualityadjusted life year qualityadjusted life year gain unique repeat intraveinous infusion allogeneic mesenchymal stromal cell severe systemic sclerosis 12 month extracost per severe adverse event grade equal ctcae avoid unique repeat intraveinous infusion allogeneic mesenchymal stromal cell severe systemic sclerosis 12 month",
    "DESIGN": "multicentre threearm randomize placebocontrolled doubleblind phase iii trial",
    "INCLUSION CRITERIA": "adult patient refractory severe systemic scleroderma provide sign date informed consent willing comply study procedure available duration study male female age 18 70 year age systemic sclerosis patient accord american college rheumatology european league rheumatism 2013 classification criterion systemic sclerosis severe disease either disease duration year less modified rodnan skin score 20 abnormal crp mg hemoglobin 11 dl modify rodnan skin score 15 without restriction disease duration plus least one major organ involvement define respiratory involvement consisting lung diffusion capacity carbon monoxide force vital capacity 80 predict evidence interstitial lung disease chest xray high resolution compute tomography hrct scan moderate pulmonary hypertension baseline rest systolic pulmonary arterial pressure 35 mmhg 50 mmhg cardiac echocardiography mean pulmonary artery pressure 20 mmhg 40 mm hg right heart catheterization renal involvement consisting past renal crisis microangiopathic hemolytic anemia renal insufficiency explain cause systemic sclerosis cardiac involvement consist reversible congestive heart failure atrial ventricular rhythm disturbance recurrent episode atrial fibrillation flutter recurrent atrial paroxysmal tachycardia 2nd 3rd degree avblock mild moderate pericardial effusion presence mri involvement increased t1 t2 mapping late gadolinium enhancement septal sign cause organ involvement attribute systemic sclerosis contraindication inadequate response unwillingness undergo autologous hematopoietic stem cell transplantation determine patient physician judgement contraindication inadequate response unwillingness adverse event necessitate discontinuation conventional immunosuppressive therapy mycophenolate mofetil methotrexate women reproductive potential must use highly effective contraception men reproductive potential must use condom 10 health insurance nb authorize contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable implantable progestogenonly hormonal contraception intrauterine device iud intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomise partner sexual abstinence preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom",
    "EXCLUSION CRITERIA": "age 18 year 70 year pregnancy unwillingness use adequate contraception lifethreatening endorgan damage define diffuse capacity lung carbon monoxide correct hemoglobin 30 predict left ventricular ejection fraction 40 cardiac echocardiography pulmonary hypertension baseline rest systolic pulmonary arterial pressure 50 mmhg cardiac echocardiography mean pulmonary artery pressure 40 mmhg right heart catheterization glomerular filtration rate 30ml min active chronic hepatitis asat alat upper limit normal neoplasms less year except basal cell situ cervix carcinoma concurrent myelodysplasia uncontrolled hypertension uncontrolled acute chronic infection hiv1 hiv2 infection body mass index 16 kg month 10 severe psychiatric disorder 11 bone marrow insufficiency define neutropenia 109 thrombopenia 50 109 anemia dl lymphopenia 109 12 inability provide informed consent 13 patient include another interventional clinical trial 14 patient tutelle",
    "INTERVENTION": "allogeneic adipose tissue derivedmscs mesenchymal stromal cell placebo inject slow intravenous infusion accord recipient body weight study experimental arm arm placebo month month arm mesenchymal stromal cell 2x106 cells kg injection month placebo injection month arm mesenchymal stromal cell 2x106 cells kg injection month mesenchymal stromal cell 2x106 cells kg injection month allogeneic mesenchymal stromal cell administer intravenously 45 min 1h infusion second infusion drug product mesenchymal stromal cell placebo perform absence treatmentrelated severe adverse events trsae patients include arm arm opportunity accord willingness receive either arm arm mesenchymal stromal cell 2x106 cells kg injection end study unblinding evidence mesenchymal stromal cell injection safety provide placebo",
    "STATISTICS": "propose conduct multicenter threearm randomize doubleblind placebocontrolled trial enroll total 18 systemic sclerosis patient patient randomize one two treatment arm infusion mesenchymal stromal cell month infusion mesenchymal stromal cell month month placebo arm total patient per arm use randomization block size inclusions stagger allow detection severe adverse event prior inclusion subsequent patient accord follow waiting rule least one week two consecutive randomization interval least one month every three randomization continuous monitoring primary endpoint sponsor implement allow continuous bayesian toxicity monitoring stopping rule implement primary endpoint cell infusion see section 13 detail first analysis first patient complete month visit analysis trsae month month visit final analysis stopping rule define base estimate probability risk treatmentrelated severe adverse events trsae 15 criterion probability posteriori probability severe adverse event 15 posterior probability trsae trsae estimate use bayesian approach beta density stopping rule fulfil criterion 70 mean high probability great 15 risk trsae interim analysis result present dsmb recommendation case early stopping subsequent patient randomize patient treat thus far follow result analyze describe formal statistical test sample size bayesian framework nevertheless one invoke frequentist framework anticipate expected precision term safety indeed 18 infusion patient infusion patient infusion able estimate risk severe adverse events 10 width exact 95 confidence interval equal 32 consider independence infusion"
  },
  "UVB": {
    "TITLE": "multicenter randomize prospective trial compare efficacy safety adalimumab tocilizumab severe uveitis behcet disease",
    "JUSTIFICATION": "uvb first randomized prospective head head study compare adalimumab tocilizumab sight threaten uveitis bd antitnf use bd uveitis 15 year incidence blindness bd dramatically reduce recent year use biologics firm evidence randomize controlled trial directly address best induction therapy severe bd uveitis bd uveitis consider devastating inflammatory ocular disease risk visual loss reach 25 year 80 patient bilateral involvement contrasting immunosuppressor interferonalpha biotherapies act rapidly highly effective steroid spar thus prevent occurrence cataract glaucoma however antitnf fail demonstrate sustainable complete remission 50 severe sight threaten uveitis little publish information use biologics antitnf severe bd uveitis tocilizumab use success severe resistant case one promising biologics bd il6 expression correlate bd activity immunological data provide strong rationale target bd tocilizumab despite strong rationale compound yet approve bd guarantee innovative nature study aim select drop arm evidence efficacy already exist",
    "OBJECTIVE": "assess benefit tocilizumab comparatively adalimumab sightthreatening behcet disease uveitis week 16 primary endpoint efficacy define complete remission ocular involvement complete resolution retinal vasculitis macular edema prednisone prednisolone prednisone stock market low equal mg day week 16 randomization estimate compare change best correct visual acuity time complete remission week 12 24 36 48 evaluate compare safety adalimumab tocilizumab evaluate compare change macular edema evaluate compare change sign ocular inflammation evaluate compare effect retinal vessel leakage evaluate compare effect adalimumab tocilizumab steroid spar evaluate compare change ocular inflammation anterior chamber evaluate compare number time relapse uveitis characteristic uveitis worsen 10 evaluate compare time treatment failure patients consider treatment failure following criterion meet least eye new active inflammatory retinal vascular lesion macular edema worsen best correct visual acuity line 2step increase anterior chamber cell grade 2step increase vitreous haze grade relative baseline 11 estimate compare effect extra ophthalmologic manifestation behcet disease 12 estimate compare mean change sf36 quality life behcet disease quality life measure bdqol 13 estimate compare change behcet disease current activity form behcet syndrome activity score secondary endpoint measures corticosteroid sparing percent meeting target low mg day kg prednisone prednisolone prednisone stock market mean dose week 16 cumulative dose time response onset measures acutephase reactant erythrocyte sedimentation rate esr creactive protein crp week 12 16 24 36 48 rate time occurrence relapse worsen study relapse define reappearance clinical paraclinical feature active disease occurrence new lesion progression preexist lesion changes behcet disease current activity form week 16 24 changes behcet syndrome activity score week 16 changes organ involve bd week 12 16 24 36 48 changes quality life sf36v2 tm health survey behcet disease quality life measure bdqol week 16 24 safety tolerability treatment bd patient assess frequency severity adverse clinical event week 12 16 24 36 48 10 time treatment failure time occurence 11 changes tyndall flare vitreous haze week 16 24 36 48 12 changes best correct visual acuity snellen score week 16 24 36 48 13 changes central retinal thickness measure optical coherence tomography week 16 24 36 48 14 percentage patient central retinal thickness 300 micron week 16 24 36 48 15 percentage patient without retinal vessel leakage retinal angiography week 16 week 24 36 48 case retinal vasculitis",
    "DESIGN": "bayesian design phase ii randomize clinical trial aim compare new treatment reference base binary end point offer great flexibility simplicity inference monitoring patient safety evidence efficacy small randomized trial",
    "INCLUSION CRITERIA": "adult patient sightthreatening behcet disease associate uveitis age 18 inclusion provide write informed consent prior performance studyspecific procedure diagnosis behcet disease accord international criteria behcet disease see appendix 18 history aphtosis diagnosis noninfectious intermediate posterior panuveitis least one eye fulfil international study group classification criteria standardization uveitis nomenclature sun criterion posterior pan uveitis sight threaten uveitis define accord validated international definition line drop visual acuity 10 10 scale retinal inflammation macular oedema retinal vasculitis chest xray posteroanterior lateral ctscanner result within 12 week prior inclusion evidence active tuberculosis active infection malignancy female subject childbearing potential premenopausal female capable become pregnant negative serum pregnancy test plasmatic urinary subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study month stop therapy tocilizumab adalimumab respectively birth control method may consider highly effective method achieve failure rate less per year use consistently correctly consider highly effective birth control method accord ctfg recommendation method include female subject combine estrogen progestogen containing hormonal contraception associate inhibition ovulation oral intravaginal transdermal progestogenonly hormonal contraception associate inhibition ovulation oral injectable implantable intrauterine device iud intrauterine hormonereleasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence consider highly effective method define refrain heterosexual intercourse entire period risk associate study treatment reliability sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle subject male subject use condom vasectomy documentation azoospermia sexual abstinence negative tb test obtain within 12 week prior inclusion potential subject positive interferongamma release assay quantiferontb gold tspot tb test eligible chest xray show evidence suggestive active tb disease clinical sign symptom pulmonary extrapulmonary tb disease subject latent tb infection already receive prophylactic tb treatment must agree advance complete treatment course treatment start late inclusion 10 affiliation social security system patients affiliate universal medical coverage cmu eligible study",
    "EXCLUSION CRITERIA": "infectious uveitis masquerade syndrome uveitis due cause bd uveitis active tuberculosis history untreated tuberculosis severe infection positive hiv antibody positive hepatitis surface antigen positive hepatitis rna result obtain within month prior inclusion history malignancy within year prior inclusion carcinoma situ cervix nonmetastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reaction monoclonal antibody history multiple sclerosis demyelinate disorder hypersensitivity active substance excipient imp auxiliary medicine active suspect ocular infection active suspect systemic infection 10 history intestinal ulceration diverticulitis 11 known porphyria 12 laboratory value assess inclusion neutrophil 103 mm3 platelet count 80 103 mm3 asat alat uln 13 treatment antitnf tocilizumab therapy within month prior inclusion 14 patient azathioprine mycophenolate mofetil methotrexate time inclusion drug must withdraw prior receive tocilizumab adalimumab dose day 15 stage iii iv new york heart association cardiac insufficiency 16 severe renal glomerular filtration rate 30ml min liver insufficiency prothrombin 50 without cause 17 live attenuate vaccine within 30 day prior inclusion 18 breastfeeding pregnant woman",
    "INTERVENTION": "collection free informed consent eligible patient sight threaten behcet disease uveitis randomize one group randomization visit day arm adalimumab 80 mg day 40 mg subcutaneous week 11 13 15 arm tocilizumab 162 mg subcutaneous week 15 week applicable",
    "STATISTICS": "experimental design open multicenter randomize clinical trial stratify characteristic initial uveitis behcet disease retinal inflammation retinal vascularitis macular edema accord diagnosis newly diagnose relapse disease evaluation primary assessment criterion 16 week primary assessment criterion review scientific committee blind randomization rct use bayesian design phase ii randomize national multicenter clinical trial aim compare new treatment reference base binary endpoint complete remission week 16 offer great flexibility simplicity inference monitoring patient safety evidence efficacy small randomized trial use betabinomial model noninformative prior berry 2006 posterior probability remission rate least 65 estimate arm probability rate remission arm arm compute indicate tocilizumab group adalimumab group use bayesian inference framework denote probability remission arm inclusion patient arm complete remission observe using beta prior posterior probability still beta distribution give +y +n due natural conjugate property beta family binomial sampling setting efficacy drug arm first assess comparison historical minimal value interest sometimes call minimum required treatment remission rate set 65 trial thus compute 65 similar analysis perform arm however randomized phase ii setting selection new drug mostly base evaluate potential benefit experimental treatment thus one may consider drop new drug study rather low posterior probability drug beneficial target minimal level compute posterior probability difference remission rate two experimental arm kawasaki 2012 great zero tocilizumab group adalimumab group consider bayesian design interim analysis perform without alpha spending inclusion 30 patient 65 80 65 80 80 trial stop 65 10 65 10 correspond arm stop following patient include arm 65 10 65 10 trial stop"
  },
  "COMBINATION-LOCK01": {
    "TITLE": "combinationlock01 impact aminoglycosidesbased antibiotic combination protective isolation outcome criticallyill neutropenic patient sepsis randomized factorial design randomize pragmatic trial",
    "JUSTIFICATION": "sepsis remain lead cause icu admission neutropenic patient condition remain associate high morbidity mortality hospital mortality 60 vasopressor require full protective isolation include geographic isolation technical isolation highefficiency air filtration digestive decontamination prove efficient patient profound prolong neutropenia regard infection rate however study bias perform 40 year ago recent study perform patient less profound neutropenia perform without digestive decontamination partial protective isolation lead however negative result importantly isolation demonstrate limit access patient room associate suboptimal monitoring increased rate severe avoidable adverse event may explain uneven use protective isolation hematology ward expert suggestion appraise protective isolation benefit use large well conduct rct neutropenic patient suspected sepsis urgent broad antibiotic therapy mandatory failure initiate adequate antibiotic therapy within hour associate 10 fold increase adjusted mortality current idsa guideline recommend use preferentially large antipseudomonas betalactam therapy routine antibiotic combination use aminoglycosides controversial recommend one hand meta analysis suggest notonly lack benefit association also increase rate renal failure trend towards high mortality rate aminoglycosides use hand subgroup analysis lowlevel evidence study suggest however benefit aminoglycosides criticallyill patient patient severe sepsis documented gram negative infection along line recent cochran systematic review recent french guideline focus neutropenia management criticallyill patient advocate additional trial field focus sick patient current study aim assess benefit protective isolation systematic use aminoglycosides combination antibiotic therapy criticallyill patient cancerrelated neutropenia sepsis septic shock intend perform 2x2 factorial design randomize pragmatic trial compare one hand benefit protective isolation versus protective isolation hand benefit systematic aminoglycosides antibiotic combination versus systematic combination",
    "OBJECTIVE": "evaluate impact day90 mortality two strategy separately use 2x2 factorial design rct intervention routine association aminoglycoside initial antibiotic therapy compare standard care intervention lack routine use protective isolation compare standard care primary endpoint day90 mortality evaluate impact studied intervention day28 hospital outcome incidence severity duration aki incidence clinically apparent loss hear rate adherence hand hygiene rate select adverse event rate nosocomial bacterial viral fungal infection episodes organ support icu stay organ support duration failure initial antibiotic therapy antibiotic duration rate aminoglycosides overdosage overuse secondary endpoint day28 hospital mortality incidence severity aki accord kdigo definition major adverse kidney events day28 day 90 composite death new renal replacement therapy persistent renal dysfunction incidence clinically apparent loss hear end icu stay day 90 rate adherence adequate hand hygiene assess external observer incidence density select serious adverse event include unexpected cardiac arrest incidence density new bacterial viral fungal episode number day free organ support therapy mechanical ventilation vasopressor rrt day 28 rate clinical cure frequency initial antibiotic therapy inadequate regard microbiological documentation number day free antibiotic therapy day28 duration aminoglycoside therapy rate aminoglycoside overdosage accord residual concentration overuse compare expert recommendation",
    "DESIGN": "prospective randomize open label control multicenter 2x2 factorial pragmatic clinical trial check eligibility criterion patient randomize accord balanced scheme allocate one arm intervention aminoglycoside either systematic addition aminoglycosides probabilistic antibiotic therapy maximum day aminoglycoside specific predefined indication isolation either protective isolation geographical technical air filtration universal measure expand mask viral epidemic episode",
    "INCLUSION CRITERIA": "adult patient admit intensive care age 18 year admitted one participate icu sepsis septic shock define sepsis3 definition underlying tumor allogeneic stem cell transplantation hematological malignancy neutropenia define either absolute neutrophil count 500 mm3 leucocyte 1000 mm3 relate underlying malignancy treatment informed defer consent",
    "EXCLUSION CRITERIA": "pregnancy breastfeed moribund patient death expect within 48 hour attend physician previous participation study affiliation social security patients legal protection accord french law patient receive injection aminoglycosides day precede icu admission contraindication aminoglycosides mention spc section hypersensitivity amikacin antibiotic aminoglycoside family excipient amikacin use patients documented allergy aminoglycosides myasthenia gravis concomitant administration intravenous polymyxin delay onset sepsis inclusion 24 hour",
    "INTERVENTION": "intervention association aminoglycoside initial antibiotic therapy intervention lack routine use protective isolation weak protective isolation intervention antibiotic therapy without systematic adjunction aminoglycosides intervention standard care protective isolation",
    "STATISTICS": "according previous study study group day90 mortality studied population expect 60 assuming 15 target effect intervention compare respective control type error rate 05 power 80 group include 170 patient basis twosided logrank test correlation expect intervention main effect estimate interaction intervention test aucune analyse intermediaire est prevue"
  },
  "INTORETAK": {
    "TITLE": "multicentre randomize prospective trial evaluate efficacy safety infliximab tocilizumab refractory relapse takayasu arteritis",
    "JUSTIFICATION": "takayasu arteritis vasculitis unknown origin result progressive thickening stenosis large medium artery aorta major branch pulmonary artery first line therapy takayasu arteritis consist high dose corticosteroid mukhtyar et al 2009 20 50 case respond corticosteroids alone subsequent resolution symptom stabilization vascular abnormality shelhamer et al 1985 maksimowicz mckinnon et al 2007 although secondline agent methotrexate azathioprine mercaptopurine mycophenolate mofetil may result initial remission relapse remain common prednisone taper maksimowiczmckinnon et al 2007 thus 50 corticosteroid resistant relapse takayasu arteritis patient may achieve sustain remission addition methotrexate hoffman et al 1994 last decade biologics antitumor necrosis factor alpha anti tnf antiinterleukin6 antiil6 use thirdline treatment refractory relapse takayasu arteritis almost 90 corticosteroid methotrexate resistant takayasu arteritis case respond infliximab anti tnf sustain remission obtain 37 76 case schmidt et al 2012 comarmond et al 2012 mekinian et al 2012 tocilizumab antiil6 give similar result 68 sustained remission refractory takayasu arteritis abisror et al 2013 irrespective classical cardiovascular risk factor systemic inflammation corticosteroid use play pivotal role occurrence cardiovascular thrombotic event cves roubille et al 2015 cves overlap takayasu arteritis complication primordial drastically taper corticosteroid vasculitis therefore hypothesize infliximab tocilizumab achieve remission 70 refractory relapsing takayasu arteritis case corticosteroid associate secondline agent intoretak first randomize prospective study takayasu arteritis original design test infliximab tocilizumab propensity achieve 70 sustained remission refractory relapsing takayasu arteritis evaluate jointly arm",
    "OBJECTIVE": "obtain arm 70 patient month posttreatment prednisone prednisolone 1mg kg per day inactive disease national institute health score last month proportion month posttreatment patient prednisone prednisolone 1mg kg per day sustain inactive disease national institute health score month month biological therapy since treatment among randomized patient arm estimate incidence relapse month post treatment arm estimate incidence traitement failure month post treatment arm estimate incidence revascularization procedure endovascular surgical require due disease 12 month posttreatment arm estimate cumulative dose prednisone prednisolone 12 month posttreatment arm estimate incidence adverse event 12 month post treatment arm estimate mean change sf36 qualityoflife value day treatment 12 month posttreatment arm estimate proportion new vascular lesion 12 month posttreatment arm measure angiocomputorized tomography magnetic resonance imaging angiography incidence relapse define national institute health criterion month day1 treatment incidence revascularization procedure endovascular surgical day treatment month posttreatment incidence traitement failure month day1 treatment disease still active accord national institute health criterion proportion month day1 treatment patient prednisone prednisolone 1mg kg per day sustain inactive disease modified national institute health score without criterion month month biological therapy day1 treatment among randomized patient arm incidence relapse define modified national institute health criterion without criterion month month day1 treatment incidence traitement failure month day1 treatment disease still active accord modify national institute health criterion without criterion cumulative dos prednisone prednisolone arm 12 month day1 treatment incidence adverse event grade iii iv 12 month day1 treatment mean change quality life questionnaire sf36 day treatment 12 month treatment proportion new vascular lesion 12 month day1 treatment assess measure angioct mr angiography",
    "DESIGN": "open randomize clinical trial base simon twostage design simon 1989 use separately arm randomization thus allocation concealment arm insure absence selection bias allocate experimental treatment patient betweenarm comparison test estimate difference end point treatment arm provide",
    "INCLUSION CRITERIA": "adult patient refractory relapse takayasu arteritis diagnosis takayasu arteritis least criteria american college rheumatology meet appendix age disease onset 1st symptom 40 year old limb claudication anisotension 10mm hg brachial systolic arterial pressure decreased brachial artery pulse one artery bruit subclavian artery aorta arteriogram abnormality arteriographic narrowing occlusion entire aorta primary branch large artery proximal upper low extremity due arteriosclerosis fibromuscular dysplasia similar cause change usually focal segmental otherwise least two major one major two minor criterion four minor criterion ishikawa criterion modify sharma meet appendix three major criterion left mid subclavian artery lesion severe stenosis occlusion present mid portion point cm proximal vertebral artery orifice cm distal orifice determine angiography right mid subclavian artery lesion severe stenosis occlusion present mid portion right vertebral artery orifice cm distal orifice determine angiography characteristic sign symptom least one month duration include limb claudication pulselessness pulse difference limb unobtainable significant blood pressure difference 10 mmhg systolic blood pressure difference limb fever neck pain transient amaurosis blur vision syncope dyspnea palpitation ten minor criterion high esr unexplained persistent high esr 20 mm westergren diagnosis presence evidence patient history carotid artery tenderness unilateral bilateral tenderness common artery palpation neck muscle tenderness unacceptable hypertension persistent blood pressure 140 90 mmhg brachial 160 90 mmhg popliteal aortic regurgitation annuloaortic ectasia auscultation echocardiography angiography pulmonary artery lesion lobar segmental arterial occlusion equivalent determine angiography perfusion scintigraphy presence stenosis aneurysm luminal irregularity combination pulmonary trunk unilateral bilateral pulmonary artery determine angiography left mid common carotid lesion presence severe stenosis occlusion mid portion cm length point cm distal orifice determine angiography distal brachiocephalic trunk lesion presence severe stenosis occlusion distal third determine angiography descending thoracic aorta lesion narrowing dilation aneurysm luminal irregularity combination determine angiography tortuosity alone unacceptable abdominal aorta lesion narrowing dilation aneurysm luminal irregularity aneurysm combination 10 coronary artery lesion document angiography age 30 year absence risk factor like hyperlipidemia diabetes mellitus active disease accord international criterion national institute health appendix least following criterion meet criterion least following systemic characteristic without cause identify erythema nodosum fever 38c week polyarthralgia arthritis episcleritis criterion least following clinical sign appear since previous visit carotidodynia vascular claudication pain along arterial pathway constitute transient ischemic stroke acute coronary syndrome angina abolition pulse vascular bruit anisotension criterion least following biological sign creactive protein 10 mg fibrinogen orosomucoide haptoglobine criterion least following radiological sign arterial wall thickening wall contrast measurement angiomri angiotdm appearance new vascular lesion angiomri angio tdm refractory relapsing disease symptomatic severe arterial involvement refractory relapsing disease consider one following condition meet inability taper corticosteroid 1mg kg day within month disease still active inability taper corticosteroid 10mg day within month inability discontinue corticosteroid year treatment relapse disease gradual decrease corticosteroid therapy symptomatic severe arterial involvement define follow stroke retinopathy symptomatic coronary artery stenosis symptomatic pulmonary artery stenosis symptomatic mesenteric artery celiac trunk stenosis symptomatic renal artery stenosis patients one immunosuppressive agent methotrexate azathioprine mercaptopurine mycophenolate mofetil leflunomide ciclosporine hydroxychloroquine change dosage within last 30 day unless allergy intolerance contraindication immunosuppressive agent age 158 year old weight 40 120 kg medical followup university general hospital france social insurance willing able provide write informed consent willing able comply treatment followup procedure require study protocol female subject childbearing age negative serum pregnancy test pregnancy plan within 12 month subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study adequate contraceptive measure include hormonal method use two cycle prior screening oral contraceptive pill contraceptive patch contraceptive vaginal ring barrier method contraceptive sponge diaphragm use conjunction contraceptive foam jelly condom use conjunction contraceptive foam jelly intrauterine method iud sterilization tubal ligation monogamous relationship vasectomized partner abstinence chest xray result posteroanterior lateral chest ct within 12 week prior inclusion randomization visit evidence active tuberculosis active infection malignancy tuberculosis assessment meet one following condition active tuberculosis infection treatment achieve completion least week treatment latent tuberculosis infection negative tuberculin skin test interferon gamma release assay quantiferon tb gold tspot tb test potential subject positive tuberculin skin test interferon gamma release assay inclusion eligible chest xray show evidence suggestive active tuberculosis infection clinical sign symptom pulmonary extrapulmonary tuberculosis infection subject latent tuberculosis infection complete full currently receive since least week treatment latent tuberculosis infection negative human immunodeficiency virus serology negative hepatitis rna hepatitis surface antigen within month",
    "EXCLUSION CRITERIA": "active tuberculosis untreated latent tuberculosis infection currently treat less week evidence active infection include chronic infection infection require treatment antibiotic within week prior inclusion randomization visit infection positive human immunodeficiency virus serology positive hepatitis rna positive hepatitis surface antigen pregnancy lactation inability comply study guideline inability provide informed consent alcohol drug abuse investigator opinion could prevent subject fulfil study requirement would increase risk study procedure severe renal insufficiency creatinine clairance 30ml min 73m2 hepatic dysfunction show aspartate transaminase ast alanine transaminase alt level 5fold upper limit normal heart failure stage iii iv nyha history malignant neoplasm except adequately treat basal squamous cell carcinoma skin solid tumor treat curative therapy disease free least year history multiple sclerosis demyelinate disorder history severe allergic anaphylactic reaction infliximab chimeric murine monoclonal antibody tocilizumab respective excipients prednisone prednisolone history immediate hypersensitivity reaction iodinate gadoliniumbased contrast medium cytopenia hemoglobin dl absolute neutrophil platelet count 80 live attenuate vaccine week enrolment recombinant kill virus vaccine week inclusion ransomization visit use following systemic treatment specify period atreatment biologic therapy infliximab adalimumab certolizumab pegol golimumab anakinra tocilizumab etanercept abatacept ixekizumab secukinumab ustekinumab alemtuzumab within month prior inclusion randomization visit bpast treatment rituximab within past 12 month past treatment rituximab 12 month ago lymphocytes count return normal time inclusion randomization visit ctreatment systemic alkylating agent within month prior inclusion randomization visit cyclophosphamide chlorambucil indication initiate infliximab tocilizumab another active disease takayasu arteritis lack affiliation social security benefit plan beneficiary assignee presence following onongoing ontreatment disease process microscopic polyangiitis granulomatosis polyangiitis eosinophilic granulomatosis polyangiitis polyarteritis nodosa cogan syndrome behcet disease kawasaki disease atypical mycobacterial infection deep fungal infection lymphoma lymphomatoid granulomatosis type malignancy mimic vasculitis cryoglobulinemic vasculitis systemic lupus erythematosus rheumatoid arthritis mixed connective tissue disease overlap autoimmune syndrome known constitutive immunodeficiency",
    "INTERVENTION": "arm patient receive infliximab 5mg kg intravenously week 14 22 follow prescription recommendation month arm patient receive tocilizumab 8mg kg intravenously week 12 16 20 24 follow prescription recommendation month",
    "STATISTICS": "randomize 25 patient arm arm null hypothesis response rate 40 test onesided alternative response rate 70 0248 type error rate power 8061 first stage include 10 patient arm response observe patient arm stop otherwise 15 additional patient accrue null hypothesis reject 14 response observe 25 patient"
  },
  "TRIBECA": {
    "TITLE": "multicenter randomize doubleblind study compare efficacy safety belimumab treatment noninfectious active cryoglobulinemia vasculitis compare placebo",
    "JUSTIFICATION": "cryoglobulinemia vasculitis associate significant morbidity mortality require therapeutic intervention management noninfectious mixed cryoglobulinemia vasculitis currently base corticosteroid rituximab last decade several group report efficacy anti cd20 monoclonal antibody rituximab patient cryoglobulinemia vasculitis rituximab infusion prove effective main vasculitis sign complete clinical response 6570 patient however cryoglobulinemic vasculitis relapse note 40 patient within day nineteen month last rituximab infusion previously show serum blys concentration correlate serum cryoglobulin level cryoglobulinemia vasculitis cryoglobulinemia associate non hodgkin lymphoma agreement data systemic lupus erythematosus sjogren syndrome also observe decrease blys binding br3 stain correlate disease severity following rituximab serum blys concentration significantly increase may favour survival autoreactive cell clone relapse cryoglobulinemia vasculitis recent study show rituximab reset defective early cell tolerance checkpoint obvious solution prevent rise baff level precipitate flare disease follow rituximab therapy thus achieve sustain remission disease would combine rituximab baff blockade mouse combination cell depletion baff inhibition remove cell marginal zone follicular compartment effectively either treatment alone combination cell depletion baff blockade superior cell depletion alone respect reduce number plasmablast plasma cell well reduce disease severity three different mouse model lupus addition promise result observe patient cryoglobulinemia vasculitis treat rituximab plus belimumab good safety profile",
    "OBJECTIVE": "evaluate efficacy belimumab compare placebo patient noninfectious active cryoglobulinemia vasculitis complete clinical response rate vasculitis symptom week 25 corticosteroid withdrawal prednisone mg day week 12 secondary objective safety tolerability treatment assess frequency severity adverse clinical event complete partial improvement organ involve baseline non clinical clinical improvement response rate rate complete renal response rate cryoglobulinemia clearance rate negativation rheumatoid factor activity rate normalization c4 complement level early failure rate week non clinical response week clinical relapse rate time relapse two treatment group cumulative dose corticosteroid receive two treatment group evolution gammaglobulin cd19+ cell level quality life score sf36 appendix two treatment group rate infection severe complication lymphoma bvas activity score appendix secondary endpoint safety tolerability treatment assess frequency severity adverse clinical event week 25 week 48 complete partial non clinical response rate week 13 week 25 week 48 complete renal response rate week 13 week 25 week 48 rate cryoglobulinemia clearance negativation rheumatoid factor activity normalization c4 complement level week 13 week 25 week 48 rate early failure non clinical response week clinical relapse rate define de novo appearance reappearance manifestation attributable cryoglobulinemia vasculitis 48 week follow rate time relapse baseline week 48 cumulative dose prednisone week 25 week 48 quality life score sf36 baseline week 25 week 48 rate infection severe complication 48 week followup evolution gammaglobulin cd19+ level baseline week 48 bvas activity score baseline week 13 week 25 week 48",
    "DESIGN": "bayesian phase ii randomize clinical trial aim evaluate best treatment strategy cryoglobulinemia vasculitis base difference response rate measure week 25 randomization phase ii prospective randomize multicentre double blind study group belimumab administer subcutaneously 200mg weekly week week 24 group ii placebo belimumab administer subcutaneously weekly week week 24 randomization centralize stratify previous treatment history naive patient versus relapse patient severity vasculitis extensive skin necrosis glomerulonephritis multiple mononeuropathy myocarditis digestive central nervous system specific involvement ratio group group corticosteroid taper scheme initial dose 30 mg day following schedule reduction prednisone apply group long disease inactive 30 mg day week 0w2 20 mg day w2w4 15 mg day w4w6 10 mg day w6w8 mg day w8w10 w10w12 strategy stop glucocorticoid leave investigator discretion stopping glucocorticoid therapy week 12 step prednisone dose reduce absence sign vasculitis activity",
    "INCLUSION CRITERIA": "adult patient noninfectious active cryoglobulinemia vasculitis age 18 year written inform consent active cryoglobulinemia vasculitis initiation rituximab define clinically active vasculitis skin joint renal peripheral nerve central neurological digestive pulmonary cardiac involvement history positive cryoglobulinemia affiliated national french social security system receive rituximab induction therapy within week infusion dose discretion investigator female subject childbearing potential must negative serum urinary pregnancy test inclusion visit confirm monthly study least 92 day half life post last dose subject reproductive potential male female willingness use contraceptive measure adequate prevent subject subject partner become pregnant study week prior administration 1st dose study agent 92 day last dose study agent therefore subject agree following complete abstinence intercourse week prior administration 1st dose study agent 92 day last dose study agent sexual inactivity abstinence must consistent preferred usual lifestyle subject periodic abstinence calendar ovulation symptothermal post ovulation method withdrawal acceptable method contraception consistent correct use follow acceptable method birth control month prior start study agent study 92 day last dose study agent oral contraceptive either combine progestogen alone injectable progestogen implants levonorgestrel etonogestrel estrogenic vaginal ring percutaneous contraceptive patch intrauterine device iud intrauterine system ius failure rate state product label male partner sterilization vasectomy documentation azoospermia prior female subject entry study male sole partner subject definition document refers outcome investigator designee medical examination subject review subject medical history study eligibility obtain via verbal interview subject subject medical record double barrier method condom occlusive cap diaphragm cervical vault cap plus spermicidal agent foam gel film cream suppository allow method contraception effective use consistently correctly accordance product label investigator responsible ensure subject understand properly use method contraception hiv negative serology negative hbs ag test hbc ab test hcv negative serology negative hcv rna positive hcv serology within month inclusion neutrophils anc 1x109",
    "EXCLUSION CRITERIA": "patient vasculitis unrelated cryoglobulinemia patient non active cryoglobulinemia vasculitis initiation rituximab patients inactive vasculitis follow rituximab administration may include excluded concomitant medication 365 day prior investigational medicinal product belimumab placebo biologic investigational agent abetimus sodium anti cd40l antibody bg9588 idec 131 investigational agent applies drug approve sale country use 180 days prior investigational medicinal product belimumab placebo intravenous cyclophosphamide 30 days prior investigational medicinal product belimumab placebo half life whichever great nonbiologic investigational agent investigational agent applies drug approve sale country use live vaccine within 30 day prior baseline concurrently investigational medicinal product belimumab placebo history malignant neoplasm within last year carcinoma situ cervix excise basal cell squamous cell carcinoma skin lowgrade hemopathy indication specific treatment progressive multifocal leukoencephalopathy evidence serious suicide risk include history suicidal behaviour last month suicidal ideation last month investigator judgment pose significant suicide risk history primary immunodeficiency significant igg deficiency igg level 400 mg dl significant iga deficiency iga level 10 mg dl accord result obtain within month prior inclusion visit history major organ transplant hematopoietic stem cell marrow transplant renal transplant 10 infection history currently suppressive therapy chronic infection tuberculosis pneumocystis cytomegalovirus infection require hospitalization use parenteral iv im antibiotic antibacterial antiviral antifungals antiparasitic agent within 60 day inclusion visit 11 current drug alcohol abuse dependence history drug alcohol abuse dependence within 365 day prior inclusion visit 12 historically positive hiv test accord result obtain within month prior inclusion visit 13 hepatitis status accord result obtain within month prior inclusion visit serologic evidence current past hepatitis infection base result test hbsag hbcab follow patients positive hbsag hbcab exclude positive test hepatitis rna 14 history hypersensitivity anaphylactic reaction parenteral administration belimumab corticosteroid excipients treatment administer study 15 women child bearing potential included please see special instruction inclusion criterion 16 pregnant breast feeding woman 17 intercurrent significant medical psychiatric illness investigator considers would make candidate unsuitable study 18 patients legal protection unable consent 19 participation another interventional study",
    "INTERVENTION": "belimumab benlysta administer subcutaneously 200 mg weekly week week 24 placebo belimumab administer subcutaneously weekly week week 24",
    "STATISTICS": "bayesian phase ii randomize clinical trial aim evaluate treatment strategy cryoglobulinemia vasculitis base difference response rate measure week 25 randomization randomized phase ii trial still poorly use still large use singlearm phase ii trial result interpret relative historical control subject introduce selection bias confound may limit validity conclusion thus plan phase ii randomize trial appear worthy investment consider finite patient financial resource design adapt binary outcome observe end fixed followup period analyze use absolute difference proportion show greatly reduce sample size requirement thus use approach phase ii randomize trial propose simon wittes ellenberg ss aim control probability detect give difference response rate hypothesize 70 patient receive placebo belimumab 85 treat belimumab achieve complete remission cryoglobulinemia vasculitis week 25 week 25 steroid therapy stop mg day week 12"
  },
  "MSC-SLE": {
    "TITLE": "treatment severe refractory systemic lupus erythematosus injection allogeneic mesenchymal stem cell derive umbilical cord",
    "JUSTIFICATION": "systemic lupus erythematosus rare prevalence 40 50 100 000 person heterogeneous autoimmune autoinflammatory disease affect sex race peak incidence prevalence among black people predilection woman 3rd4th decade life systemic lupus erythematosus characterize successive period flare remission may vary duration quality prognosis severe form systemic lupus erythematosus affect lung heart brain addition renal involvement improve still evolution remain pejorative subset patient whose 10 year mortality remain 10 15 even tertiary referral center 20 year new prospective clinical trial course systemic lupus erythematosus demonstrate effectiveness new biological therapy yet make long awaited breakthrough treatment severe systemic lupus erythematosus antiblys monocolonal antibody gain indication moderately active systemic lupus erythematosus addition serious adverse side effect progressive multifocal leukoencephalopathy observe several biologics auto disease patient dampen expect benefit systemic lupus erythematosus subject resistant 1er 2nd line conventional treatment need develop effective therapy long term side effect base new immunomodulatory immunosuppressive strategy according vitro immunomodulatory property ability induce tissue repair mechanism mesenchymal stem cell propose new therapy several auto disease include systemic lupus erythematosus use allogeneic umbilical cordderived mesenchymal stem cell base experimental human clinical data particularly produce nanjing team pr sun china also logical select systemic lupus erythematosus patient severity criterion use worldwide validate efficacy antiblys therapy similarly analysis expected result take account criterion similar comparable use pivotal clinical trial trial unique opportunity set collaboration saintlouis aphp clinical expert center cell therapy auto disease university college london cell manufacturing",
    "OBJECTIVE": "main objective assess tolerance allogeneic umbilical cord derive mesenchymal stem cell administration severe systemic lupus erythematosus refractory standard therapy cyclophosphamide mycophenolate mofetil corticosteroid without anti cd20 primary endpoint immediate tolerance assess first injection 10 day allogeneic mesenchymal stem cell injection accord standard ctcae side effect secondary objective feasibility allogeneic uc mesenchymal stem cell administration treatment severe systemic lupus erythematosus subject refractory conventional therapy tolerance three month injection consider observed morbidity overall survival systemic lupus erythematosus treat subject year procedure analysis biological clinical response routine clinical biological examination criterion monitor lupus use selena sledai bilag sf36 eq5d sri slicc systemic lupus erythematosus score analysis efficacy 3months injection allogeneic uc mscs accord proportion subject major clinical response rcm percentage subject partial clinical response cpr 12 month followup study evaluation immunomodulatory effect mesenchymal stem cell routine laboratory criterion include immunophenotyping every month followup period analysis specific cytokine production month month month analysis mesenchymal stem cell immunogenicity month month month secondary endpoint safety tolerance assess injection within first 10 day follow mesenchymal stem cell injection month month month month 12 accord side effect define ctcae standard miller results cancer treatment cancer 1981 47 207 214 treatmentrelated toxicity analyze accord international world health organization maximum degree toxic attack body injection consider tolerate toxicity criterion grade proportion subject major clinical response proportion subject partial response clinic pcr 12 month study followup 12 month month month month month 12 disease activity measure bilag score 72 selenasledai 105 every month compare inclusion end followup period month month month month 12 sri response rate measure every three month month month month month 12 followup sri response define point reduction selena sledaiscore new bilag score organ one new bilag score worsening increase overall evaluation physician compare inclusion value presence comorbidities accord sclicc systemic lupus erythematosus index month every three month study followup month month month month 12 charlson comorbidity index eligibility quality life assess short form 36 version sf36v2 eq5d injection every month end monitoring period month month month month 12 month percentage subject average dose prednisone reduce 25 compare month world health organization mg day week 40 52 average daily corticosteroid dose measure every month end monitoring period mo month month month month 12 number treatment failure define one following end stage renal disease require dialysis transplantation sustain double creatinine value two low value observe screen baseline confirm four week later active lupus nephritis attribute active systemic lupus erythematosus define either two criterion double value proteinuria proteinuria 24 hour subject world health organization 24 hour baseline proteinuria 24 hour subject world health organization 1g 24 hour baseline ii nephropathy 25 increase serum creatinine respect value baseline simultaneously value proteinuria double least 24 hour hematuria two positive urine test strip presence cell cylinder two criterion must confirm twice 2week interval need steroid therapy intravenously plasmapheresis immunoglobulin iv immunosuppressive therapy treat aggravation systemic lupus erythematosus standard immunological biological marker include lymphocyte immunophenotyping complete blood count creatinine proteinuria 24h autoantibody antidna antibody native anas complement system c3 c4 ch50 immunophenotyping month month every three month followup period study month month month month 12 10 specific cytokine production month month month inclusion 11 analysis mesenchymal stem cell immunogenicity month month month accord antihla antibody dosage crossmatch analysis",
    "DESIGN": "single center phase iii open study national recruitment within fai2r network immunosuppressive immunomodulatory action allogeneic mscs umbilical cord healthy donor allow beneficial action patient severe systemic lupus erythematosus resistant conventional treatment",
    "INCLUSION CRITERIA": "systemic lupus erythematosus active subject refractory prior standard therapy patient age 18 year 70 year diagnosis systemic lupus erythematosus accord acr criterion positive antinuclear antibody subjects sustained disease activity define selena sledai systemic lupus erythematosus activity index baseline inefficacy adverse effect necessitate discontinuation first second line therapy systemic lupus erythematosus include prednisone orally mg day equivalent least 28 day least one following immunosuppressive therapy month total cyclophosphamide iv bolus 500 mg month month minimum ii mycophenolate mofetil orally equivalent dose 2000 mg day least 90 day iii azathioprine orally dose mg kg day least 90 day iv methotrexate orally parenterally dos 20mg week least 90 day leflunomide orally dose 10mg day least 90 day vi rituximab anticd20 intravenous bolus 375 mg month week four week total dose twice day two week vii cyclosporine orally dose 55 mg kg day least 90 day viii belimumab intravenously subcutaneous monthly bolus 10 mg kg infusion least month patient world health organization receive treatment systemic lupus erythematosus stable dos minimum 30 day prior eligibility include one following treatment prednisone equivalent alone combine antimalarial treatment antiinflammatory steroidal immunosuppressant negative pregnancy test woman childbearing age men woman using effective contraceptive method treatment within month end treatment men partner childbearing age signed informed consent affiliation social security",
    "EXCLUSION CRITERIA": "subjects pregnancy breastfeeding lack appropriate contraception study duration presence renal failure calculated creatinine clearance 30 ml min cardiac failure clinical sign congestive heart failure leave ventricular ejection fraction 40 echocardiography uncontrolled ventricular arrhythmia hepatitis define abnormal level transaminase ast alt normal relate disease activity respiratory disease mean pap 50 mmhg echocardiography respiratory failure define rest blood pressure oxygen pao 70 mmhg paco2 50 mmhg without oxygen severe psychiatric disorder include severe psychosis relate systemic lupus erythematosus would prevent give informed consent undergo procedure active neoplasia concomitant myelodysplasia except basal cell carcinoma squamous cell carcinoma situ cervix carcinoma bone marrow failure define neutropenia 109 thrombocytopenia 30 109 anemia dl lymphopenia cd4 200 106 cause another disease systemic lupus erythematosus acute chronic uncontrolled infection hiv htlv1 hepatitis hbs ag surface antigen hepatitis positive pcr optional pcr patient receive belimumab intravenously subcutaneous within month baseline receive rituximab cell deplete biologic therapy within month baseline current substance abuse recent within 60 day history substance abuse patient period exclusion national roster researcher 10 patient linguistic psychological incapacity sign informed consent 11 patient already include another study time 12 poor patient compliance patient legal protection",
    "INTERVENTION": "phase iii allogeneic umbilical cord derivedmscs inject slow intravenous infusion accord weight recipient patient group study dos 106 csm kg 106 csm kg 106 csm kg injection 30min 1h intravenous infusion na",
    "STATISTICS": "initially subject initial dose 106 csm kg recipient weight include follow subject enrol dose 106 ms kg high probability excessive toxicity 106 mesenchymal stem cell kg 106 csm kg low probability excessive toxicity 106 csm kg toxicity criterion describe ctcae classification patient cohort scan sequential bayesian approach estimate probability toxicity administer dose allow adaptation function toxicity observe dose previous subject"
  },
  "PCL-2": {
    "TITLE": "primary plasma cell leukemia prospective phase ii study incorporate daratumumab chemotherapy stem cell transplantation",
    "JUSTIFICATION": "primary plasma cell leukemia ppcl rare form plasma cell malignancy 24 multiple myeloma poor prognosis overall survival 12 month conventional chemotherapy bortezomibbased regimen show promising result small retrospective study transplantation auto allograft may improve overall survival select young patient ifm group recently publish prospective study 40 ppcl patient alternate bortezomibdexamethasone doxorubicin cyclophosphamide pad vcd induction high dose melphalan plus autologous stem cell transplantation hdm autologous stem cell transplantation follow reduced intensity conditioningallograft ricallo second hdm autologous stem cell transplantation plus consolidation maintenance bortezomiblenalidomidedexamethasone lenalidomide overall 27 patient 69 responder induction 35 achieve good partial response good one patient underwent syngeneic allograft 25 hdm autologous stem cell transplantation 16 subsequently receive ricallograft second transplant follow consolidation maintenance median progressionfree survival overall survival 15 36 month respectively overall survival seem superior double transplant maintenance group compare allotransplant group landmark analysis italian group also recently report prospective trial ppcl involve 23 patient treat lenalidomidedexamethasone overall median progressionfree survival overall survival 14 28 month respectively nine 15 patient eligible transplant could receive hdm autologous stem cell transplantation induction progressionfree survival overall survival 27 month reach respectively daratumumab monoclonal antibody cd38 highly express plasma cell highly effective relapsed refractory patient multiple myeloma alone combination lenalidomide combination daratumumab bortezomiblenalidomidedexamethasone dara bortezomiblenalidomidedexamethasone recently test newly diagnose multiple myeloma patient impressive result acceptable tolerability subcutaneous formulation daratumumab also test context new safety concern aim improve hematological response survival ppcl patient propose combine daratumumab subcutaneous bortezomiblenalidomidedex dara bortezomiblenalidomidedexamethasone induction follow double hdm autologous stem cell transplantation prolonged consolidation year dara bortezomiblenalidomidedexamethasone year lenalidomide year",
    "OBJECTIVE": "primary objective determine best overall response rate completion induction phase good partial response good primary endpoint good partial response good rate completion induction phase accord international myeloma work group response criterion main secondary objective evaluate progressionfree survival secondary objective assess overall hematological response rate evaluate overall survival assess safety toxicity accord national cancer institute ctcae assess cytogenetic abnormality tumoral plasma cell analyze prognostic value minimalresidual disease sequence completion induction second consolidation len consolidation end treatment evaluate quality life eortc qlqc30 domain score secondary endpoint progressionfree survival overall survival time progression duration response overall hematological response rate assess safety type frequency severity relationship adverse event study treatment change vital sign physical exam incidence treatment emergent adverse event serious adverse event laboratory abnormality use national cancer institute common toxicity criterion common toxicity criterion v4 evaluate response accord chromosomal structural abnormality del 17p 14 11 14 14 16 14 20 amp 1q del 1p minimal residual disease assess nextgeneration sequence quality life eortc qlqc30 domain score",
    "DESIGN": "induction phase inclusion trial patient receive day dexamethasone according local practice one dose doxorubicine 30 mg month iv cyclophosphamide 750 mg month iv may also add reduce tumoral mass minimize risk tumor lysis syndrome tls induction treatment month subject receive 28 day cycle dara bortezomiblenalidomidedexamethasone induction therapy describe agent dose day route cycle day daratumumab 1800 mg 15 22 cycle 15 cycle bortezomib 11 mg month lenalidomide 25 mg day day 21 cycle dexamethasone 20 mg 15 16 22 iv 23 start dose lenalidomide reduce depend renal function patients impaired renal function calculate measure creatinine clearance 50 ml minute lenalidomide dose reduction otherwise receive full dose lenalidomide 25mg tumorlysis prophylaxis monitoring require induction treatment accord local practice ii disease assessment local assessment perform end induction determine patient continue study responding patient response sd circulate plasma cell pursuit study nonresponding patient response sd circulate plasma cell study mobilization harvesting stem cells stem cell mobilization perform use cyclophosphamide recommend dose month cycle stem cell harvest base response mobilization use gcsf plerixafor permit per institutional practice sufficient stem cell harvest enable two transplant 106 cd34 kg high dose melphalan autologous stem cell transplantation n1 eligible patient start intensification high dose melphalan week stem cell collection mephalan 200mg month conditioning therapy patient creatinine clearance 30 ml min melphalan dose reduce 140 mg month stem cell reinfusion subject single reinfusion stem cell minimum 106 cd34 kg 2448 hour highdose melphalan permit tolerance engraftment recovery day 160 post autologous stem cell transplantation subjects monitor successful engraftment support therapy administer accord institutional study group standard first consolidation 60 day consolidation therapy start time complete hematological recovery accord investigator opinion subject fit enough tolerate subsequent systemic therapy within month autologous stem cell transplantation subjects receive 28day cycle dara bortezomiblenalidomidedexamethasone daratumumab 1800 mg day day 15 bortezomib mg month day day day 15 day 22 lenalidomide 25 mg day day 21 dexa 20 mg iv day day day 15 day 22 high dose melphalan autologous stem cell transplantation n2 subjects receive melphalan 200mg month conditioning therapy patient creatinine clearance 30 ml min melphalan dose reduce 140 mg month stem cell reinfusion subject single reinfusion stem cell minimum 106 cd34 kg 2448 hour highdose melphalan permit tolerance engraftment recovery day 160 post autologous stem cell transplantation second consolidation phase year consolidation therapy start time complete hematological recovery accord investigator opinion subject fit enough tolerate subsequent systemic therapy within month autologous stem cell transplantation phase conduct accord two step consolidation year patients receive dara bortezomiblenalidomidedexamethasone every month cycle daratumumab 1800 mg day bortezomib mg month day day day 15 day 22 lenalidomide 25 mg day day 21 dexamethasone 20 mg iv day day day 15 day 22 consolidation year patient receive lenalidomide every 28 day lenalidomide 25 mg day day 21 28 day note treatment period lenalidomide dose readjust accord patient renal function status dose adaptation follow usual recommendation",
    "INCLUSION CRITERIA": "screening eligibility investigator responsible keep record subject sign informed consent form entry study subject screen eligibility must take place within 21 day prior initiation therapy patient must meet eligibility criterion enter study male female patient 18 69 year old patient primary plasma cell leukemia disease define recent international myeloma working group international myeloma work group 2021 circulate plasma cell peripheral blood smear voluntary write consent must give performance study related procedure part standard medical care understanding consent may withdraw patient time without prejudice future medical care eastern cooperative oncology group performance status performance status eligible high dose melphalan therapy autologous stem cell transplantation total bilirubin upper limit normal range alanine aminotransferase aspartate aminotransferase upper limit normal range calculated creatinine clearance 20 ml min mdrd formula use calculate creatinine clearance value female patient postmenopausal least year screening visit surgically sterile childbearing potential agree practice effective method contraception time time sign informed consent form 90 day last dose study drug agree practice true abstinence line preferred usual lifestyle subject periodic abstinence calendar ovulation symptothermal postovulation method withdrawal acceptable method contraception 10 male patient even surgically sterilize status post vasectomy must agree one following agree practice effective barrier contraception entire study treatment period 90 day last dose study drug agree practice true abstinence line preferred usual lifestyle subject periodic abstinence calendar ovulation symptothermal postovulation method withdrawal acceptable method contraception 11 patients agree share study medication person return unused study drug investigator abstain donate blood take study drug therapy one week follow discontinuation study drug therapy 12 must able adhere study visit schedule protocol requirement 13 affiliated appropriate social security system",
    "EXCLUSION CRITERIA": "male female patient 18 69 year old history malignancy within year date inclusion exception squamous basal cell carcinoma skin carcinoma skin carcinoma situ cervix breast noninvasive lesion opinion investigator concurrence coordinate investigatior consider cured minimal risk recurrence within year prior history symptomatic myeloma previous chemotherapy myeloma except corticotherapy dexamethasone 40 mg day max uncontrolled medical condition comorbidity might interfere subject participation pregnant breast feeding females known positive hiv known seropositive hepatitis except setting sustained virologic response svr define viremia least 12 week completion antiviral therapy seropositive hepatitis define positive test hepatitis surface antigen hbsag subjects resolved infection ie subject hbsag negative positive antibody hepatitis core antigen antihbc antibody hepatitis surface antigen antihbs must screen use realtime polymerase chain reaction pcr measurement hepatitis virus hbv dna level pcr positive exclude exception subjects serologic finding suggestive hbv vaccination anti hbs positivity serologic marker known history prior hbv vaccination need test hbv dna pcr patient severe renal failure require dialysis clairance creatinine 20 ml min 10 prior local irradiation within two week first dose however exception patient allow remain treatment phase study make radiation therapy pathological fracture site enhance bone healing treat postfracture pain refractory narcotic analgesic pathologic bone fracture fulfil criterion disease progression 11 evidence central nervous system cns involvement 12 unable take corticotherapy daratumumab bortezomib lenalidomide study entry 13 ongoing active infection especially ongoing pneumonitis 14 ongoing cardiac dysfunction specify uncontrolled hypertension mi within month unstable angina pectoris cardiac arrhythmia grade high 15 patients left ventricular ejection fraction 40 lvef 40 16 use experimental drug therapy within 15 day screen 17 grade toxicity unresolved 18 inability unwillingness comply birth control requirement 19 unable take antithrombotic medicine study entry 20 major surgery within 14 day enrolment 21 serious medical psychiatric illness could investigator opinion potentially interfere completion treatment accord protocol 22 known allergy study medication analogue excipients various formulation agent 23 known gastro intestinal disease gastro intestinal procedure could interfere oral absorption tolerance daratumumab lenalidomide include difficulty swallow 24 adult guardianship curatorship legal protection",
    "INTERVENTION": "bortezomib daratumumab lenalidomide dexamethasone",
    "STATISTICS": "primary endpoint trial good partial response good rate completion induction phase accord international myeloma work group response criterion previous publish phase ii trial 36 patient achieve good partial response good induction using phase one stage hern design lowest acceptable response rate 35 p0 expect response rate 60 p1 type type error level 20 26 patient need account 10 nonevaluable patient 29 patient recruit"
  },
  "ITAC": {
    "TITLE": "multicenter randomize prospective trial compare efficacy safety infliximab cyclophosphamide severe behcet disease",
    "JUSTIFICATION": "itac first randomized prospective head head study compare infliximab cyclophophamide severe manifestation behcet disease behcet disease systemic vasculitis arterial venous vessel size involve young patient 12 45 year behcet disease significantly increase morbidity mortality therape utic management behcet disease depend clinical presentation organ involve although colchicine nonsteroidal antiinflammatory agent topical treatment often sufficient mucocutaneous joint involvement aggressive approach immunosuppressive agent warrant severe manifestation retinal vasculitis cardiovascular neurological involvement early recognition vigorous use immunosuppressive high dose steroid change prognosis patient severe behcet disease behcet disease severe systemic vasculitis lead 5year mortality rate 15 patient major vessel neurological involvement cyclophosphamide use lifethreatening behcet disease 40 year however outcome severe complication behcet disease still poor european league rheumatism eular recommendation update 2016 management behcet disease advocate cyclophosphamide antitnf plus glucocorticoid lifethreatening manifestation neurological major vessel involvement recommendation vascular disease neurological involvement base largely expert opinion uncontrolled evidence open trial observational study need properly design control clinical trial apparent tnfa antagonist use success severe resistant case addition incidence blindness behcet disease dramatically reduce recent year use antitnf however firm evidence randomize controlled trial directly address best induction immunosuppressive therapy severe behcet disease manifestation physicians still prescribe compound offlabel use therefore aim assess best induction therapy severe difficult treat behcet disease patient",
    "OBJECTIVE": "assess benefit infliximab comparatively cyclophosphamide severe lifethreatening behcet disease primary assessment criterion complete clinical response week 22 randomization estimate compare rate time occurrence relapse worsen estimate compare cumulative dose steroid estimate compare adverse event estimate compare mean change sf36 qualityoflife see appendix estimate compare rate remission accord organ involve compare change acutephase reactant estimate compare change cns involvement estimate compare change cardiovascular involvement survival event free survival estimate compare change behcet disease manifestation estimate compare change behcet disease current activity form see appendix assess serum concentration measurement tnfa inhibitor secondary endpoint complete clinical response week 12 48 remission cns cardiovascular involvement week 12 22 48 measures corticosteroid sparing percent meeting target mg day kg prednisone week 22 48 mean dose week 12 22 48 cumulative dose week 12 22 48 time response onset measures acutephase reactant creactive protein crp every week relapse time relapse relapse define reappearance clinical paraclinical feature active disease occurrence new lesion week 48 rate relapse worsening time occurrence worsen worsening define progression preexist lesion week 22 48 rate worsen gobal survival week 22 48 event free survival week 22 48 define occurrence death relapse worsening safety tolerability treatment behcet disease patient assess frequency severity adverse clinical event week 22 change quality life sf36v2tm health survey week 12 22 see appendix changes cns involvement physical exam cerebral medullar magnetic resonance imaging week 12 22 changes vascular involvement physical exam vascular doppler us angioct imaging biologically normalization reactive protein week 12 22 changes cardiological involvement physical exam echocardiography normalization left ventricular function disappearance cardiac thrombosis cardiac magnetic resonance imaging diseappearance gadolinium enhancement normalization left ventricular function biologically normalization troponin reactive protein week 12 22 changes organ involve behcet disease serum concentration measurement tnfa inhibitor week 22 change behcet disease current activity form see appendix week 12 22",
    "DESIGN": "bayesian design phase ii randomize clinical trial aim compare new treatment reference base binary end point offer great flexibility simplicity inference monitoring patient safety evidence efficacy small randomize trial collection free informed consent eligible patient active behcet disease randomize one group randomization visit day arm infliximab 5mg kg intravenously week 12 18 arm cyclophosphamide 7g month month intravenously week 12 16 20 patient receive corticosteroid regimen patient inclusion randomisation visit oral prednisone mg kg day 80 mg day following schedule reduction prednisone apply group long disease inactive week 8mg kg day week 7mg kg day week 6mg kg day week 10 5mg kg day week 12 4mg kg day week 14 3mg kg day week 16 2mg kg day week 22 1mg kg day",
    "INCLUSION CRITERIA": "adult pediatric patient severe lifethreatening behcet disease age 12 year old written inform consent informed consent obtain legal guardian accordance regional law regulation patient 12 17 year age diagnosis behcet disease accord international criterion behcet disease icbd see appendix life threaten active behcet disease define following disease category accord validated international definition major vessel disease arterial aneurysm arterial stenosis myocarditis major deep vein thrombosis inferior vena cava superior vena cava cardiac cavity thrombosis pulmonary embolism supra hepatic vessel renal mesenteric vessel diagnosis major vessel involvement use vascular doppler sonography echocardiography angioct scan cardiac magnetic resonance imaging central nervous system involvement encephalitis meningoencephalitis myelitis diagnosis neurobehcet cns involvement base objective neurological symptom associate neuroimaging cns medullar magnetic resonance imaging finding suggestive behcet disease related cns involvement cerebrospinal fluid csf findings show aseptic inflammation may associate chest xray result posteroanterior lateral within 12 week prior inclusion evidence active tuberculosis active infection malignancy female subject childbearing age negative pregnancy test subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study month stop therapy adequate contraceptive measure include hormonal method use two cycle prior inclusion oral contraceptive pill contraceptive patch contraceptive vaginal ring barrier method contraceptive sponge diaphragm use conjunction contraceptive foam jelly condom use conjunction contraceptive foam jelly intrauterine method iud sterilization tubal ligation monogamous relationship vasectomized partner abstinence potential subject positive interferon gamma release assay quantiferontb gold tspot tb test positive tuberculin skin test month eligible chest xray show evidence suggestive active tb disease clinical sign symptom pulmonary extrapulmonary tb disease subject latent tb infection already receive prophylactic tb treatment must agree advance complete treatment course 10 hiv negative serology negative hbs ag test month",
    "EXCLUSION CRITERIA": "subjects include study meet following criterion evidence active tuberculosis hiv active hbv infection hbs ag+ pregnancy lactation take oral daily dose glucocorticoid 20 mg prednisone equivalent week continuously prior inclusion visit take 3000 mg methylprednisolone week prior inclusion visit alcohol drug dependance severe renal creatinine clairance 30ml min 73m2 preexisting hemorrhagic cystitis liver insufficiency hepatic encephalopathy urinary obstruction heart failure stage iii iv nyha history malignancy within year prior inclusion carcinoma situ cervix excise basal cell squamous cell carcinoma skin 10 history multiple sclerosis demyelinate disorder 11 history severe allergic anaphylactic reaction cyclophosphamide infliximab 12 infectious disease infection require treatment intravenous antibiotic within week prior inclusion history recurrent infection 14 laboratory value assess inclusion hemoglobin dl wbc 103 mm3 platelet count 70 103 mm3 15 use following systemic treatment specify period treatment systemic biologic therapy cyclophosphamide within month prior inclusion azathioprine mycophenolate mofetil methotrexate time inclusion drug must withdraw prior receive cyclophosphamide infliximab dose day 16 live attenuate vaccine within week prior inclusion recombinant kill virus vaccine permit 17 lack affiliation social security benefit plan beneficiary assignee patients affiliate universal medical coverage cmu eligible study",
    "INTERVENTION": "infliximab 5mg kg intravenously week 12 18 cyclophosphamide 7g month month intravenously week 12 16 20",
    "STATISTICS": "experimental design multicentric open multicenter randomize clinical trial stratify characteristic initial behcet disease evaluation primary assessment criterion 22 week primary assessment criterion final measure corticosteroid sparing review scientific committee blind randomization rct use bayesian design phase ii randomize national multicentre clinical trial aim compare new treatment reference base binary endpoint complete clinical response week 22 offer great flexibility simplicity inference monitoring patient safety evidence efficacy small randomized trial"
  },
  "FOCUS": {
    "TITLE": "randomize control multicenter study compare efficacy safety adalimumab mycophenolate mofetil steroid dependent non infectious uveitis",
    "JUSTIFICATION": "focus first prospective randomize study compare standard care mycophenolate mofetil adalimumab recently active non infectiuous uveitis steroid dependency firm evidence randomize trial compare classical immunosuppressive compound biological agent identify best treatment condition burden non infectiuous uveitis reduce use immunosuppressive agent biologics raise question compound preferentially use recently active non infectiuous uveitis steroid dependency",
    "OBJECTIVE": "primary objective objective compare efficacy adalimumab 80mg day 40mg 14 day week week 35 subcutaneously standard care mycophenolate mofetil 2g day orally 36 week recently active noninfectious intermediate posterior uveitis panuveitis steroid dependency primary endpoint primary efficacy endpoint treatment failure rate 36 week treatment failure define following least one eye new active inflammatory chorioretinal retinal vascular lesion worsening best correct visual acuity line step increase anterior chamber cell grade vitreous haze relative baseline noabsence steroid discontinuation week 13 week 19 per protocol without aor additional immunosuppressive drug injectable steroid study treatment permanent discontinuation secondary objectives comparing adalimumab 80mg day 40mg 14 day week week 35 subcutaneously standard care mycophenolate mofetil 2g day orally 36 week evaluate cumulative incidence treatment failure week 55 inclusion evaluate change best correct visual acuity best correct visual acuity logmar baseline week week 55 evaluate change ocular inflammation anterior chamber vitreous baseline week week 55 evaluate change sign include vessel leakage baseline week week 55 evaluate presence macular edema baseline week week 55 evaluate quality life relate uveitis inclusion week 55 evaluate steroid spar effect baseline week 55 evaluate number time relapse uveitis characteristic uveitis worsen baseline week 55 evaluate effect underlie systemic disease appropriate baseline week 55 evaluate safety adalimumab mycophenolate mofetil week 55 secondary endpoints time treatment failure week 55 logmar best correct visual acuity eye week week week 12 week 16 week 20 week 24 week 30 week 36 week 55 anterior chamber cell grade week week week 12 week 16 week 20 week 24 week 30 week 36 week 55 vitreous haze grade sun criterion eye week week week 12 week 16 week 20 week 24 week 30 week 36 week 55 central retinal thickness eye baseline week week week 12 week 16 week 20 week 24 week 30 week 36 week 55 proportion patient central macular thickness 300 micron week week week 12 week 16 week 20 week 24 week 30 week 36 week 55 time optical coherence tomographic evidence macular edema least one eye week 55 nei visual functioning questionaire25 vfq25 composite score week 12 week 24 week 36 measures corticosteroid sparing percent meeting target mg kg day prednisone mean change mean dose week 55 cumulative dose cumulative incidence relapse number relapse week 55 clinical manifestation underlying disease depend underlying disease evaluate week 55 safety tolerability treatment assess frequency severity adverse event treatment discontinuation baseline week 55",
    "DESIGN": "prospective phase iii clinical trial multicenter openlabel two arm randomize clinical trial compare efficacy safety adalimumab standard care mycophenolate mofetil subject recently active intermediate posterior uveitis panuveitis despite steroid use oral prednisone mg day prednisone available use oral corticosteroid replacement prednisone equivalent prednisone dose oral corticosteroid stable dose least week prior first study drug administration day",
    "INCLUSION CRITERIA": "adult patient recently active noninfectious uveitis despite oral prednisone mg day equivalent prednisone doseoral corticosteroid equivalent dose prednisone stock market prednisone available use oral corticosteroid replacement prednisone equivalent dose oral corticosteroid equivalent recently active disease define presence least follow parameter either eye within month prior inclusion visit active chorioretinal retinal vascular lesion presence macular edema optical coherence 2+ anterior chamber cell standardization uveitis nomenclature sun criterion 2+ vitreous haze national eye institute nei sun criterion eligibility criterion check screen visit take place four week maximum prior inclusion visit inclusion randomization visit adult patient meet following criterion may include study provide write informed consent prior performance studyspecific procedure 18 year age diagnosis noninfectious intermediate posterior panuveitis least one eye fulfil international study group classification criteria standardization uveitis nomenclature sun criterion posterior pan uveitis confirm documented medical history recent activity non infectiuous uveitis define presence least follow parameter either eye within month prior inclusion visit despite 7mg day oral prednisone active chorioretinal retinal vascular lesion presence macular edema optical coherence 2+ anterior chamber cell standardization uveitis nomenclature sun criterion 2+ vitreous haze national eye institute nei sun criterion chest xray posteroanterior lateral ctscanner result within 12 week prior inclusion evidence active tuberculosis active infection malignancy potential subject positive interferongamma release assay quantiferontb gold tspot tb test inclusion eligible chest xray show evidence suggestive active tb disease clinical sign symptom pulmonary extrapulmonary tb disease subject latent tb infection already receive prophylactic tb treatment must agree advance complete treatment course female subject childbearing potential negative pregnancy test inclusion subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study month month stop therapy mmf adalimumab respectively unless sterility confirm simultaneous use two complementary method contraception preferable methods may consider highly effective method achieve failure rate less per year use consistently correctly consider highly effective birth control method accord ctfg recommendation method include female subject combine estrogen progestogen containing hormonal contraception associate inhibition ovulation oral intravaginal transdermal progestogenonly hormonal contraception associate inhibition ovulation oral injectable implantable intrauterine device iud intrauterine hormonereleasing system ius bilateral tubal occlusion vasectomise partner sexual abstinence context guidance sexual abstinence consider highly effective method define refrain heterosexual intercourse entire period risk associate study treatment reliability sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle subject male subject use condom vasectomy documentation azoospermia sexual abstinence affiliated social security system",
    "EXCLUSION CRITERIA": "subjects include study meet following criterion infectious uveitis masquerade syndrome idiopathic uveitis permit isolated anterior uveitis monocular patient active tuberculosis positive hiv serology hcv hbs ag test history malignancy within year prior inclusion carcinoma situ cervix nonmetastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reaction monoclonal antibody mycophenolate mofetil rifampicin isoniazid fluorescein infection require treatment intravenous antibiotic within week prior inclusion history multiple sclerosis demyelinate disorder 10 laboratory value assess inclusion hemoglobin 8g dl wbc 103 mm3 platelet count 80 103 mm3 glomerular filtration rate 30ml min transaminases time upper normal value 11 use following systemic treatment specify period treatment systemic alkylating agent within 12 month prior inclusion cyclophosphamide chlorambucil live attenuate vaccine within week prior inclusion 12 stage iii iv new york heart association cardiac insufficiency 13 pregnancy breastfeed 14 legal protection 15 participation another interventional study involve human participant exclusion period end previous study involve human participant applicable",
    "INTERVENTION": "eligible patient recently active non infectiuous uveitis randomize ratio arm adalimumab 80mg day 40mg 14 day week week 35 subcutaneously arm standard care define mycophenolate mofetil day orally 36 week treatment group receive corticosteroid regimen patient non infectiuous uveitis receive oral prednisone 10 mg day oral corticosteroid equivalent maximum 35 mg day prednisone oral corticosteroid equivalent prednisone dose prednisone stock marketif prednisone available use oral corticosteroid replacement prednisone equivalent dose equivalence common prednisonetapering programme apply group decrease discontinuation week 13 week 19 long disease inactive arm standard care define mycophenolate mofetil day orally 36 week",
    "STATISTICS": "prospective twoarm randomize openlabel phase iii trial compare adalimumab standard care mycophenolate mofetil base binary primary endpoint treatment failure week 36 treatment randomization stratify retinal vasculitis presence macular oedema underlie disease idiopathic uveitis underlying disease associate steroid dose inclusion 20mg vs 20mg trial conduct use group sequential design one interim analysis 50 primary observation complete efficacy futility early stopping rule specifically assume probability treatment failure primary endpoint 50 soc control population versus 20 alternative hypothesis adalimumab total number 106 patient 53 per randomization arm require ensure 90 power one sided type error risk account one interim analysis 50 primary observation complete use lan demets brien flemingtype riskspending function define efficacy futility nonbinding early stopping rule moreover plan include total 120 patient 60 per randomization arm account potential 10 losttofollowup"
  },
  "ICE": {
    "TITLE": "isatuximab type cryoglobulinaemia prospective pilot study",
    "JUSTIFICATION": "cryoglobulinaemia define presence immunoglobulin serum reversibly precipitate form gel temperature drop 37c redissolve upon rewarming classification include three subgroup base ig composition type cryoglobulinaemia consists one isotype subclass immunoglobulin types ii iii classify mixed cryoglobulinaemia include igg igm component overall cryoglobulinaemia consider rare disease 10 000 general european north american population although prevalence likely high area mediterranean basin mixed cryoglobulinaemia vasculitis multiorganic disease involve kidney joint skin peripheral nerve type cryoglobulinaemic vasculitis search underlying plasmacell neoplasm mandatory cryoglobulinaemia compose igg often find multiple myeloma monoclonal gammapathy unknown significance course mixed cryoglobulinaemia vasculitis varies widely prognosis influence mixed cryoglobulinaemia induced damage vital organ co morbidity associate underlying disease type cryoglobulinaemic vasculitis plasma cell associate disorder crossroad autoimmunity plasmacell neoplasm treatment modulate accord underlie associated disease severity internal organ involvement overall 10year survival diagnosis cryoglobulinaemic syndrome range 50 90 case renal involvement main therapeutic goal must cure underlying haematological disease overwhelmingly plasmacell neoplasm common neoplasia multiple myeloma predominantly associate type cryoglobulinaemia hyperviscosity 50 case treating underlying monoclonal disorder associate improvement stabilization cryoglobulinaemic symptom patient type cryoglobulinemia although negativation serum cryoglobulins achieve half patient alkylating agent bortezomib main therapeutic option associate side effect include neuropathy patients present symptomatic hyperviscosity require urgent therapeutic intervention use plasma exchange plasmapheresis remove cryoglobulins circulation standard care international guideline treatment type cryoglobulinemia isatuximab anticd38 monoclonal antibody effective treat relapsed refractory multiple myeloma autoreactive plasma cell represent key player autoimmune disorder particularly type cryoglobulinemia type cryoglobulinemia model plasma cell associate disorder crossroad autoimmunity plasmacell neoplasm however rituximab fails target population poorly effective condition thus unmeet need plasma cell target therapy type cryoglobulinemia clonal plasma cell type cryoglobulinemia express surface cd38 provide rationale use isatuximab cryoglobulinemia although biology clonal plasma cell type cryoglobulinemia distinct al amyloidosis model hematological disease associate monoclonal ig whose tumor mass low al amyloidosis anticd38 target therapy highly efficient monotherapy treatment naive patient relapsers thus isatuximab represent highly promising therapy type cryoglobulinemia could use monotherapy",
    "OBJECTIVE": "primary objective assess complete clinical response rate isatuximab type igg cryoglobulinemia primary endpoint complete clinical response rate cryoglobulinemia vasculitis symptom week 20 secondary objective safety tolerability treatment assess frequency severity adverse clinical event early complete response rate week 12 complete partial improvement organ involve baseline non clinical clinical improvement response rate week 12 week 20 rate cryoglobulinemia clearance rate negativation rheumatoid factor activity rate normalization c4 complement level early failure rate week non clinical response week clinical relapse rate time relapse course plasma cell associate disorder evolution gammaglobulin level quality life score sf36 appendix rate infection severe complication birmingham vasculitis activity score appendix immunomonitoring deep immunophenotyping cytokine production spectrometry fish analysis single plasma cell repertoire secondary endpoint safety tolerability treatment assess frequency severity adverse clinical event week 20 complete partial nonclinical response rate week 12 week 20 rate cryoglobulinemia clearance negativation rheumatoid factor activity normalization c4 complement level week 12 week 20 rate early failure nonclinical response week rate renal complete remission define proteinuria 5g 24h proteinuria creatininuria 50 mg mmol disappearance hematuria glomerular filtration rate 60ml min 73m2 week 12 week 20 clinical relapse rate define de novo appearance reappearance manifestation attributable cryoglobulinemia vasculitis 48 week followup rate time relapse baseline week 48 course plasma cell associate disorder week 12 week 20 mean change gammaglobulin level baseline week 20 quality life assess mean variation sf 36 20 week rate infection severe complication 48 week followup proportion patient remain remission birmingham vasculitis activity score baseline week 12 week 20 evolution immunomonitoring deep immunophenotyping cytokine production spectrometry fish analysis single plasma cell repertoire baseline week 12 week 20",
    "DESIGN": "phase pilot prospective study 21 patient type igg cryoglobulinemia treat isatuximab isatuximab perform intravenously 10mg kg day week week week week every week total 12 infusion phase ii prospective multicenter study french plasma cell neoplasm cryoglobulinemia network compose hematologist internist rheumatologist dermatologist nephrologists patient receive subsequently therapy 21 patient type igg cryoglobulinaemia treat isatuximab isatuximab administred intravenously 10mg kg day week week week week every week total 12 infusion",
    "INCLUSION CRITERIA": "adult patient type igg active cryoglobulinemia vasculitis age 18 year written inform consent monoclonal gammopathy unknown significance monoclonal igg component active cryoglobulinemia vasculitis define positive history positive type igg cryoglobulinemia clinically active cryoglobulinemia skin joint renal pulmonary cardiovascular muscular digestive central peripheral neurological involvement treated naive relapsers type cryoglobulinemia patient affiliated national french social security system contraception male participant male participant must agree use highly effective method contraception participation period least month last dose study treatment refrain donate sperm period female participant female participant eligible participate pregnant breastfeed least one following condition female childbearing potential fcbp fcbp must negative serum urine pregnancy test sensitivity least 25 miu ml within 24 hour start study medication must apply highly effective method contraception participation period least month last dose study treatment refrain donate oocyte period hiv negative serology negative hbs ag test hcv negative serology negative hcv rna positive hcv serology within month prior inclusion",
    "EXCLUSION CRITERIA": "patient vasculitis unrelated cryoglobulinemia patient nonactive cryoglobulinemia vasculitis patient diagnosis multiple myeloma except indolent myeloma patient treat immunosuppressant alkylating agent rituximab chemotherapy plasma cell neoplasm introduce increase month prior inclusion live vaccine within 30 day prior baseline concurrently isatuximab infection require hospitalization use parenteral iv im antibiotic antibacterial antiviral antifungals antiparasitic agent within 60 day prior day active tuberculosis hiv positive positive ag hbs positive hcv rna clinically significant uncontrolled medical condition investigator opinion would expose excessive risk patient may interfere compliance interpretation study result 10 hypersensitivity history intolerance steroid mannitol pregelatinized starch sodium stearyl fumarate histidine base hydrochloride salt arginine hydrochloride poloxamer 188 sucrose component study therapy amenable premedication steroid h2 blocker would prohibit treatment agent 11 hypersensitivity active substance isatuximab premedication excipients 12 received investigational drug within 14 day prior inclusion within halflives investigational drug whichever long 13 participation another interventional study exclusion period end previous study 14 vulnerable population pregnant breastfeed woman persons deprived liberty judicial administrative decision persons psychiatric care without consent adults subject legal protection measure persons unable express consent 15 neutrophils 1000 mm3 16 platelets 75000 mm3",
    "INTERVENTION": "isatuximab administer intravenously 10mg kg day week week week week every week total 12 infusion none",
    "STATISTICS": "use onesample multiple testing procedure phase ii clinical trial report definitions fleming 1982 biometrics volume 38 page 143151 calculate sample size report definitions p0 maximum response proportion poor drug p1 minimum response proportion good drug sample size number response r+1 p0 reject number response p1 reject alpha probability reject p0 true beta probability reject p1 true summary statements ice study require 21 subject decide whether proportion responding less equal 400 great equal 700 number response 13 hypothesis 400 reject target error rate 050 actual error rate 035 number response 12 less hypothesis 700 reject target error rate 150 actual error rate 148 pilot prospective phase ii clinical trial aim evaluate safety efficacy isatuximab type cryoglobulinemia vasculitis hypothesize 70 patient receive isatuximab achieve complete remission cryoglobulinemia vasculitis week 20 week 20 continuous variable cf variable describe primary secondary objective present median iqr mean sem categorical variable present count proportion statistical comparison perform use mannwhitney test quantitative unpaired data ttest quantitative pair data kruskalwallis multiple comparison spearman correlation test correlation ttest quantitative pair data analysis use compare immunological change day week 12 20 isatuximab statistical test twotailed significance level 05"
  },
  "ETOLE": {
    "TITLE": "evaluation tomosynthesis characterization management breast",
    "JUSTIFICATION": "tomosynthesis innovative technique develop digital mammography obtain sectional image breast mammography main disadvantage image projection create overlay eliminate tomosynthesis",
    "OBJECTIVE": "evaluate birads classification obtain tomosythesis superior classification obtain conventional mammography term specificity noninferior term sensitivity joint analysis true negative false negative rate accord birads scale compare histological result followup outcome see gold standard evaluate tomosynthesis synthetic tomography allow good detection certain sign poor prognosis malignant lesion size multicentricity tumour lymph node extension skin pectoral infiltration tomosynthesis synthetic tomography modify number additional view number additional examination include ultrasound breast mri biopsy assess whether tomosynthesis reduce necessary number ultrasound compare difference rating birads obtain tomosynthesis synthetic mammography ultrasound difference obtain conventional mammography alone combine ultrasound tomosynthesis synthetic mammography change radiation dose receive patient tomosynthesis synthetic mammography improve reproducibility birads classification abnormality cost analysis tomosynthesis synthetic mammography compare mammography mammography ultrasound",
    "DESIGN": "randomized multicentric study phase iii diagnostic study accord classification gluud gluud inclusion phase 18 month tomosynthesis system instal site manufacturer patient clinical breast imaging abnormally site study period give informed consent randomize either conventional mammography tomosynthesis incidence synthetic mammography evaluation tomosynthesis characterization management breast conventional digital mammography",
    "INCLUSION CRITERIA": "women clinical breast imaging abnormality patient clinical breast imaging abnormality classify birads table patient 18 year old signed informed consent",
    "EXCLUSION CRITERIA": "patients high risk breast cancer mutation brca carrier li fraumeni history thoracic radiation exclude great sensitivity ionize radiation 15 11 patient unable give informed consent physical mental legal reason patient affiliate french social security insurance patient treatment breast cancer mammography recommended accord good practice french health authority pregnant patient",
    "INTERVENTION": "",
    "STATISTICS": "analysis comparison birads classification obtain mammography tomosynthesis rely construction simultaneous confidence interval ratio true negative rate specificity false negative rate 1sensitivity obtain technics mammography tomosynthesis arm describe alonzo et al"
  },
  "MAC-HAPLO-MUD": {
    "TITLE": "randomize prospective phase iii clinical trial compare hla 10 10 match unrelated donor haploidentical allogeneic hematopoietic stem cell transplantation myeloablative conditioning regimen",
    "JUSTIFICATION": "unrelated adult donor hlamatched recipient allelelevel hlaa dqb1 drb1 consider best choice absence hlamatched sibling patient need hematopoietic stem cell transplantation however use match unrelated donor limit prolonged time identify schedule donation match unrelated donor allow patient relapse transplantation perform limit availability fully hla match unrelated donor noncaucasian population alternative donor single hla mismatch unrelated donor unrelated umbilical cord blood graft haploidentical related donor still associate high nonrelapse mortality delay immune reconstitution recent strategy haploidentical haplo relate donor stem cell transplantation haplo stem cell transplantation improve dramatically outcomes use tcell replete graft administration posttransplantation cyclophosphamide ptcy target alloreactive cell generate early hla mismatch transplant spar regulatory cell leave unaffected nondividing hematopoietic stem cell standard posttransplant immune suppression calcineurin inhibitor cni mycophenolate mofetil retrospective study haplo stem cell transplantation ptcy associate similar overall progressionfree survival matched unrelated donor stem cell transplantation match unrelated donor stem cell transplantation low rate toxicity graft versus host disease thus potentially good result matched unrelated donor stem cell transplantation reduce intensity condition regimen phase iii randomize trial currently address question france elderly patient use reduced intensity condition regimen haplomudelederly01 phrck 14045 pi blaise institut paoli calmettes randomized prospective phase iii clinical trial compare hla 10 10 match unrelated donor haplo stem cell transplantation myeloablative conditioning regimen urgently need answer question",
    "OBJECTIVE": "main objective improve 1year progression free survival without acute grade iiiv graft versus host disease without moderate severe chronic graft versus host disease use haplo donor compare 10 10hla matched unrelated donor myeloablative stem cell transplantation primary endpoint 1year progression free survival without grade iiiv acute graft versus host disease without moderate severe chronic graft versus host disease 65 haplo stem cell transplantation versus 50 10 10hla match unrelated donor secondary objective compare two arm term clinical biological outcome kinetic haematopoietic reconstitution graft failure graft versus host disease progression free survival relapse non relapse mortality overall survival interval inclusion transplant rehospitalizations treatment related morbidity quality life chimerism immune reconstitution search prognostic factor main outcome globally arm search treatmentbycovariate interaction main outcome secondary endpoint interval inclusion transplant absolue number neutrophil platelet month month month month month 12 chimerism month month month month 12 month 24 acute graft versus host disease incidence grade chronic graft versus host disease incidence grade relapse incidence progression free survival severe infection ctcae grade 34 incidence veinoocclusive disease incidence cardiac toxicity nonrelapse mortality overall survival quality life questionnaire ebmt number new day hospitalization hospitalization transplantation immune reconstitution month month month month 12 month 24 lymphocytes cd4 cd8 nk lymphocytes gammaglobulines",
    "DESIGN": "randomized prospective phase iii clinical trial compare hla 10 10 match unrelated donor haploidentical allogeneic hematopoietic stem cell transplantation myeloablative conditioning regimen goal show superiority haplo stem cell transplantation primary endpoint even similar result arm obtain study might revolutionize strategy stem cell transplantation since haplo donor use priority compare match unrelated donor quick procedure cheap available almost patient",
    "INCLUSION CRITERIA": "patients 15 year age old high risk hematological malignancy indication allogeneic hematopoietic stem cell transplantation patients aged 15 55 year old aml smd smp require allogeneic stem cell transplantation least partial response malignant disease without hla match related donor strong probability related haplo donor hla10 10 match donor available patient need least match unrelated donor identify outside book bmdw bone marrow donors worldwide use easy match software include usual criterion hsct ecog severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function asat alat 5n total bilirubin 2n creatinine 150 mol except abnormality link hematological disease health insurance coverage understand informed consent optimal treatment followup prescription two effective contraception method must prescribe duration study sign write informed consent parent patient age less 18",
    "EXCLUSION CRITERIA": "patients cancer last year except basal cell carcinoma skin situ carcinoma cervix uncontrolled infection seropositivity hiv htlv1 active hepatitis yellow fever vaccine heart failure accord nyha ii bile duct obstruction preexisting acute hemorrhagic cystitis renal failure creatinine clearance 30ml min pregnancy hcg positive breastfeeding debilitate medical psychiatric illness preclude realization stem cell transplantation understanding protocol protection law tutorship curatorship unwilling unable comply protocol",
    "INTERVENTION": "haplo donor myeloablative stem cell transplantation use cyclophosphamide 50 mg kg day intravenous route d+3 d+4 stem cell transplantation conditioning regimen patient myeloid malignancy haploidentical stem cell transplantation thiotepa 5mg kg day day fludarabine 40mg month day day5 to2 iv busulfan 2mg kg day day5 to3 hlamatched unrelated donor stem cell transplantation fludarabine 30mg month day day6 to2 iv busulfan 2mg kg day day to3 patient fludarabine 30 mg month day day tbi 200 cgy twice daily day total dose 1200 cgy stem cell source bone marrow haploidentical stem cell transplantation peripheral blood stem cell hlamatched unrelated transplantation graft versus host disease prophylaxis haploidentical stem cell transplantation cyclophosphamide 50 mg kg day d+3 d+4 ciclosporine mycophenolate mmf d+5 hlamatched unrelated donor stem cell transplantation antithymocyte globuline thymogobuline mg kg total dose 5mg kg day cyclosporine day mmf day +1 absence graft versus host disease mmf stop d+35 arm",
    "STATISTICS": "justification sample size hypothesize 1year progression free survival without grade iiiv acute graft versus host disease without moderate severe chronic graft versus host disease 65 haplo stem cell transplantation versus 50 10 10hla match unrelated donor 172 patient arm 344 overall require demonstrate difference base twosided logrank test 05 power 80 hazard ratio 62 required total number event 146 bayesian interim analysis inflate interim analysis midinclusion base bayesian computation stop rule base modeling log hazard ratio main endpoint spiegelhalter 1994 non informative prior loghr consider terminal analysis observation required number event"
  },
  "SHORTCUT": {
    "TITLE": "efficacy day versus 14 day antibiotic therapy acute pyelonephritis kidney transplant recipient multicentre randomize noninferiority trial",
    "JUSTIFICATION": "infections major cause morbidity mortality solid organ transplant recipient kidney transplant recipient urinary tract infection represent 4572 infection 30 hospitalization sepsis acute transplant pyelonephritis common complication occur 20 patient mainly first year transplantation associate increase risk acute kidney rejection longterm kidney graft dysfunction gram negative bacteria mainly coli account 70 urinary tract infection kidney transplant recipient infection favor urinary tract modifications defects immunosuppression often recurrent necessitate repeat course antibiotic selective pressure due antibiotic consumption along frequent hospital admission immunosuppression well know risk factor development antibiotic resistant infection multidrug extensively xdr drug resistant enterobacteriaceae include esbl carbapenemaseproducing organism thus increasingly observe transplant unit represent global threat new antibiotic expect next decade one main strategy limit antimicrobial resistance reduce duration antibiotic treatment day course recommend simple acute pyelonephritis apn treat fluoroquinolones parenteral lactams prolong 10 14 day presence underlying disease risk complication kt team treat patient 1421 day recommend american guideline however need extend treatment duration immunosuppressed patient poorly define concept optimal duration treatment apn kidney transplant recipient know patient exclude study urgent need reduce antibiotic consumption population high risk develop infection due resistant pathogen hypothesis daytreatment sufficient cure apn good clinical response 48h treatment kidney transplant recipient effective 14 day",
    "OBJECTIVE": "show dayantibiotic therapy inferior 14 dayantibiotic therapy treatment acute pyelonephritis kidney transplant recipient primary endpoint clinical cure additional antibiotic treatment since end antibiotic treatment main evaluation day 30 clinical cure define fever 38c symptom urinary tract infection compare arm clinical cure day 90 day 180 microbiological cure day 30 90 180 tolerance safety antibiotic hospitalization length stay antibiotic consumption total follow acquisition antibiotic resistant enterobacteriaceae kidney graft function transplant rejection day 90 day 180 total cost evaluate risk factor failure relapse recurrence evaluate efficacy antibiotic treatment end treatment day experimental arm day 14 control group secondary endpoint clinical cure day 90 180 microbiological cure day 30 90 180 incidence relapse recurrence day 30 day 90 incidence adverse event imputable antibiotic treatment kidney function assess accord mdrd modification diet renal disease ckd chronic kidney disease epidemiology collaboration epi hospitalization length stay define delay date inclusion date hospital discharge antibiotic consumption rectal carriage antibiotic resistant enterobacteriaceae inclusion day 30 microbiological cure define sterile urine uropathogene 103 cfu ml urine culture",
    "DESIGN": "multicenter control randomize noninferiority open label clinical trial parallel group day versus 14 day antibiotic treatment randomization stratify date renal transplantation year year center sex potential confounders phase iv trial",
    "INCLUSION CRITERIA": "kidney transplant recipient acute pyelonephritis age 18 year kidney transplant recipient apn define fever t38c without clinical sign symptom urinary tract infection pyuria 104 white blood cells ml 10 mm3 positive urine culture uropathogen 103 cfu ml susceptible empirically administrate antibiotic confirm suspect febrile non urinary bacterial infection urologic renal complication baseline imaging abscess obstruction favourable early response antibiotic treatment 48 60 hour first dose antibiotic effective causative uropathogen define 38c improvement resolution sign symptom urinary tract infection present diagnosis written inform consent",
    "EXCLUSION CRITERIA": "patients following condition severe complicate condition rapidly progressing disease immediately life threaten illness include limited septic shock current impede respiratory failure acute heart liver failure admission stay intensive care unit baseline obstruction urinary tract renal perinephric prostatic abscess prior inclusion study current participation another interventional study dual antibiotic therapy prophylactic antibiotic cotrimoxazole allow dose aminoside allow randomization first month post transplantation current indwell catheter include bladder catheter ureteral stent percutaneous nephrostomy tube neurogenic bladder enterocystoplasty immunodeficiency immunosuppressive therapy relate kidney transplantation include hematologic favourable early response antibiotic treatment 48 malignancy cancer asplenia neutropenia 500 neutrophils mm3 pregnancy breastfeed hypersensitivity previous severe adverse drug reaction antibiotic therapy unable unwilling judgment investigator comply protocol life expectancy month patient legal guardianship without healthcare coverage homeless patient women childbearing potential use adequate contraception",
    "INTERVENTION": "standard 14 day antibiotic duration",
    "STATISTICS": "sample size 235 group achieve 80 power detect noninferiority margin difference group proportion 05 reference group proportion 95 treatment group proportion assume 90 null hypothesis inferiority power compute case actual treatment group proportion 90 test statistic use onesided test unpooled significance level test 05"
  },
  "CAMOVID": {
    "TITLE": "camovid multicenter randomize trial evaluate efficacy safety camostat mesylate treatment sarscov2 infection covid19 ambulatory adult patient",
    "JUSTIFICATION": "since december 2019 novel coronavirus call sarscov2 severe acute respiratory syndrome coronavirus cause international outbreak respiratory illness describe covid19 22nd march 2020 2920142 confirm case covid19 include 12784 death report world health organization 31 march 2020 52827 severe case france include 3532 death spectrum symptomatic infection range mild critical infection severe 15 infected patient require hospitalization require intensive care unit admission diagnosis sarscov2 infection relies clinical symptom microbiological testing test sarscov2 infection test center use reverse transcription polymerase chain reaction nasal swab patient productive cough number investigational agent explore antiviral treatment covid19 however date control data support use specific treatment antiviral drug immunomodulatory drug efficacy covid19 unknown sarscov2 infects human cell binding spike protein membranous aminopeptidase call angiotensin convert enzyme angiotensin converting enzyme among tissue angiotensin convert enzyme expression mainly find pneumocytes enterocytes renal tubular cell podocytes cellular entry sarscov2 require protein priming cellular serine protease cellular serine protease entail protein cleavage allow fusion viral cellular membrane murine model sarscov pneumonia iwatayoshikawa et al show cellular serine protease ko mouse weaken inflammatory cytokine response reduced lung injury control mouse hoffmann et al find cellular serine protease inhibitor camostat mesylate block viral entry reduce infection human primary pneumocytes lung cell line sarscov2 also show serum convalescent sars patient crossneutralized sars2s driven entry another study perform bojkova et al show camostat mesylate reduce cytopathogenic effect due sarscov2 human colonic cell line camostat mesylate serine protease inhibitor commonly use japan dose 600 mg day successfully safely use treat pancreatitisassociated pain postoperative reflux oesophagitis side effect report rare dos nausea diarrhea hypersensitivity case cytopenia less hyperkaliemia abnormal hepatic function less 05 hypothesize camostat mesylate initiate early sarscov2 infection reduce viral infection viral cytopathogenic effect block sarscov2 entry cell therefore prevent deterioration toward severe form covid19",
    "OBJECTIVE": "objective evaluate efficacy camostat mesylate treatment sarscov2 infection highrisk adult patient confirmed covid19 require initial hospitalization term hospitalization need day 21 randomization primary endpoint proportion patient hospitalize covid19 deterioration world health organization die without hospitalization day day 21 indicative basis criterion hospitalization presence following respiratory rate 24 min rest sp02 95 room air blood pressure 100 mmhg lethargy unconsciousness brutal overall deterioration lethargy elderly haut conseil la sante publique reason require hospitalization leave discretion physician secondary objective adult patient diagnose laboratory confirm covid 19 require initial hospitalization evaluate impact camostat mesylate compare placebo safety day 21 efficacy term need hospitalization covid19 management independent blinded committee review overall clinical improvement day 21 clinical efficacy term intensive care need day 21 clinical efficacy term time hospitalization day 21 clinical efficacy respiratory function day 21 overall survival day 21 90 randomization patientreported outcome initial symptom day 21 virological serological immunological efficacy day 90 include surrogacy assessment candidate marker day 90 renal complication day 21 liver complication day 21 covid19 transmission within household secondary endpoint adverse event aes number aes number serious aes saes investigational medication discontinuation reason 21 day independent endpoint adjudication committeereviewed proportion patient hospitalize day day 21 covid19 deterioration independent eac review patient file blind randomize group determine whether hospitalization criterion relate covid19 world health organization covid19 clinical improvement ordinal scale day 14 21 oms descriptor score progression scale uninfected clinical virological evidence infection ambulatory limitation activity limitation activity hospitalized hospitalized oxygen therapy mild disease hospitalized oxygen mask nasal prong hospitalized hospitalized oxygen non invasive ventilation severe high flow disease intubation mechanical ventilation mechanical ventilation additional organ support pressor renal replacement therapy extra corporeal membrane oxygenation dead dead admission intensive care unit within 21 day inclusion number day alive without hospitalization 21 day initiation invasive mechanical ventilation covid19 severe within 21 day inclusion initiation oxygentherapy covid19 within 21 day inclusion overall survival day 90 number day alive without symptom day 21 sarscov2 virological assessment day day day 14 day 21 nasal swab droplet quantification sars cov2 rnaemia sarscov2 serological assessment day day day 14 day 21 plasma il6 il1b tnfa il8 level day 14 peripheral blood lymphocyte phenotyping telomere length measurement day day day 14 acute kidney failure define least serum creatinine increase 3mg dl 51 time baseline oliguria 5ml kg kdigo2012 scale within 21 day serum electrolyte estimate glomerular filtration rate day 14 21 liver transaminase gammagt alkaline phosphatase day 14 21 percentage covid19 affected individual share household day 14",
    "DESIGN": "multicenter singleblinded placebocontrolled twoarm parallel randomized phase iii trial",
    "INCLUSION CRITERIA": "ambulatory adult highrisk patient laboratory confirm covid19 require initial hospitalization patients 18 year old patients increase risk severe covid19 belonging one following group age 50 year body mass index 30 kg month diabetes hypertension chronic renal failure egfr 60 ml min chronic heart disease asthma chronic obstructive pumonary disease cystic fibrosis chronic liver disease chronic neurological disease solid organ transplant bone marrow transplant sickle cell anemia major thalassemia active currently treat year diagnose cancer active currently treat year diagnose malignant blood disease immunosuppressive treatment observe month laboratory confirm sarscov2 infection mild covid19 fulfil following criterion positive sarscov2 rtpcr nasal saliva swab sample positive sarscov2 antigen test perform within 96h inclusion visit clinical symptom sign consistent sarscov2 infection include limited fever upper respiratory tract infection sign digestive sign muscle pain anosmia dysgueusia informed consent participate trial patients must able willing comply study visit procedure",
    "EXCLUSION CRITERIA": "initial need hospitalization covid19 management define following severity criterion respiratory rate 24 min rest sp02 95 room air blood pressure 100 mmhg lethargy unconsciousness brutal overall deterioration lethargy elderly recommendation haut conseil la sante publique reason require immediate hospitalization leave discretion physician pregnancy breastfeed participation another interventional drug trial subject protect law guardianship curatorship absence health insurance known hypersensitivity camostat mesylate known person share household already include study participation another covid19 ambulatory interventional study patients complete full sarscov2 vaccine immunization procedure less week prior covid19 diagnosis last vaccine injection perform less week prior covid19 diagnosis",
    "INTERVENTION": "camostat mesylate oral administration 600mg day 100mg every hour 14 day day day 14 placebo tablet follow schedule investigational drug",
    "STATISTICS": "descriptive analysis use either frequency percentage categorical variable median interquartile range quantitative variable number miss value report primary endpoint probability hospitalization within 21 day compare group use twosided test secondary endpoint compare across group use fisher exact test compare probability group wilcoxon rank sum test compare quantitative endpoint analysis perform intentiontotreat principle twosided significancelevel use comparison secondary endpoint"
  },
  "GREEN": {
    "TITLE": "randomized doubleblind multicenter placebocontrolled efficacy safety study glenzocimab use addon therapy top mechanical thrombectomy acute ischemic stroke",
    "JUSTIFICATION": "emergent reperfusion main goal acute ischemic stroke therapy endovascular therapy recommend within hr stroke onset 24 hr follow perfusion image criterion despite major benefit associate mechanical thrombectomy 50 patient remain disabled month reperfusion rate mechanical thrombectomy critical determine functional outcome however complete reperfusion obtain 50 patient due least part erratic embolus noreflow process thrombus composition analysis show platelet rich clot resistant alteplase suggest platelet inhibition represent relevant target improve reperfusion nevertheless currently available molecule recommend acute phase due associate sich risk therefrom still need safe efficient antithrombotic agent administrable acute phase without induce bleeding risk order reduce size clot favour cerebral reperfusion result obtain escalate dose phase actimis study show promising safety data completion five cohort dose progression carry study dsmb member recommend use high dose 1000 mg consolidation phase 60 acute ischemic stroke patient recruit 12 treat high dose experience symptomatic ichs low rate asymptomatic intracranial hemorrhage similar incidence saes susars comparison patient treat low dose 125 250 500 mg placebo consolidation phase conduct additional 106 acute ischemic stroke patient parallelgroup design glenzocimab 000 mg versus placebo addon reperfusion standard care global safety result combine phase 166 concern incidence symptomatic ichs observe dose event 102 patient 000 mg event 66 patient glenzocimab group low one show placebo group events 64 patient incidence nonsymptomatic ichs observe alldose 30 events 102 patient 30 000 mg 20 events 66 patient 30 glenzocimab group low compare placebo group 30 events 64 patient 48 kaplanmeier curve show reduced mortality dose 000 mg glenzocimab group compare placebo group value 03 04 respectively twenty death occur phase ib 15 phase 2a 12 strokerelated outcome glenzocimab 1000 mg show favorable safety profile term hemorrhagic event well generally include patient age 80 year 40 population despite concomitant medical condition though power showing efficacy study glenzocimab 1000 mg show real benefit term death rate show decrease proportion patient severe level handicap encouraging result confirm ongoing future study platelet glycoprotein vi gpvi belong immunoglobulin superfamily expression restrict megakaryocyte platelet lineage gpvi key receptor collagen play major role platelet activation platelet recruitment thrombus growth studies also demonstrate gpvi platelet receptor polymerized fibrin interaction contribute thrombus growth reformation furthermore inhibition gpvi impair hemostasis subject genetic acquire gpvi deficiency prone excessively bleed gpvi therefore major target growth stabilization thrombus offer new therapeutic approach high safety profile study aim evaluate efficacy gpvi inhibitor glenzocimab addition endovascular therapy current protocol allow standard care use thrombolysis depend routine practice study site particular simpler mode administration tenecteplase single bolus injection lead many site adopt tenecteplase alternative alteplase acute ischemic stroke patient",
    "OBJECTIVE": "primary objective evaluate efficacy glenzocimab addition endovascular therapy compare endovascular therapy plus placebo whether associate intravenous thrombolysis functional outcome day 90 secondary objectives evaluate impact glenzocimab addition endovascular therapy compare endovascular therapy whether associate intravenous thrombolysis plus placebo overall survival day 90 year evaluate impact glenzocimab addition endovascular therapy compare endovascular therapy whether associate intravenous thrombolysis plus placebo reperfusion end endovascular therapy early clinical improvement 24 hr symptomatic intracranial haemorrhage 24 hr overall intracranial haemorrhage 24 hr serious adverse event saes suspect unexpected serious adverse reaction susars 24 hr day 90 bleedingrelated event bres 24 hr day 90 quality life day 90 year evaluate cost effectiveness glenzocimab addition endovascular therapy compare endovascular therapy plus placebo primary efficacy endpoint primary efficacy endpoint functional outcome day 90 assess modified mrs day 90 15 day secondary endpoints efficacy favourable functional outcome define mrs score day 90 proportion patient severe handicap mrs day 90 overall survival day90 year early reperfusion outcome stroke volume brain imaging 24 hr reperfusion end mechanical thrombectomy procedure assess etici score early neurological improvement nihss 24 hrs eq5d5l day 90 year safety incidence symptomatic nonsymptomatic intracranial hemorrhages 24 hr incidence symptomatic intracranial hemorrhages 24 hr incidence nonsymptomatic intracranial hemorrhages 24 hr incidence nature severity adverse events saes susars bleedingrelated events bres treatmentemergent adverse events teaes 24 hr day discharge 30 day 90 day incidence bleedingrelated event 90 day antiglenzocimab antibody baseline predose month least 50 patient cost effectiveness cost per qaly quality adjust life year gain use glenzocimab addition endovascular therapy cost per patient mrs score gain use glenzocimab addition endovascular therapy",
    "DESIGN": "national multicenter prospective randomize ratio parallel group doubleblinded placebo control phase ii iii study category",
    "INCLUSION CRITERIA": "patients 18 clinical diagnosis acute ischemic stroke large cerebral vessel occlusion 24 hr symptom onset patient see last time well eligible endovascular therapy base perfusion imaging time window 624 hour age 18 year old age18 year significant prestroke disability prestroke mrs must equal indication endovascular therapy within timewindow 24 hr participant treat without intravenous thrombolysis present clinico radiological mismatch define nihss10 aspect score occlusion cervical intracranial internal carotid artery proximal middle cerebral artery middle cerebral artery month month magnetic resonance angiography possible ct angiography informed consent sign patient inform consent sign family members trustworthy person condition allow express consent write per 11116 situation urgently absence family members trustworthy person patient enrol consent participate research request soon condition patient allow consent postmenopausal woman define menses 12 month without alternative medical cause wocbp highly effective birth control method place achieve failure rate less per year last least month imp administration birth control method may consider highly effective wocbp include combine estrogen progestogen containing hormonal contraception associate inhibition ovulation intravaginal transdermal progestogenonly hormonal contraception associate inhibition ovulation injectable implantable intrauterine device iud intrauterine hormonereleasing system ius bilateral tubal occlusion vasectomized partner birth control method may consider highly effective men last month imp administration include vasectomy use condom combine highly effective birth control method wocb partner please note hormonal contraception risk factor thromboembolic event attention call reconsider pass acute stroke phase women childbearing potential wocbp must negative serum urine pregnancy test baseline women childbearing potential fertile define woman follow menarche become post menopausal unless permanently sterile undergone hysterectomy bilateral salpingectomy bilateral oophorectomy affiliation social security health insurance",
    "EXCLUSION CRITERIA": "contraindications endovascular therapy contraindication contrast agent preexisting neurologic psychiatric disease mrs unknown symptom onset last seem well 24 hour patients need immediate dual antiplatelet therapy administration significant mass effect midline shift confirm ct magnetic resonance imaging gastrointestinal urinary tract hemorrhage previous 21 day patient intracranial haemorrhage known platelet count 100 000 mm3 10 pregnant breastfeed woman 11 known hypersensitivity glenzocimab excipients 12 known severe renal insufficiency grades 45 glomerular filtration rate 30ml min 73m2 13 participation another interventional clinical trial within 30 day prior inclusion 14 persons deprive liberty judicial administrative decision person subject psychiatric care section 32121 et 32131 person admit health social institution purpose research 11216 15 adults subject legal protection measure 11218 16 patient family patient unable give opinion express inability return protocol visit 17 patient receive anticoagulant heparin within 48 hour elevated aptt greater upper limit normal laboratory current use oral anticoagulant ex warfarin inr current use direct thrombin inhibitor direct factor xa inhibitor already mention nonauthorized concomitant treatment 18 patient already receive another humanized fragment monoclonal antibody suspicion hypersensitivity withdrawal consent patient wish withdraw trial persons deprive liberty judicial administrative decision person subject psychiatric care section person admit health social institution purpose research 11216",
    "INTERVENTION": "nonauthorized concomitant treatments patients receive experimental therapy 90 day study participation addition aforementioned exclusion criterion patient receive dual antiplatelet therapy require intra extracranial stent thrombolysis tenecteplase glenzocimab infusion authorized concomitant treatments symptomatic treatment use routinely disease relate symptom allow patient involve trial specific treatment adverse event also permit thrombolysis alteplase antiplatelet monotherapy allow glenzocimab start soon possible addition alteplase details treatment procedure must record ecrf glenzocimab act017 acticor biotech formulate iv administration sterile product 20 mm sodium citrate 130 mm sodium chloride buffer ph supply clinical trial use vial contain 50 ml drug product concentration 10 mg ml vial contain 500 mg glenzocimab two vial 2x500 mg glenzocimab administer concomitantly eligible patient total daily dose 1g placebo glenzocimab nacl acticor biotech iv administration supply clinical trial use vial 50 ml two vial placebo glenzocimab administer concomitantly eligible patient administered study treatment glenzocimab placebo per central randomization allocation study group patient randomize one arm receive glenzocimab arm placebo addition endovascular therapy endovascular therapy add research glenzocimab placebo intend administer iv infusion hr 14 dose administer 15minute bolus 34 dose administer 5h45min slow infusion proposed scheme obtain rapid effect emergency phase cover period time long enough avoid downstream complication",
    "STATISTICS": "interim analysis perform 30 patient enrolment achieve 78 patient control group consider distribution mrs 10 17 19 17 16 06 15 calculate sample 258 patient would yield power 80 detect treatment effect associate 85 consider twosided value 05 plan interim analysis 78 patient brien fleming scheme increase sample size 260 first interim analysis consider statistically significant value 0054 final analysis consider statistically significant value 0492 interim analysis also allow stop futility futility bound calculate use brien fleming type beta spending inclusion 78 patient statistic wald test value associate 523 favour placebo group trial terminate futility"
  },
  "TEOREM": {
    "TITLE": "multicenter randomize doubleblind clinical trial assess benefit adherent invasive coli eradication adult ileal ileocolonic crohn disease",
    "JUSTIFICATION": "current medical treatment crohn disease consist immunosuppressive drug therapy corticosteroid azathioprine methotrexate antitnf monoclonal antibody agent control symptom crohn disease patient withdrawal lead disease relapse also associate serious side effect infection lymphoma cancer liver toxicity antitnf monoclonal antibody efficient cost prohibitive moreover year roughly 10 responder antitnf become refractory treatment often become tolerized drug future crohn disease drug small molecule biologics antagonize proinflammatory cytokine gut homing lymphocyte yet similar safety issue immunosuppressive agent currently use current therapeutic algorithm crohn disease take account site inflammation composition intestinal microbiota moreover dysregulated intestinal immunity overproduction proinflammatory cytokine component crohn disease pathophysiology intestinal microbiota abnormal play important role pathogenesis crohn disease coli specie adhesive invasive property adherentinvasive coli describe ileal mucosa patient crohn disease adherent invasive coli find 36 patient ileal crohn disease control role adherent invasive coli crohn disease thoroughly investigate several laboratory around world show adherent invasive coli proinflammatory could play important role intestinal inflammation associate crohn disease may important therapeutic target randomized trial propose novel approach treatment crohn disease individualize patient colonize adherent invasive coli prescribe fdaapproved antibiotic show active bacteria vitro treatment discontinue 12 week hope obtain clinical endoscopic remission patient randomize experimental arm trial successful first kind facilitate new era clinical research patient crohn disease concomitant infection adherent invasive coli",
    "OBJECTIVE": "primary objective trial assess whether 12week treatment ciprofloxacin rifaximin superior placebo obtain endoscopic remission adherent invasive coli colonized patient ileal crohn disease without involvement caecum right colon primary endpoint overall response week 12 use centralize anonymous blind reading ileocolonoscopies overall response define segmental response least one segment cdeis baseline 20 increase cdeis segment cdeis segment segmental response segment cdeis baseline define case isolated aphtoid ileitis colitis decrease 50 lesion otherwise either decrease 50 surface ulceration either deep superficial loss deep ulceration present inclusion 20 increase superficial ulcerated surface secondary objective cid test correlation endoscopic remission adherent invasive coli eradication 12 week cid assess evolution endoscopic lesion week 12 cid assess rate clinical remission without steroid antitnf surgery 48 week patient whose adherent invasive coli eradicate patient reach primary endpoint cid assess rate biological remission study cid assess side effect experimental placebo group secondary endpoint endoscopic remission 12 week assess centralized reading ileocolonoscopies define cdeis segment cid mean variation segmental cdeis 12 week centralized reading ileocolonoscopies cid complete endoscopic remission 12 week centralized reading ileocolonoscopies define cdeis segment cid ulceration 12 week cid clinical remission define cdai 150 without steroid antitnf resection surgery crohn disease 12 48 week cid biological remission defined crp serum level mg fecal calprotectin 250 week 12 24 36 48 cid side effect",
    "DESIGN": "phase ii clinical trial multicentre prospective randomize doubleblind placebocontrolled adaptive clinical trial two parallel arm cid experimental arm oral ciprofloxacin 500 mg bid oral rifaximin 800 mg bid 12 week cid control arm placebo ciprofloxacin bid placebo rifaximin bid 12 week",
    "INCLUSION CRITERIA": "crohn disease adult patient infect adherent invasive coli cid age 18 80 year cid crohn disease ileum without involvement caecum right colon cid severe lesion confine within ileum right colon define segmental cdeis ileum right colon segmental cdeis segment transverse leave colon rectum cid informed consent participate study cid crohn disease either clinically inactive active severe cdai 450 cid patient clinically active disease cdai 150 prescription steroid treatment budesonide prednisone prednisolone independently entry study note patient without previous surgery crohn disease without crohn disease anal lesion without drain fistula seton enrol cid patients clinically active disease cdai 150 respond budesonide initial dose mg prednisone prednisolone initial dose 40 mg 70 point decrease cdai pre inclusion inclusion visit patient clinically inactive disease cdai 150 cid patients colonize adherent invasive coli initial ileal biopsy",
    "EXCLUSION CRITERIA": "cid ileal stenosis cross endoscope cid infliximab treatment receive less week preinclusion study cid methotrexate azathioprine start less three month preinclusion cid adalimumab treatment receive less week preinclusion study cid vedolizumab treatment receive less week preinclusion study cid hypersensitivity ciprofloxacin quinolones excipients cellulose microcrystalline crospovidone maize starch magnesium stearate silica colloidal anhydrous hypromellose titanium dioxide e171 macrogol 4000 cid treatment tizanidine probenecid theophylline xanthine derivatives phenytoin oral anticoagulant ropinirole cid hypersensitivity rifaximin excipients sodium starch glycolate type glycerol distearate colloidal anhydrous silica talc microcrystalline cellulose hypromellose titanium dioxide disodium edentate propylene glycol red iron oxide e172 cid previous extensive ileal surgery meter measure pathology surgical report cid short bowel syndrome cid need intestinal resection fistula abscess intestinal obstruction cid renal failure creatinine clearance 30 ml min 73m2 cid liver failure factor 50 cid past history epilepsy cid health insurance cid pregnant lactate woman cid refusal double effective contraception ie hormonal barrier method intrauterine device barrier method double barrier method highly effective method contraception hormonal contraceptive combine oral contraceptive patch vaginal ring injectables implant intrauterine device iud intrauterine system ius vasectomy tubal ligation effective method barrier method contraception male condom female condom cervical cap diaphragm contraceptive sponge cid patients already include biomedical research observational study registry cohort",
    "INTERVENTION": "association two antibiotic cid oral ciprofloxacin tablet 500 mg every 12 hour 12 week cid oral rifaximin tablet 200 mg 800 mg every 12 hour 12 week association two placebo placebo correspond antibiotic manufacture tablet appearance administrate every 12 hour 12 week",
    "STATISTICS": "data analyze intenttotreat basis trial base upon adaptive scheme allow reestimation required number included patient sample size reestimation ssr design take account uncertainty endoscopic remission rate week 12 placebo arm thus one interim unblind statistical analysis perform one half patient successively enrol primary endpoint analysis concern comparison main end point ie percentage endoscopic remission group compare use chisquare test unless validity violate fisher exact use secondary endpoint analyze whole sample size reach"
  },
  "SALMA": {
    "TITLE": "phase ii clinical trial assess combination sulfasalazine standard care induction therapy newly diagnose acute myeloid leukemia patient 60 year old salma study",
    "JUSTIFICATION": "nonfavorable acute myeloid leukemia old patient unmet medical need acute myeloid leukemia heterogeneous clonal myeloid neoplasm abnormal proliferation impaired differentiation hematopoietic stem myeloid progenitor cell impede normal hematopoiesis despite significant progress make understand acute myeloid leukemias oncogenesis past decade disease remain devastate 18 000 new case every year europe fiveyear overall survival 17 median age diagnosis acute myeloid leukemia 69 year cure rate patient old 60 improve recent decades standard care newly diagnose acute myeloid leukemia include 7+3 cytarabine anthracyclin combination follow repeated course high dose cytarabine without allogeneic hematopoietic stem cell transplantation recent advance standard care approach include addition multikinase inhibitor midostaurine induction consolidation patient flt3 gene mutations maintenance oral azacitidine completion induction without consolidation patient ineligible transplantation use liposomal formulation cytarabinedaunorubicin combination instead conventional 7+3 patient highrisk features patient old 60y adequate performance status comorbidities deem fit intensive chemotherapy 7+3 induction course combine day idarubicin 7day continuous cytarabine arac infusion induce complete remission complete remission incomplete platelet recovery 64 case nonfavorable cytogenetics recent advance supportive care patient notably progress antifungal armementarium lower toxicity 7+3 induction course early date rate within 510 range however despite high complete remission low early date rate 7+3 median eventfree survival remain month patient 60 year old nonfavorable cytogenetics owe frequent relapses improving antileukemic efficacy 7+3 induction course contribute good long term prognosis patients however modification 7+3 induction course must rely additional toxicity limit risk early date jeopardize postremission therapy repositioning drug excellent safety profile appear promising approach regard 10 nonfavorable risk acute myeloid leukemia old patient represent unmet medical need novel option improve efficacy 7+3 induction course thus necessary end induction measurable residual disease predict longterm outcome old acute myeloid leukemia patient treat intensively standardization molecular technique development multiparameter flow cytometry assay make possible assess measurable residual disease different time point course acute myeloid leukemia therapy virtually patients 11 old patient treat 7+3 measurable residual disease measure end induction course time point base npm1c transcript npm1mutated patient multiparameter flow cytometry assay leukemia aberrant immunophenotypes laip leukemic stem cell lsc method predict longterm outcome 12 npm1mutated patient young 60 role end induction measurable residual disease assess relative npm1c transcript level also well established 13 although data scarcer old patients 14 altogether end induction measurable residual disease appear relevant surrogate endpoint estimate efficacy alternative induction regimen old acute myeloid leukemia patient non favorable cytogenetics cystine import targetable vulnerability acute myeloid leukemia metabolic rewiring leukemic cell increasingly recognize targetable vulnerability acute myeloid leukemia leukemic stem cells endow increased quiescence chemoresistance 15 specific metabolic profile may instance underpin remarkable efficacy azacitidinevenetoclax combination patient ineligible 7+3 16 17 leukemic stem cell notably rely high level cysteine amino acid fuel glutathione synthesis maintain low level reactive oxygen species 18 chemical depletion intracellular pool cysteine precursor cystine preclinical antileukemic activity vitro 19 query transcriptional profile multiple acute myeloid leukemia patient cohort identify close correlation expression stemness program active cysteine metabolism pathway querying crispr screen conduct 500+ cancer cell line reveal specific dependence acute myeloid leukemia cell line cysteine metabolism among gene belong pathway high expression slc7a11 identify bear poor prognostic relevance acute myeloid leukemia cohort genetic silencing slc7a11 reduce viability colony formation acute myeloid leukemia cell line cysteine dependent fashion slc7a11 encode xct neutral amino acid antiporter import cystine glutamate xct antiport broadly express acute myeloid leukemia cell line three chemical inhibitor xct different chemical backbone include erastin s4 carboxyphenylglycine sulfasalazine highly concordant cystinedependent anti leukemic activity panel 20 acute myeloid leukemia cell line data suggest cystine import could represent targetable vulnerability acute myeloid leukemia sulfasalazine repurposed inhibit cystine import acute myeloid leukemia sulfasalazine broadly available well tolerate antiinflammatory medicine approve treatment ulcerative colitis rheumatoid arthritis 20 intact sulfasalazine metabolite 5aminosalicylic acid sulfapyridine competitively inhibit xct 21 sulfasalazine thus ideal candidate drug repurposing acute myeloid leukemia vitro sulfasalazine inhibit viability 12 primary acute myeloid leukemia specimen 10fold increase sensitivity compare cd34+ hematopoietic stem progenitor cell heathly donor sulfasalazine ic50 acute myeloid leukemias 176m 40m versus 94mm 21mm healthy cd34+ cell 0011 sulfasalazine 250m concentration range peak plasma concentration sulfasalazine healthy individuals 22 also significantly reduce vitro longterm culture initiate potential primary acute myeloid leukemia sample finally twicedaily intraperitoneal administration single agent sulfasalazine significantly reduce leukemic burden two distinct acute myeloid leukemias patientderived xenograft model finally compassionate administration oral sulfasalazine 20day period patient advanced refractory acute myeloid leukemia result transient clinically meaningful cytoreduction mechanistic study find sulfasalazine induce global metabolic rewiring cysteine onecarbon pathway result glutathione depletion reactive oxygen specie dependent cell death partly correspond ferroptosis 23 total protein expression slc7a11 correlate sulfasalazine activity thus sulfasalazine repurposed inhibit cystine import impair leukemic viability acute myeloid leukemia sulfasalazine improve efficacy anthracycline cytarabine combination chemotherapy preclinical acute myeloid leukemia model two distinct acute myeloid leukemia cell line anthracycline daunorubicin identify among panel acute myeloid leukemia drug one top synergism combine sulfasalazine observation may underpin reactive oxygen specie inducing potential anthracyclins 24 cohort 48 primary acute myeloid leukemia sample addition sulfasalazine low concentration mimic trough concentration healthy donors 22 significantly increase antileukemic activity combination daunorubicin arac total leukemic bulk gpr56+ leukemic stem cell nichelike ex vivo drug screen platform combine stromal coculture hypoxia plasmalike medium 25 finally addition sulfasalazine regimen combine day anthracycline adriamycin day cytarabine maximally tolerate regimen immunocompromised nogexl mouse far decrease leukemic burden patient derive xenografts model significantly prolong survival adriamycincytarabine chemotherapy alone pardieu et al manuscript preparation data present 2021 annual meeting european hematology association data support clinical evaluation addition sulfasalazine 7+3 acute myeloid leukemia addition sulfasalazine standard care chemotherapy manageable repurposing sulfasalazine inhibit xct investigate alone standard care chemotherapy solid tumors 2628 first study conduct singleagent sulfasalazine 10 highly debilitated patient high grade progress glioblastoma terminate prematurely base lack efficacy trial toxicity sulfasalazine low dos 56 mostly neurological suggestive tumorspecific poor tolerability possibly cause drug related peritumoral edema 26 conversely another doseescalation study single agent sulfasalazine 12 14 day 11 patient advanced gastric cancer identify 12 maximal tolerate dose grade anorexia dose limit toxicity grade aes include elevate ast bilirubin fatigue nausea vomit hyponatremia grade hematological grade non hematological adverse event trial median number sulfasalazine cycle range 14 mean relative dose intensity 85 dose level 60 maximal tolerate dose 12 28 finally phase study combine sulfasalazine thrice daily 21 day cisplatin pemetrexed day sulfasalazine cycle conduct 15 patient advanced nonsmallcell lung cancer maximal tolerate dose day recommended phase dose rp2d day dose limit toxicity include grade elevation ast alt aminotransferase level hypotension pneumonitis anorexia overall combination appear manageable promise activity note term overall response rate progressionfree survival compare historical controls 27 antitumor activity sulfasalazine continue explore solid tumor nct nct04205357 overall addition sulfasalazine chemotherapy appear feasible carefully design dose escalation phase trial collectively preclinical finding provide strong rationale clinical evaluation addition sulfasalazine standard care 7+3 induction regimen nonfavorable acute myeloid leukemia patient old 60 year purpose phase study evaluate safety feasibility strategy provide preliminary signal efficacy identify potential biomarkers",
    "OBJECTIVE": "primary objective phase assess safety characterize doselimiting toxicity identify maximal tolerate dose anticipate recommended phase ii dose rp2d combination sulfasalazine idarubicin cytarabine arac patient newly diagnose nonfavorable acute myeloid leukemia probability dose limit toxicity exceed 33 end induction cycle idarubicin arac sulfasalazine treatment day 42 phase ii assess preliminarily antileukemia efficacy combination idarubicin arac sulfasalazine mainly phase ii newly diagnose nonfavorable acute myeloid leukemia reference historical data complete remission rate define eln 2022 guideline measurable residual disease centralize flow cytometry primary endpoint phase documentation dose escalation dose limit toxicity identification maximal tolerate dose anticipate recommended phase ii dose rp2d dose limiting toxicity dose limit toxicity define safety observation period correspond induction cycle idarubicin arac sulfasalazine day 42 events occur onset second treatment cycle salvage consolidation consider dose limit toxicity following event consider dose limiting toxicity unless event attribute investigator clearly identifiable cause underlying illness disease progression concurrent illness concomitant medication prolonged myelosuppression define grade neutropenia thrombocytopenia day 42 start therapy later without evidence leukemia assess bone marrow aspiration biopsy grade hemorrhage day 42 grade non hematological toxicity day 42 exception grade infection grade fever neutropenia nb grade infection grade fever neutropenia consider dose limit toxicity grade nausea vomit diarrhea manage grade within 72 hour symptomatic treatment grade asymptomatic liver enzymes elevation improve grade within 72 hour onset grade tumor lysis syndrome resolve within 72 hour onset medical treatment maximal tolerated dose maximal tolerate dose define target dose limiting toxicity rate 33 assess dose escalation phase continual reassessment method recommended phase ii dose rp2d rp2d anticipate maximal tolerate dose however could equal one dose level low maximal tolerate dose determine interaction data safety monitor board insofar dose level validate pharmacokinetics pharmacodynamics study efficacy preliminary data phase ii measurable residual disease negative complete response end induction day 2842 per eln 2022 criteria complete response define complete remission complete remission cri complete remission incomplete hematologic recovery mean complete remission platelet count 100 000 absolute neutrophil count 1000 crh complete remission partial hematologic recovery mean complete remission fulfil complete remission cri peripheral blood count criterion platelet count 50 000 absolute neutrophil count 500 measurable residual disease negativity define 8color bone marrow fcm measurable residual disease end induction note npm1transcript base measurable residual disease bm pb carry exploratory endpoint npm1mutated patient secondary objective characterize pharmacokinetics pharmacodynamics sulfasalazine idarubicin arac administer combination dose escalation phase 1a confirm phase trial describe phase trial response leukemia treatment survival patient 12 month end induction visit document far phase ii trial safety profile confirm rp2d idarubicin arac sulfasalazine combination secondary endpoint assessment safety safety outcome measure assess continuously study monitoring ecgs clinical laboratory value integral safety assessment adverse event treatment emergent adverse event treatmentrelated teaes evaluate accord nci ctcae version serious adverse event define per protocol accord ema ich criterion causality relationship experimental treatment assess investigator frequency duration maximal severity treatment emergent adverse event treatmentrelated teaes teaes lead treatment discontinuation serious adverse event death document phase ii trial patients follow treatment relate teaes return grade baseline deem irreversible investigator pharmacokinetics assess sulfasalazine metabolite idarubicin metabolite arac allow determine pharmacokinetics model sulfasalazine early late time point confirm lack interaction sulfasalazine idarubicin arac pharmacokinetics plan detail section pharmacokinetic study conduct patient recruit phase part trial assess pharmacokinetics sulfasalazine main metabolite asa mesalazine sulfapyridine mostly involve adverse event pharmacokinetics perform day 14 pharmacokinetics profiling cytarabine idarubicine idarubicinol day confirm lack drugdrug interaction following pharmacokinetics parameter determine use non compartmental analysis winnonlin pharsight corporation maximum plasma concentration cmax maximum plasma concentration time tmax area plasma concentration time curve auc clearance mean residence time distribution volume vd pharmacokinetic analysis dose sulfasalazine administer orally together 200 ml water patient fast overnight meal permit blood sampling drug give blood sample obtain day predose 8h first sulfasalazine dose day predose 10 20 40 1h 24h start idarubicin injection day 14 predose 6h first sulfasalazine dose blood sample collect heparinized tube immediately collection tube invert several time keep approximately centrifugation tube centrifuge 10 min 1500g within 60 min collection separate plasma plasma separate aliquot polypropylene screwcap tube place 80c analysis sample label patient identification study identification sample number actual date time sample collect plasma concentration sulfasalazine metabolite determine validated ultraperformance liquid chromatography tandem mass spectrometry method 28 pharmacodynamics pharmacodynamic assay aim demonstrate reactive oxygen specie induction upon sulfasalazine exposure relative pretreatment level peripheral blood repeat bone marrow aspiration shorttime period unethical blood sample pharmacodynamics day effect sulfasalazine alone day combined effect sulfasalazine idarubicin arac pharmacodynamics assay include plasma level malondialdehyde glutathione reduced oxidized two robust biomarkers oxidative stress biomarkers previously involve ferroptosis sulfasalazine mode action preclinical result 29 assess patient time point regardless white blood cell count percentage circulate leukemic cell patient circulate leukemic cell reactive oxygen specie level peripheral blood mononuclear cell flow cytometry h2dcfda antileukemia activity response end induction assessment day 2842 per eln 2022 criteria morphologic leukemiafree state blastic criterion response bone marrow aspirate absence extramedullary disease requirement hematologic recovery partial response absence circulate blast absence extramedullary disease decrease bone marrow blast percentage 25 decrease pretreatment bone marrow blast percentage least 50 overall response rate define complete remission cri crh morphologic leukemia free state partial response rate primary refractory disease define patient lack criterion define response complete remission cri crh morphologic leukemia free state partial response end induction assessment exclude patient death aplasia death due indeterminate cause define per eln 2022 criterion death aplasia death due indeterminate cause define per eln 2022 criterion survival assessment 12 month eventfree survival event define non achievement hematologic response include complete remission cri crh hematologic relapse progressive disease initiation subsequent antileukemic therapy exclude hydroxyurea deaths prior one event mention reasons subsequent therapy initiation include intolerance resistance hematologic relapse unsatisfactory measurable residual disease evolution type intensive lessintensive best supportive care frame clinical trial offlabel compassionate use prospectively record duration response relapse free survival overall survival incidence subsequent allogeneic hematopoietic stem cell transplantation overall respond patient specifically apart specific mention hematological endpoint define accord late recommendation european leukemia network eln currently 2022 eln recommendation",
    "DESIGN": "phase iii open label multicenter clinical trial subsequent phase phase doseescalation design use survival continual reassessment method identify maximal tolerate dose recommend phase ii dose rp2d phase ii extension rp2d choose data safety monitoring board confirm safety rp2d preliminarily document clinical efficacy",
    "INCLUSION CRITERIA": "patients 60 year recently diagnose non favorable acute myeloid leukemia eligible intensive chemotherapy patients age 60 year old newly diagnose acute myeloid leukemia short course treatment hydroxyurea steroid acceptable patients acute myeloid leukemia secondary antecedent myelodysplastic syndrome mds myeloproliferative neoplasm mpn eligible therapyrelated acute myeloid leukemia eligible intensive chemotherapy accord investigator opinion multiparameter flow cytometry screen compatible multiparameter flow cytometry based measurable residual disease monitor accord eln criterion phase ii ecog performance status ast alt upper limit normal total direct serum bilirubin upper limit normal unless consider due leukemia estimated glomerular filtration rate 50 ml min accord mdrd equation written inform consent obtain prior screening procedure eligible national health insurance france",
    "EXCLUSION CRITERIA": "myeloid sarcoma 20 bone marrow blast patient receive vaccine injection live attenuated virus last three week proven central nervous system leukemic involvement favorable risk cytogenetics 15 17 21 inv 16 16 16 pmlrara runx1runx1t1 cbfb myh11 fusion transcript presence flt3itd tkd mandate treatment midostaurin concurrent therapy cytotoxic drug within week first study dose hydroxyurea control blood count permit patients plan receive cpx351 myelodysplasiarelated change therapyrelated acute myeloid leukemia previous treatment sulfasalazine last year ongoing treatment sulfasalazine aminosalicylic acid 5asa ulcerative colitis inflammatory rheumatism history allergic reaction sulfonylarylamines sulfonamide salicylate sulfasalazine excipients history allergic reaction idarubicin idarubicin excipients history allergic reaction cytarabine cytarabine excipients known glucose 6phosphate dehydrogenase deficiency known acute intermittent porphyria porphyria variegata uncontrolled systemic fungal bacterial viral infection define ongoing signs symptoms relate infection without improvement despite appropriate treatment uncontrolled active malignant disease within prior 12 month exclude myelodysplastic syndrome cutaneous basal cell carcinoma insitu carcinoma cervix breast local malignancy excise known human immunodeficiency virus infection human immunodeficiency virus related malignancy clinically active hepatitis hepatitis infection inability swallow known malabsorption syndrome condition may significantly impair absorption oral study medication participation another therapeutic interventional clinical study within 30 day enrolment administration therapy consider investigational use nonapproved indication context research investigation within drug halflives whichever longer prior first dose study drug previous treatment anthracyclines contraindication use anthracyclines include uncontrolled coronary disease severe renal failure severe hepatic failure recent myocardial infarction symptomatic congestive heart failure severe cardiomyopathy significant arrhythmia estimate investigator lvef 53 assess echocardiography muga anterior treatment idarubicin anthracyclines anthracenediones beyond maximum cumulative dose contraindication use cytarabine include degenerative toxic encephalopathy condition require treatment digoxin concurrent severe uncontrolled medical condition could compromise participation study females pregnant breastfeeding man whose sexual partner woman childbearing potential unwillingness inability man woman use highly effective contraceptive method entire treatment period least month completion protocol treatment highly effective contraception method include combine estrogen progestogen containing hormonal method associate inhibition ovulation intrauterine device surgical sterilization include bilateral tubal occlusion partner vasectomy sexual abstinence preferred usual lifestyle patient male patient must freeze donate sperm start screening throughout treatment period month administration final dose study medication heterosexually active woman childbearing potential unwillingness inability use highly effective contraceptive method describe entire treatment period least month administration final dose study medication women regard childbearing potential postmenopausal least year without menses surgically sterile least month enrollment female patient must donate retrieve use ovum time screening throughout treatment period 12 week administration final dose study medication female patient must agree breastfeed time screening throughout protocol period life day administration final dose study medication adults subject legal protection order unable give consent persons deprive freedom judicial administrative decision person hospitalize without consent virtue article 32121 l3213 subject provision article 11218",
    "INTERVENTION": "investigational medicinal product sulfasalazine approve market year treatment inflammatory disease tablets dose 500 mg oral route water follow dose level test phase dose level bid hence day 07 dose level tid hence day 07 dl1 tid hence day 014 dl2 tid hence day 014 dl3 tid hence day 014 dl4 tid hence day 014 dl5 four time per day hence day 014 dose level patient receive standard care idarubicin arac backbone consider auxiliary medicinal product clinical trial consist drug dose administration days time idarubicin 12 iv 30mn day mg month day cytarabine 200 civ 24h day mg month day two drug body area cap month dose escalation conduct accord survival continual reassessment method number patient assess dose level depend safety observation patients hospitalize induction course least day 21 achievement neutrophil count 500 thereafter discharge accord judgment investigator medical condition allow nonhematological treatmentemergent aes resolve grade patients adequate iv hydration sulfasalazine exposure following end induction visit patient continue follow treatment relate teaes 30 day follow end sulfasalazine exposure postinduction therapy relapse survival 12 month end induction visit treatments beyond end induction leave clinician choice may include consolidation chemotherapy oral maintenance allogeneic stem cell transplantation alfa guideline postremission therapy acute myeloid leukemia patient 60 year old treat intensively provide protocol appendices minimal followup transplantation relapse death additional year study exit undertaken none",
    "STATISTICS": "phase bayesian adaptive dose escalation design use trial objective allow sequential monitoring data trial use current evidence straightforward inference safety efficacy decision making select evaluate optimal dose design rely bayesian continual reassessment method phase cohort size maximum sample size 20 patients 30 target dose limiting toxicity rate definition maximal tolerate dose 33 within end induction observation window timetoevent extension continual reassessment method survcrm design use depend anticipated accrual rate compare dose limit toxicity observation window 31 allow accounting rightcensored toxicity observation sequential maximal tolerate dose estimation dose assignment process phase ii phase complete provide estimate maximal tolerate dose rp2d determine base data safety monitor board recommendation accord safety data efficacy signal phase inclusion criterion phase addition additional inclusion criterion laip detect baseline fcm assessment relate primary endpoint complete response negative measurable residual disease based historical data rate measurable residual disease negative complete response study population estimate 50 british aml16 data 12 spanish pethema data 32 british aml17 data freeman pers comm simon minimax twostage design use phase simon optimal twostage designs phase ii clinical trials controlled clinical trials 1989 10 110 phase ii assessment require maximum total 44 subject decide whether proportion responding less equal 50 great equal 70 first stage among first 22 included patient number response low equal r1 11 phase ii stop early futility otherwise r1 12 enrollment continue maximum 44 patient overall number response become 28 hypothesis 50 reject target type error rate 05 total number response 27 less hypothesis 70 reject target type ii error rate 15 note phase patient treat rp2d choice include analysis assessable fcm measurable residual disease presence laip"
  },
  "ERYTHROSIM": {
    "TITLE": "randomize prospective trial evaluate efficacy anticd38 monoclonal antibody isatuximab treatment pcra major abo mismatch allogeneic hematopoietic stem cell transplantation",
    "JUSTIFICATION": "quarter allogeneic hematopoietic stem cell transplantation perform situation major abo mismatch expose patient risk immunological pure red cell aplasia transplant pcra transplant define anemia low reticulocyte count 10 day 60 despite good leucocyte platelet engraftment full donor chimerism associate persistence recipient hemagglutinins antia antib antibody bone marrow evaluation perform show erythroid hypoplasia red blood cell transfusion necessary every two week remission lead impaired quality life anemia repeat hospitalization iron overload need iron chelation therapy treatments currently use inefficient anti cd20 monoclonal antibody epo steroid plasma exchange proteasome inhibitor risk severe acute gvhd donor lymphocytes infusion pure red cell aplasia demonstrate associate persistence recipient plasma cell anticd38 monoclonal antibody target plasma cell secrete hemagglutinins responsible pcra promising treatment case report literature support rapid sustain efficacy chapuy nejm 2018 bathini amjhematol 2019 rautenberg bmt 2019 salas et al eur haematol 2019 preethi et al blood cell mol dis 2020 yates et al transfusion 2021 prospective randomized evaluation efficacy safety context necessary",
    "OBJECTIVE": "main objective efficacy treatment pure red cell aplasia isatuximab allogeneic hematopoietic stem cell transplant compare supportive care control group reduction pure red cell aplasia resolution time day primary endpoint time obtention transfusion independence patient pure red cell aplasia time interval randomization correspond month posttransplant resolution pure red cell aplasia date resolution reticulocytopenia treat anticd 38 monoclonal antibody isatuximab secondary objective evaluate two arm term clinical biological outcome reduction red blood cell transfusion need isatuximab evolution iron overload adverse event relate isatuximab context allogeneic sct ctcae grade group month posttransplant quality life functional repercussion chronic anemia iterative transfusion iron overload day 29 month randomization overall survival without relapse month month month 12 month 15 posttransplant identify prognostic factor spontaneous resolution pure red cell aplasia major abo mismatch day 60 month type donor cell stem cell condition regimen occurrence acute chronic graft versus host disease discontinuation immunosuppression evaluate interest followup group hemagglutinins compare arm term ofcost effectiveness cost isatuximab treatment hospitalization transfusion support chelation treatment secondary endpoints number red blood cell transfusion randomization ferritin level month month month 15 posttransplant adverse event ctcae grade randomization quality life questionnaire eortc qlqc30 v3 day 60 day 100 month month month 12 month 15 posttransplant factors associate spontaneous resolution pure red cell aplasia day 60 month posttransplant antibody level anti anti titer day 60 day 100 month posttransplant visit day 15 day 29 day 45 month month month post randomization number day hospitalization transfusion support chelation treatment",
    "DESIGN": "randomized prospective phase ii clinical trial assess efficacy safety anticd38 antibody isatuximab patient persistent pure red cell aplasia month allogeneic hsct including patient day 60 transplant help define factor associate unresolved pure red cell aplasia month thus identify patient could benefit isatuximab treatment earlier future interim analysis perform observation 22 event primary endpoint trial",
    "INCLUSION CRITERIA": "allogeneic stem cell transplant recipient 15 year age old pure red cell aplasia patients aged 15 year old receive allogeneic hematopoietic stem cell transplantation condition major abo mismatch pcra define persistent red blood cell transfusion dependence day 60 posttransplant reticulocyte count 10 despite full donor chimerism good leucocyte platelet 50g recovery relapse progression underlie disease contraception method must prescribe duration clinical trial use effective contraceptive method treatment woman childbearing age continue abstinence heterosexual intercourse accept man study treatment period least month last dose study treatment refrain donate sperm period health insurance coverage sign write informed consent parent patient age less 18",
    "EXCLUSION CRITERIA": "patients aged 15 year relapse underlie disease leucocyte chimerism 95 pure red cell aplasia relate parvovirus b19 infection positive blood pcr known hiv+ hepatitis active infection active tuberculosis pregnancy hcg positive breastfeeding patient receive recombinant human erythropoietin patient receive proteasome inhibitor bortezomib example patient receive thrombopoietin receptor agonist artpo patient receive plasma plasmapheresis exchange transplant planned receive investigational drug within 14 day halflives investigational drug whichever long clinically significant uncontrolled medical condition investigator opinion would expose excessive risk patient may interfere compliance interpretation study result hypersensitivity active substance history intolerance steroid mannitol pregelatinized starch sodium stearyl fumarate histidine base hydrochloride salt arginine hydrochloride poloxamer 188 sucrose component study therapy amenable premedication steroid h2 blocker would prohibit treatment agent debilitating medical psychiatric illness tutorship curatorship understand informed consent optimal treatment followup",
    "INTERVENTION": "isatuximab treatment dose 10 mg kg intravenous route first injection isatuximab perform randomization month day second injection may perform day 15+ 2d reticulocyte 10 third day 29+ 2d reticulocyte 10 patients assess day day 15 day 29 day 45 month month month month randomization",
    "STATISTICS": "bilateral logrank test consider sample size 45 randomized patient 30 experimental group median transfusion independence h1 month 15 control group median transfusion independence h1 month achieve power 86 alpha risk 05 considering 50 patient include day 60 randomize month 90 patient include interim analysis perform observation 22 event primary endpoint trial"
  },
  "EQUAALL01": {
    "TITLE": "evaluation longterm health status quality life adult survivor philadelphianegative acute lymphoblastic leukemia lymphoma treat intensive pediatric pediatricinspiredinspired protocol",
    "JUSTIFICATION": "overall survival adult patient 1559y philadelphia negative acute lymphoblastic leukemia lymphoma dramatically improve use full pediatric pediatric inspired protocol graall2003 05ll03fralle2000 aim reduce risk relapse adopt intensive chemotherapeutical schedule approach lead global improvement overall survival 5yos 57 whatever patient age responsible excess treatmentrelated mortality patient old 45 year 5ytrm patient 45y 19 pediatric longitudinal study point long term leukemia survivor increase risk develop specific adverse event like dysmetabolic syndrome obesity decrease fertility organ dysfunction osseous event impaired cognitive function study aim evaluate impact term longterm event qol adult patient receive intensified therapeutic approach recently implement adult cooperative group",
    "OBJECTIVE": "evaluate prevalence late effect adult patient treat 10 year ago intensified pediatric inspire protocol graall2003 05ll03fralle2000 expose patient increase cumulative dos chemotherapy central nervous system irradiation allogeneic transplant total body irradiationbased regimen boost irradiation central nevous system primary endpoint thus define prevalence adverse event include metabolic trouble dysmetabolic syndrome dyslipidemia diabetes osseous event osteoporosis cardiac vascular trouble neurologic trouble lung dysfunction endocrinal trouble ophthalmological trouble fertility disorder secondary neoplasia evaluate quality life patient correlate prevalence late effect qol status previous social situation previous medical condition treatment scheme include administration protocol phase delayed intensification maintenance centralnervous system irradiation allogeneic sct graftversus host disease occurrence elaborate riskadapted recommendation longterm followup adult patient treat reinforce therapeutic strategy secondary endpoint thus prevalence metabolic trouble dysmetabolic syndrome dyslipidemia diabetes prevalence osseous event osteoporosis prevalence cardiac vascular trouble prevalence neurologic trouble prevalence lung dysfunction prevalence endocrinal trouble quality life sf36 prevalence ophthalmological trouble prevalence fertility disorder prevalence secondary neoplasia",
    "DESIGN": "multicenter crosssectional interventional minimal risk constraint human research study",
    "INCLUSION CRITERIA": "adult patient age 1559y diagnosis treat ten year ago ph1negative acute lymphoblastic leukemia lymphoma patient philadelphianegative treat accord pediatriclike pediatricinspired protocol graall fralle without allogeneic transplant patients old 15 year old less 60 year old diagnosis patient followup first complete remission 10 year patient give inform signed consent baseline examination",
    "EXCLUSION CRITERIA": "patient experience relapse within past year philadelphia positive patient",
    "INTERVENTION": "",
    "STATISTICS": "analysis handle left data truncation give patient survive 2016 able include study approximately 1000 patient include graall2003 2005 among 630 august 2009 considering 363 630 patient alive last followup opportunity include patient treated accord protocol 80 inclusion success approximately 300 patient recruit allow assess prevalence trouble 95 ci width assume 10 prevalence 10 assume 30 prevalence detection respectively also allow reach statistical power least 80 detecting"
  },
  "EFRAIM-II": {
    "TITLE": "empirical steroid antifungal immunocompromised patient acute respiratory failure undetermined etiology multicenter doubleblind randomize control trial",
    "JUSTIFICATION": "acute respiratory failure lead reason icu admission immunocompromised patient failure identify acute respiratory failure etiology associate increased mechanical ventilation mortality rate confirm large efraim study publish 2017 undetermined acute respiratory failure etiology affect 609 1611 38 patient day 402 25 patient day 199 12 patient overall associate case fatality 55 vs 40 patient lung biopsy autopsy finding patient invasive fungal infection steroid sensitive affection organize pneumonia non infectious interstitial involvement drugrelated pulmonary toxicity lung infiltration underlying disease lymphoma carcinomatous lymphangitis systemic vasculitis connective tissue disease etc lead etiology study evaluate survival benefit empirical steroid antifungal immunocompromised patient acute respiratory failure undetermined etiology",
    "OBJECTIVE": "main objective reduce 90day mortality immunocompromised patient acute respiratory failure undetermined etiology day3 intervention would evaluate impact steroid isavuconazole 14 day icu discharge primary endpoint mortality day 90 secondary study objective evaluate early empirical therapy affect icu hospital day28 mortality whether steroid increase proportion patient icu acquire microbiologically document bacterial infection within month follow randomization proportion patient invasive fungal infection within month follow randomization proportion patient hsv vzv cmv reactivation within month follow randomization whether steroid complicate severe hypokalemia meq newly acquire decompensated diabetes severe newly acquire hypertension whether isavuconazole favor emergence infection aspergillus mucorale specie decreased sensitivity isavuconazole occurrence candida infection steroid affect psychiatric symptom posttraumatic stress disorder anxiety depression month early intervention improve quality life month secondary end point icu mortality hospital mortality day 28 mortality proportion patient icu acquire microbiologically document bacterial infection proportion patient invasive fungal infection within month follow randomization proportion patient hsv vzv cmv reactivation within month follow randomization occurrence severe hypokalemia meq decompensated diabetes severe newly acquire hypertension emergence aspergillus specie decreased sensitivity isavuconazole incidence candida infection incidence posttraumatic stress disorder iesr anxiety depression month hads quality life month sf36",
    "DESIGN": "multicenter doubleblind randomize controlled trial base 2x2 factorial design",
    "INCLUSION CRITERIA": "immunecompromised patient acute respiratory failure undetermined etiology either intervention steroids antifungal associate improved day90 survival acute respiratory failure lead reason icu admission immunocompromised patient admission age 18 year 90 year immunosuppressive drug solid organ transplant solid tumor hematological malignancy primary immune deficiency icu admission acute respiratory failure define respiratory distress tachypnea respiratory rate 30 min cyanosis labour breathing need 6l standard oxygen maintain spo2 95 high flow oxygen noninvasive invasive mechanical ventilation establish acute respiratory failure etiology 24 hour hospital admission patient admit least 24 hour hospital informed consent sign patient informed consent sign family members trustworthy person condition allow express consent write per 11116 situation urgently absence family members trustworthy person patient enrol consent participate research request soon condition patient allow consent note patient pneumocystis pneumonia include give treatment require use neither antifungal drug corticosteroid",
    "EXCLUSION CRITERIA": "patient improve enough discharge icu inclusion documented invasive fungal infection require antifungal therapy patient needing receive prophylactic empirical antifungal treatment clinical care patient receive corticoid therapy palliative care comfort measure intubate resuscitate patient include pregnant breastfeeding social security coverage known hypersensitivity isavuconazole excipients cresemba specialty treatment ketoconazole ritonavir cyp3a4 inductor 10 short qt syndrome patient family history short qt syndrome 11 liver insufficiency stage 12 moribund patient 13 participation another interventional research acute respiratory failure 14 person deprive liberty 15 person subject psychiatric care 16 patient enforced hospitalization 17 adults legal protection unable give consent 18 isolated hi",
    "INTERVENTION": "methylprednisolone give day dose mg kg day three day recommend fibrosing pneumonitis deeply hypoxemic patient day daily dose taper mg kg day day follow mg kg day day day 14 isavuconazole give dose 200 mg every hour day administration daily day 14 icu discharge event occur first patients one arm receive isavuconazole methylprednisolone whith establish interaction investigator must check smpc need information available placebo methylprednisolone placebo isavuconazole",
    "STATISTICS": "interim analysis perform recruitment 120 patient 50 day90 death whichever occur first"
  },
  "RECORDS": {
    "TITLE": "rapid recognition corticosteroid resistant sensitive sepsis",
    "JUSTIFICATION": "world health organization estimate yearly 30 million people develop sepsis 11million die aprocchs phase placebocontrolled trial demonstrate absolute reduction sepsis mortality hydrocortisone+fludrocortisone number factor may positively negatively impact corticosteroid cs benefit sepsis",
    "OBJECTIVE": "compare effect hydrocortisone plus fludrocortisone vs placebo composite death persistent organ dysfunction define continued dependency mechanical ventilation new renal replacement therapy vasopressor assess 90 day intensive care unit adult different biological profile immune response corticosteroid bioactivity primary endpoint death persistent organ dysfunction define continued dependency mechanical ventilation renal replacement therapy vasopressor score sequential organ failure assessment score score 90 day mortality healthrelated quality life month daily organ function score sequential organ failure assessment score score day 10 14 28 90 daily secondary infection 90 day daily blood urinary level glucose sodium potassium 28 day daily gastroduodenal bleeding 28 day daily cognitive function muscle strength day 28 90 180 day",
    "DESIGN": "multiarms parallel blind randomize control trial precede 6month runin observational period observational phase runin period interventional phase",
    "INCLUSION CRITERIA": "n1 interventional phase n1 patients 18 year old admitted intensive care unit proven suspected infection main diagnosis community acquire pneumonia relate sepsis vasopressor dependency norepinephrine epinephrine vasopressin dopamine phenylephrine septic shock singer 2016 vasopressor maintain mean blood pressure least 65 mmhg lactate level mmol acute respiratory distress syndrome ards ranieri 2012 acute onset within one week apparent clinical insult progression respiratory syndrome bilateral opacity chest image explain pulmonary pathology pleural effusion atelectasis nodule etc evidence heart failure volume overload pao2 fio2 300 mm hg peep cm h2o patient world health organization sign informed write consent whevener able consent ascent representant whenever present time screen inclusion patients world health organization test one records specific biomarkers circi endocan gilz dualspecificity phosphatase monocyte distribution width lymphopenia transcriptomic srs2 endotype pcr covid19 pcr influenza pcr respiratory virus cutaneous vasoconstrictor response glucocorticoids affiliation social security system universal health coverage couverture maladie universelle couverture maladie universelle patients guardianship curatorship include patients case simple emergency legal definition include patients manage covid 19 biological sample available",
    "EXCLUSION CRITERIA": "n1 interventional phase pregnancy expected death withdrawal lifesustaining treatment within 48 hour previously enrol study formal indication corticosteroid accord recent international guideline vaccination live virus within past month hypersensitivity hydrocortisone fludrocortisone microsined betamethasone dipropionate excipients spc women childbearing potential use contraception nursing woman patient include stratum applicable apply cream infect ulcerated area",
    "INTERVENTION": "observational phase runin period additional biological sample restrospective part covid patient telephone followup interventional phase investigational product placebo administer patient basis records signatures investigational product include hydrocortisone hemisuccinate 50 mg one intravenous injection every hour alpha fludrocortisone 50 one tablet per day via nasogastric tube treatment stop day patient leave intensive care unit whichever occurs first without taper",
    "STATISTICS": "enroll total 1800 patient adaptative trial sites expect enroll least 1or patient per month enrol 376 evaluable patient per arm study 80 power detect 10 absolute risk reduction 45 35 correspond 20 relative risk reduction"
  },
  "KAPKEY": {
    "TITLE": "phase ii multicentric study pembrolizumab classic endemic kaposi sarcoma",
    "JUSTIFICATION": "classic endemic kaposi sarcoma lymphangioproliferations associate human herpes virus hhv8 treatment poorly codify chemotherapies give best 3060 transient response interferon response frequent drug often poorly tolerate elderly patient therefore new therapy need classic kaposi sarcoma represent ideal model evaluate new drug since patient receive concomitant immunosuppressive regimen antiviral therapy pembrolizumab antipd1 monoclonal antibody recently show improve survival several solid tumor kaposi sarcoma data available role pd1pdl1 axis significant pdl1 expression hhv8associated pleural effusion lymphoma kaposi sarcoma sample recently report experience classical endemic kaposi sarcoma support role pathway expression pdl1 subpopulation cell also nk cell peripheral blood cell patient expression pdl1 tumor cell kaposi sarcoma lesion study evaluate benefit safety profile pembrolizumab classic endemic kaposi sarcoma",
    "OBJECTIVE": "simon 2stage optimal design main objective assess whether pembrolizumab clinically inactive partial+complete response probability truly active partial+complete response probability 30 classic endemic kaposi sarcoma use simon stage optimal design primary endpoint best overall response rate define occurrence complete response partial response follow actg criterion record start treatment month beginning specific systemic therapy kaposi sarcoma occur month extension phase event truly active conclusion simon 2step optimal design extension phase would perform evaluate element extension phase would perform far evaluate efficacy pembrolizumab setting additional 20 patient include obtain accurate estimate treatment effect 24 month primary endpoint extension phase best overall response rate accord actg criterion record start treatment month start kaposi sarcoma specific systemic therapy occur month secondary objective simon stage optimal design extension stage assess safety profile pembrolizumab classic endemic kaposi sarcoma characterize efficacy pembrolizumab relate pharmacodynamics assessment secondary endpoint efficacy endpoint different aspect clinical response evaluate best overall response rate accord pga criterion 24 month beginning specific systemic therapy kaposi sarcoma occur month response rate month month month month 12 month 18 month 24 accord actg pga criterion response rate number lesion month month month month 12 month 24 best response define follow pga response rate size target lesion month month month month 12 month 24 atbest response define follow pga response rate tumor infiltration target lesion month month month month 12 andmonth 24 best response define follow pga response rate lymphedema circumference scale absence painful ooze month month month 12 month 24 best response define follow pga time response define time first response record start treatment time progression define time start treatment progression patient response rate accord actg pga criterion month month 12 month 18 month 24 extension stage 10 duration response define time start response progression patient achieve partial complete response 11 quality life follow qlc30 dlqi kaposi baseline cycle cycle 10 cycle 15 every month eot early study termination month 24 safety endpoint safety assess term drug toxicity evaluate clinic laboratory parameter score accord common terminology criteria adverse events version study",
    "DESIGN": "uncontrolled openlabel multicentric phase ii study",
    "INCLUSION CRITERIA": "adult classic endemic kaposi sarcoma patient meet following criterion may include study simon 2stage optimal design extension stage classic endemic histologically confirm kaposi sarcoma progressive disease kaposi sarcoma 10 lesion involve one limb segment involvement body surface kaposi sarcoma least lesion 5mm kaposi sarcoma least cutaneous tumor available repeated pharmacodynamics evaluation willing provide tissue cutaneous biopsy tumor lesion least week washout kaposi sarcoma specific therapy include chemotherapy immunotherapy provide write informed consent prior performance study specific procedure 18 year age day sign informed consent performance status ecog performance scale demonstrate adequate organ function hematological absolute neutrophil count 000 mm3 platelets 100 000 mm3 hemoglobin dl renal calculated creatinine clearance 30ml min use mdrd formula hepatic ast sgot alt sgpt 5xuln serum total bilirubin 5xuln direct bilirubin uln participant total bilirubin level 5xuln female subject childbearing potential negative serum pregnancy within 72 hour prior receive first dose study medication health insurance",
    "EXCLUSION CRITERIA": "patient meet following criterion must include study simon 2stage optimal design extension stage know history organ transplantation receive systemic steroid therapy form immunosuppressive therapy within day prior first dose trial treatment kaposi sarcoma symptomatic visceral involvement unless therapeutic option available previously receive treatment antipd1 antipd l1 antipdl2 antictla4 antibody antibody drug specifically target tcell costimulation immune checkpoint pathway uncontrolled infection hiv hbv hcv infection diagnosis immunodeficiency relate result chronic infection patients known hepatitis hepbsag+ control infection serum hepatitis virus dna pcr limit detection receive antiviral therapy hepatitis permit patients controlled infection must undergo periodic monitoring hbv dna per local standard must remain antiviral therapy least month beyond last dose investigational study drug patients know hcv ab+ control infection undetectable hcv rna pcr either spontaneously response successful prior course antihcv therapy permit active infection require systemic therapy hypersensitivity pembrolizumab keytruda excipients prior anticancer monoclonal antibody mab within last week recover grade selection adverse event due agent administer week earlier prior chemotherapy target small molecule therapy radiation therapy within week half life prior study day recover grade selection adverse event due previously administer agent note participant grade neuropathy exception criterion may qualify study note subject receive major surgery must recover adequately toxicity complication intervention prior start therapy know additional malignancy progress require active treatment exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergo potentially curative therapy situ cervical cancer active autoimmune disease require systemic treatment past year use disease modify agent corticosteroid immunosuppressive drug replacement therapy eg thyroxine insulin physiologic corticosteroid replacement therapy adrenal pituitary insufficiency etc consider form systemic treatment patients vitiligo type diabetes mellitus hypothyroidism psoriasis non require systemic treatment permit enroll active noninfectious pneumonitis know history noninfectious pneumonitis require steroid severe pulmonary disease hypoxia know psychiatric substance abuse disorder would interfere cooperation requirement trial pregnant breastfeeding expect conceive father child within projected duration trial willing use adequate contraceptive method study visit throughout study period 120 day last dose study therapy receive live vaccine within 30 day prior first dose trial treatment participate trial currently participate participate study investigational agent within week first dose treatment history current evidence condition therapy laboratory abnormality might confound result trial interfere subject participation full duration trial best interest subject participate opinion treating investigator patient guardianship curatorship",
    "INTERVENTION": "simon 2stage optimal design phase development phase ii treatment pembrolizumab route intraveinous infusion dose regimen 200 mg per infusion every week duration treatment month cycle extension stage phase development phase ii treatment pembrolizumab route intraveinous infusion dose regimen 200 mg per infusion every week duration treatment 24 month 35 cycle confirmed complete response define simon stage optimal design occur 24 month month pembrolizumab treatment cycle last cycle complete response observe confirm least month pembrolizumab stop na",
    "STATISTICS": "simon 2stage optimal design multicenter uncontrolled phase ii study base stage phase ii simon optimal design sample size computation base statistical hypothesis regard treatment effect main endpoint best overall response rate 05 type error 90 statistical power sample size compute assess whether drug inactive partial+complete response probability truly active partial+complete response probability 30 based hypothesis compute patient would accrue stage necessary inclusion stop month 9th inclusion wait primary endpoint trial stop conclusion inactivity response observe stage otherwise additional patient recruit total sample size 17 patient least response indicate drug effective enough case observe response end stage stage directly begin withouit stop extension stage 20 patient include extension stage consider main analysis expected complete best overall response rate complete response partial response month 14 20 70 would obtain 95 ci interval complete response rate equal 46 88 secondary analysis perform 20 patient include extension stage plus 17 patient include simon stage optimal design expect best overall response rate month 26 37 70 analysis reach 95 ci interval complete response rate equal 53 84"
  },
  "UPFRONT-MUD": {
    "TITLE": "upfront match unrelated donor transplantation pediatric patient idiopathic aplastic anemia phase ii feasibility study",
    "JUSTIFICATION": "pediatric patient idiopathic aplastic anemia respond well adult immunosuppressive therapy ist longterm risk relapse ciclosporine dependence clonal evolution high uk investigator report 5year estimate failurefree survival ist 13 contrast 44 successive child receive match unrelated donor hematopoietic stem cell transplantation excellent estimate 5year failure free survival 95 forty child previously fail ist excellent result upfront fully match unrelated donor hematopoietic stem cell transplantation become attractive firstline option 2005 2014 uk cohort 29 child idiopathic aplastic anemia thus receive matched unrelated donor hscts firstline therapy receive ist prior hematopoietic stem cell transplantation results excellent low graft versus host disease rate death idiopathic pneumonia cohort compare historical matched control transplant outcomes upfront unrelated cohort hematopoietic stem cell transplantation similar matched related donor hematopoietic stem cell transplantation superior ist unrelated hematopoietic stem cell transplantation postist failure since many investigator offer front match unrelated donor hematopoietic stem cell transplantation pediatric patient worldwide however result treat extreme caution design retrospective excellent front match unrelated donor hematopoietic stem cell transplantation may arise use alemtuzumab conditioning regimen alemtuzumab easily available worldwide formal quality oflife assessment moreover strategy highly dependent donor identification caucasian patient high likelihood match unrelated donor donor availability thus know many patient eventually receive hematopoietic stem cell transplantation risk infections complications cause unexpected donor delay cancellation prospective trial thus urgently need address feasibility procedure term timing delay offer matched unrelated donor hematopoietic stem cell transplantation condition regimen nothing know use regimen non alemtuzumabbased setting",
    "OBJECTIVE": "main objective realize upfront hematopoietic stem cell transplantation within month match unrelated donor identify primary endpoint upfront match unrelated donor hematopoietic stem cell transplantation effectively perform within month 60 day identification match unrelated donor secondary objective clinical biological outcome graft failure graft versus host disease progression free survival relapse nonrelapse mortality overall survival quality life chimerism immune reconstitution secondary endpoints graft failure incidence neutrophils platelet engraftment day 100 first day consecutive day neutrophils first day consecutive day platelet 20 absolute number neutrophil platelet month month month month month 12 day last platelet red blood cell transfusion acute graft versus host disease incidence month month date maximum grading first line treatment response steroid treatment course case steroid refractory graft versus host disease chronic graft versus host disease incidence date grading month 24 relapse incidence month 12 month 24 progression free survival month 12 month 24 incidence cmv ebv infection month 12 severe infection ctae grade 34 month month month 12 month 24 nonrelapse mortality month 24 overall survival month 24 quality life questionnaire pedqql inclusion post transplantation month month month 12 month 24 chimerism month month month month 12 immune reconstitution analyze nk regulatory cell level peripheral blood month month month 12 month 24 posttransplantation ferritin level month month month 12 month 24",
    "DESIGN": "phase ii multicenter national prospective cohort study",
    "INCLUSION CRITERIA": "pediatric patient age less 18 year idiopathic aplastic anemia indication treatment severe aplastic anemia moderate aplastic anemia require transfusion patients age 18years old pediatric patient age less 18 year idiopathi aplastic anemia indication treatment severe aplastic anemia moderate aplastic anemia require transfusion good probability hla10 10 matched unrelated donor available patient need least match unrelated donor identify within book bmdw bone marrow donors worldwide use easy match software include usual criterion allosct lansky 70 16 year karnofsky 70 16 year severe uncontrolled infection adequate organ function asat alat 5n total bilirubin 2n creatinine clearance 70 high normal value age health insurance coverage beneficiaire ou ayant droit contraception method young girl men childbearing age must prescribe duration research parents read understand information note sign write informed consent patient agreement depend age seek typical presentation aplastic anemia posthepatitis nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable transdermal progestogenonly hormonal contraception intrauterine hormonalreleasing system ius man absence permanent sterilization condom",
    "EXCLUSION CRITERIA": "patients match related donor available uncontrolled infection seropositivity hiv htlv1 active hepatitis define positive pcr hbv hcv associate hepatic cytolysis renal failure creatinine clearance 70 high normal value age pregnant hcg positive breastfeeding heart failure accord nyha ii preexisting acute hemorrhagic cystitis urinary tract obstruction yellow fever vaccine within month transplantation debilitating medical psychiatric illness preclude understand inform consent well optimal treatment followup depend age understanding contraindication treatment use research",
    "INTERVENTION": "conditioning regimen patient age less 14 year fludarabine 30mg month day day day cyclophosphamide 30 mg kg day day day antithymocyte globulin 75 mg kg day day day patient age 14 fludarabine 30mg month day day day cyclophosphamide 30 mg kg day day day anti thymocyte globulin 75 mg kg day day day total body irradiation gray day however allow realize tbi fludarabine local planning reason tbi day antithymocyte globulin day et day fludarabine day day tbi day fludarabine day day cyclophosphamide day stem cell source bone marrow minimal target dose 4x108 nucleated cells kg recipient ideal body weight graft less rich minimum target dose administer discretion physician graft versus host disease prophylaxis graft versus host disease prophylaxis consist association cyclosporine plus methotrexate iv cyclosporine mg kg day year post hematopoietic stem cell transplantation plus methotrexate iv 10mg month give day+1 subsequently mg month day +3 day+6 prevention ebv reactivation rituximab 150mg month iv day+5 post hematopoietic stem cell transplantation infusion rituximab precede administration anti pyretic antihistaminic paracetamol diphenhydramine",
    "STATISTICS": "justification sample size use simon minimax twostage phase design demonstrate success primary outcome 70 patient consider treatment valuable option less 45 consider unacceptable interim analysis interim analysis perform 12 inclusion trial terminate receive upfront match unrelated donor hematopoietic stem cell transplantation study end conclusion inefficacy otherwise inclusion pursue total 25 patient conclude treatment efficacy least 16 success identify among 25 patient"
  },
  "HAPLORESCUE": {
    "TITLE": "haploidentical allogeneic hematopoietic stem cell transplantation posttransplant cyclophosphamide rescue patient graft failure phase ii study",
    "JUSTIFICATION": "prognosis patient graft failure dismal transplantation sole option longterm survival currently consensus concern therapeutic option patient primary secondary within 60 day posttransplantation graft failure find new donor within acceptable delay challenge literature poor subject overall survival patient 30 year situation thus represent today challenging unmet medical need recently haploidentical haplo relate donor stem cell transplantation haplosct improve dramatically outcomes use tcell replete graft administration posttransplantation cyclophosphamide ptcy target alloreactive cell generate early hla mismatch transplant spar regulatory cell leave unaffected nondividing hematopoietic stem cell standard posttransplant immune suppression calcineurin inhibitor cni mycophenolate mofetil group retransplanted patient experience two consecutive graft failure successfully manage third haplosct son use ptcy retrospectively collect analyze data 26 primary graft failure patient transplant 2011 2017 15 center behalf french society stem cell transplantation cell therapy sfgmtc study population consist mainly patient primary secondary within 60 day posttransplantation graft failure undergo haplosct receive ptcy graft versushostdisease prophylaxis 1year overall survival 60 suggest approach might valid option particular poor clinical situation need validation phase ii multicenter national prospective cohort study",
    "OBJECTIVE": "main objective rescue patient graft failure first allogeneic sct allosct use haplosct ptcy primary endpoint overall survival rate compare historical control 30 year secondary objective graft failure gvhd progression free survival relapse nonrelapse mortality interval first allosct rescue haplosct quality life chimerism immune reconstitution secondary endpoints graft failure incidence neutrophils platelet engraftment day 100 consecutive day neutrophile consecutive day platelet 20 absolute number neutrophil platelet month month month month month 12 day last platelet red blood cell transfusion use growth factor poor hematopoietic reconstitution acute gvhd incidence month month date maximum grading first line treatment response steroid treatment course case steroid refractory gvhd chronic gvhd incidence date grading month 24 relapse incidence month 12 month 24 progression free survival month 12 month 24 incidence cmv ebv infection month 12 severe infection ctae grade 34 month month month 12 month 24 nonrelapse mortality month month month 12 month 24 incidence cardiac toxicity month overall survival month 24 interval first allosct rescue haplosct quality life questionnaire eortc qlqc30 v3 inclusion posttransplantation month month 12 month 24 chimerism month month 12 immune reconstitution analyze nk regulatory cell level peripheral blood month month month month 12 month 24 posttransplantation",
    "DESIGN": "phase ii multicenter national prospective cohort study primary secondary within 60 day post transplantation graft failure rare devastate condition sct recent strategy haplo relate donor transplantation success transplantation tcell replete graft intensive immune suppression retrospective noncontrolled registry study recently suggest outcome haplosct use ptcy approach might superior actual standard care retransplantation unrelated donor moreover haplosct ptcy quick procedure cheap available almost patient study might thus favor strategy case primary secondary within 60 day post transplantation graft failure 1st sct",
    "INCLUSION CRITERIA": "patients year old hematological disease suffer primary secondary within 60 day posttransplantation graft failure 1st allogeneic hematopoietic stem cell transplantation allosct patients aged year old hematological disease suffering primary secondary within 60 day posttransplantation graft failure 1st allosct usual criterion allosct ecog severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function asat alat 5n total bilirubin 2n creatinine clearance 30ml min identification haploidentical donor brother sister parent adult child cousin absence donor specific antibody detect patient mfi 2000 antibody direct towards distinct haplotype donor recipient health insurance coverage beneficiaire ou ayant droit understand informed consent optimal treatment followup contraception method must prescribe duration research women men childbearing age must use contraceptive method within 12 month month last dose cyclophosphamide respectively sign write informed consent parent patient age less 18",
    "EXCLUSION CRITERIA": "patients aged year old uncontrolled infection seropositivity hiv htlv1 active hepatitis define positive pcr hbv hcv associate hepatic cytolysis yellow fever vaccine within month transplantation cancer last year except basal cell carcinoma skin situ carcinoma cervix uncontrolled coronary insufficiency recent myocardial infarction month current manifestation heart failure uncontrolled cardiac rhythm disorder ventricular ejection fraction 50 heart failure accord nyha ii preexisting acute hemorrhagic cystitis renal failure creatinine clearance 30ml min urinary tract obstruction pregnant hcg positive breastfeeding debilitating medical psychiatric illness preclude understand inform consent well optimal treatment followup tutorship curatorship contraindications treatment use research",
    "INTERVENTION": "conditioning regimen fludarabine 30mg month day day day cyclophosphamide 14 mg kg day day day except patient receive total dose cyclophosphamide 100mg kg first bone marrow transplantation total body irradiation gray day source stem cell source peripheral blood stem cell minimal target dose 106 cd34+ cells kg recipient gvhd prophylaxis cyclophosphamide 50 mg kg day d+3 d+4 ciclosporine day+5 residual 200 300ng mycophenolate mofetyl 15mg kg x2 day day+5 prevention ebv reactivation rituximab 150mg month day+5 post haplosct",
    "STATISTICS": "overall survival estimate use kaplan maier estimator 95 confidences intervals comparaison historical control 30 year perform use onesample logrank test propose sun et al 2011 terminal analysis perform followup last included patient"
  },
  "FIRST": {
    "TITLE": "upfront relate donor transplantation patient myelodysplastic syndrome phase trial",
    "JUSTIFICATION": "three recent prospective transplant transplant study conclude advantage overall survival transplantation patient high intermediate2 ipss risk significant kroger study 13 prospective randomize trial assess pretransplant therapy mds patient yet information extract recent study french study 162 72 patient donor receive hsct previously treat hypomethylating agent hma 71 trend good survival patient achieve complete remission pre graft therapy hr 55 088 high risk death unresponsiveness patient transform aml hr 36 008 nakamura study 384 83 patient donor transplant previously treat hma 68 multivariable cox model overall survival leukemiafree survival show excess risk patient treat hma moreover responder still high risk mortality compare patient receive pregraft therapy hr 417 0054 german study aim initiate azacytidine inclusion transplant patient cycle donor identified1 among 170 register patient 162 initiated 5aza 36 lose pregraft therapy allocation donor nodonor arm different reason include death 12 cycle 5aza 79 81 patient donor arm transplant multivariable analysis show remission status influence overall survival previous clinical trial thus suggest substantial number patient plan transplantation transplant nowadays evidence hma benefit hsct clearly identify phase study aim assess feasibility upfront hsct patient high risk mds order increase probability transplant achieve subsequent remission good survival",
    "OBJECTIVE": "primary objective demonstrate improved diseasefree survival patient undergo upfront transplantation related donor compare 35 historical prospective cohort primary endpoint disease free survival year transplantation secondary objectives clinical biological outcome overall survival incidence transplantation donor identification incidence transformation aml relapse progression engraftment acute late rejection nonrelapse mortality acute gvhd chronic gvhd severe infection ctae grade 34 cardiac event grade 24 ctae secondary endpoints overall survival 24 month inclusion transplantation non relapse mortality 24 month transplantation cumulative incidence transformation acute myeloid leukemia inclusion 24 month acute gvhd grade 100 day post hsct chronic gvhd grade year post hsct engraftment month hematological recovery donor chimerism 95 graft failure acute late rejection non engraftment year post hsct severe infection ctae grade 34 month month month 12 month 24 cardiac event grade 24 ctae month month",
    "DESIGN": "study use uncontrolled phase openlabel design increase level incidence external comparison secondly perform demethylating agent use individual patient data prospective cohort robin 2015 ii 5azacytidine use aggregate data publish randomized clinical trial kroger 2021",
    "INCLUSION CRITERIA": "adults 50 year old patient mds diagnosis transplantation indicate related donor identify inclusion criterion age 50 70 year hla match sibling donor familial haploidentical donor identify disease fulfill least one following criterion intermediate2 high risk accord classical ipss intermediate1 risk marrow fibrosis grade poor risk cytogenetics accord ipss classify high high risk accord ipss mds therapyrelated neoplasm usual criterion hsct ecog severe uncontrolled infection cardiac function compatible high dose cyclophosphamide lvf 50 adequate organ function asat alat 5n total bilirubin 2n creatinine clearance 30 ml min accord cockroft formula case transplantation haploidentical donor absence donor specific antibody detect patient mfi 1000 antibody direct towards distinct haplotype donor recipient recommend ebmt guideline contraception method must prescribe woman childbearing age study cyclophosphamide use effective contraceptive method men participation study health insurance coverage write informed consent sign nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable implantable progestogenonly hormonal contraception intrauterine device iud intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom",
    "EXCLUSION CRITERIA": "exclusion criterion marrow blast 15 time inclusion mds excess blast 10 npm1 mutation recurrent genetic abnormality relate aml 2022 chemotherapy aml like intensive chemotherapy demethylating agent treat mds current stage disponibility unrelated donor 10 10 mud absence genoidentical donor patient uncontrolled infection cancer last year except basal cell carcinoma skin situ carcinoma cervix renal failure creatinine clearance 30ml min accord cockroft formula contraindication treatment use research uncontrolled coronary insufficiency recent myocardial infarction month current manifestation heart failure uncontrolled cardiac rhythm disorder ventricular ejection fraction 50 heart failure accord nyha ii patient seropositivity hiv htlv1 active hepatitis define positive pcr hbv hcvyellow fever vaccine alive vaccine within month transplantation pregnancy hcg positive breastfeeding debilitating medical psychiatric illness would preclude give well understand inform consent optimal treatment followup protection law tutorship curatorship",
    "INTERVENTION": "",
    "STATISTICS": "twosided onesample logrank test calculate sample 55 subject achieve 90 36 power 050 significance level detect proportion surviving 5500 new group proportion survive historic control group 3500 historical proportion estimate previous french cohort study publish leukemia 2year disease free survival rate 35 observe patient donor transplant upfront contrast ebmt study report 2year disease free survival patient mds expect 55 survive proportion period 24 month subjects accrue period 24 month followup continue period 24 month last subject add probability subject experience event study 5860 expected number event study 24 assume survival time distribution group approximate reasonably well weibull distribution shape parameter 00 increase level evidence external indirect comparison secondly perform demethylating agent use individual patient data prospective cohort robin 2015 ii 5azacytidine use aggregate data publish randomized clinical trial kroger 2021"
  },
  "APARR": {
    "TITLE": "evaluation optimized allogeneic hematopoietic stem cell transplantation protocol posttransplant cyclophosphamide patient age 40 60 year old acquire aplastic anemia refractory relapse immunosuppression",
    "JUSTIFICATION": "hematopoietic stem cell transplantation major therapeutic option patient acquire aplastic anemia improved survival achieve patient young 40 year old thanks good donor selection condition regimen graft versus host disease prophylaxis together improved supportive care however never case patient age 40 overall survival hematopoietic stem cell transplantation never exceed 60 year use available sibling unrelated donor ref thus standard immunosuppressive therapy ist associate cisclosporine horse antithymocyte globuline together addition eltrombopag consider standard care adult patient old 40 year aplastic anemia ref indeed outcome patient refractory firstline ist remain poor lack nontransplant treatment poor result transplantation age ref 37 past decade significant decrease infectionrelated mortality population initial ist risk hemorrhage longterm fatigue still present moreover clonal evolution include paroxysmal nocturnal hemoglobinuria myelodysplastic syndrome mds acute myeloid leukemia still occur longterm grim prognosis mds acute myeloid leukemia ref overall survival adult patient acquire aplastic anemia refractory relapse ist outside hematopoietic stem cell transplantation thus 60 year ref recently new strategy prevent acute chronic graft versus host disease include tcell replete graft administration posttransplantation cyclophosphamide ptcy revolutionize field change extend option hematopoietic stem cell transplantation primary patient refractory relapse aplastic anemia lack hla match donor ref recently optimize baltimore protocol use ptcy strategy also appear improve engraftment reduce graft versus host disease classical setting sibling match unrelated hematopoietic stem cell transplantation outside aplastic anemia ref one first cause death hematopoietic stem cell transplantation patient old 40 year age refractory relapse aplastic anemia graft versus host disease use optimize baltimore protocol type donor haplo also sibling match unrelated transplantation within field aplastic anemia rapidly appear promising ref using optimized hematopoietic stem cell transplantation procedure marrow source stem cell ptcy strategy haploidentical donor setting also case available matched sibling unrelated donor might prevent drastically graft versus host disease eventually practice change evaluating new transplant protocol new strategy main objective aparr",
    "OBJECTIVE": "main objective demonstrate benefit term year grfs graft versus host disease graft versus host disease primary secondary graft failurefree survival 50 historical rate patient refractory relapse aplastic anemia undergo hematopoietic stem cell transplantation ref 70 use optimized hematopoietic stem cell transplantation procedure marrow source stem cell ptcy strategy patient 40 year old haploidentical donor setting primary endpoint 2year grfs follow hcst primary composite endpoint measure time hematopoietic stem cell transplantation first following event primary secondary graft failure grade 34 acute graft versus host disease severe chronic graft versus host disease death secondary objective demonstrate benefit term clinical biological outcome primary secondary graft failure mortality overall survival quality life treatment relate morbidity notably severe infection cardiac toxicity chimerism immune reconstitution secondary endpoint 100day engraftment consecutive day neutrophile consecutive day platelet 20 donor chimerism 85 total blood absolute number neutrophil platelet month month month month 12 month 24 day last platelet red blood cell transfusion acute graft versus host disease incidence grade 24 month chronic graft versus host disease incidence month 24 severe chronic graft versus host disease month 24 secondary graft failure month 12 month 24 severe infection ctcae grade 34 month month month month 12 month 24 incidence cardiac toxicity month 12 incidence cmv ebv infection month 12 mortality month 12 month 24 overall survival 12 month 24 month quality life questionnaire pretransplant month month 12 month 24 chimerism month month month month 12 month 24 immune reconstitution month month month month 12 month 24 lymphocytes cd4 cd8 nk lymphocytes gammaglobulines",
    "DESIGN": "phase ii multicenter national prospective singlearm trial",
    "INCLUSION CRITERIA": "patients age 40 60 year refractory relapse aplastic anemia ist eligible hematopoietic stem cell transplantation patients aged 40 60 year old suffering acquire refractory severe idiopathic aplastic anemia least month treatment antithymocyte globulin cyclosporine eltrombopag relapse allograft validate national multidisciplinary expertise meeting french reference centre aplastic anemia available genoidentical donor 10 10 match donor haploidentical donor absence donor specific antibody detect patient mfi 1500 antibody distinct haplotype donor recipient usual criterion hematopoietic stem cell transplantation ecog severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function asat alat 3n conjugate bilirubin 2n total bilirubin 2n available clearance creatinine 50ml min health insurance coverage women childbearing potential men must use contraceptive method participation research 12 month month last dose cyclophosphamide respectively sign write informed consent nb authorized contraceptive method woman childbearing potential absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable transdermal progestogenonly hormonal contraception intrauterine hormonalreleasing system ius sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle participant men absence permanent sterilization sexual abstinence condom individuals must meet inclusion criterion verify screen inclusion visit eligible participate study",
    "EXCLUSION CRITERIA": "patients morphologic evidence clonal evolution patient isolated bone marrow cytogenetic abnormality also eligible except chromosome abnormality complex karyotype seropositivity hiv htlv12 active hepatitis associate hepatic cytolysis cancer last year except basal cell carcinoma skin situ carcinoma cervix pregnant hcg positive breastfeeding yellow fever vaccine others live virus vaccine within month transplantation research uncontrolled coronary insufficiency recent myocardial infarction 6month current manifestation heart failure accord nyha ii ventricular ejection fraction 50 renal failure creatinine clearance 50ml min contraindication mention smpc investigator brochure medicinal product plan use trial include condition regimen graft versus host disease prophylaxis prevention ebv reactivation infection prophylaxis known allergy intolerance medicinal product excipients plan use trial include condition regimen graft versus host disease prophylaxis prevention ebv reactivation infection prophylaxis accord investigator brochure smpc debilitating medical psychiatric illness preclude understand inform consent well optimal treatment followup legal protection tutorship curatorship state medical aid participation another interventional trial medicinal product cell therapy individuals meeting exclusion criterion verify screen inclusion visit ineligible participate study",
    "INTERVENTION": "conditioning regimen thymoglobulin mg kg day mg kg day mg kg day fludarabine 30mg month day day day pre transplant cyclophosphamide 14 mg kg day day day total body irradiation gray day stem cell source bone marrow target 108 nucleated cells kg recipient body weight granulocyte colony stimulate factor give subcutaneously start day +5 mg kg day absolute neutrophil count great 109 day graft versus host disease prophylaxis cyclophosphamide 50 mg kg day d+3 d+4 tacrolimus mg kg day per divide dos 05 mg kg ivse mycophenolate mmf begin d+5 absence graft versus host disease mmf stop day 35 day 45 tacrolimus day 365 prevention ebv reactivation rituximab 150mg month intravenously day+5 post hematopoietic stem cell transplantation except patient donor ebv serology ebv pcr negative infusion rituximab precede administration antipyretic antihistaminic paracetamol diphenhydramine nb however permissible delay administration rituximab 24 hour d+5 occur sunday great safety discretion investigator",
    "STATISTICS": "sample size calculation twosided onesample logrank test calculate sample 52 subject achieve 80 power 05 significance level detect 2years grfs 70 new group year grfs historic control group 50 patient follow year analysis primary endpoint several interim analysis primary outcome measure plan every 12 month unless less 20 enrolled patient base bayesian approach end trial accrual+followup grfs estimate use kaplan meier method correspond 95 confidence interval compare historical rate use one sample twosided logrank test additional terminal analysis use external patient observational cohort propensity score weighting ensure unbiased comparison enhance level evidence treatment effect"
  }
}